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Abstract 
DNA sequencing technologies have developed quickly in the last decade, and new 
methodologies have moved into clinical practice.  These can been used to 
investigate genetic causes of neonatal cholestasis.  Neonatal cholestasis can be life-
threatening and has a varied etiology.   
In chapter 3, a targeted next generation sequencing (tNGS) assay was designed and 
assessed for suitability for detection of known mutations in genes associated with 
cholestasis.  In chapter 4, this was used to screen over 200 infants presenting with 
liver disease for mutations in the ATP8B1, ABCB11, ABCB4, NPC1, NPC2 and 
SLC25A13 genes.  Diagnoses were made in 9% and single heterozygous mutations 
were in 9% of cases.  In chapter 5, patients suspected of PFIC-related disease were 
tested for mutations in the ATP8B1, ABCB11 and ABCB4 genes.  This study 
uncovered 27 novel sequence variants, including 22 in UK patients, expanding the 
known mutation spectrum of these disorders.  In chapter 6, patients suspected of 
NPC and were tested for mutations in NPC1 and NPC2, or SLC25A13, respectively.  
These studies have identified 134 novel NPC mutations and 4 novel CD mutations. 
Current and future DNA sequencing methods are discussed, as are new diagnostic 
strategies for genetically heterogeneous conditions like infantile liver disease.  
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Chapter 1 - INTRODUCTION 
1.1. Liver anatomy and function 
1.1.1. Anatomy of the Liver 
The liver is the largest visceral organ of the human body and is located in the upper 
right hand side of the abdominal cavity, inferior to the diaphragm and ribcage and 
superior to the stomach, intestines and colon.  Superficially, the liver is divided into 
left and right lobes, where the right is six times larger than the left (see Figure 1.1).  
In addition, the right lobe includes the posterior caudate lobe and the inferior 
quadrate lobe.  The left and right lobes are separated by the falciform ligament and 
fissures for ligamentum verosum and ligamentum teres.  Alternative subdivisioning of 
the liver, termed the ‘functional anatomy’ is based upon the structure of the vascular 
and biliary structures (Dooley and Sherlock, 2011).  A major fissure called porta 
hepatis is the site of entry and exit for the vasculature, lymphatic system, hepatic 
ducts and nervous infrastructure of the liver.  Blood enters the liver from the portal 
vein and the hepatic artery and exits via the hepatic vein to the inferior vena cava, 
close to the junction with the right atrium of the heart.  The biliary system includes 
the left and right hepatic ducts, which meet to form the common hepatic duct (Figure 
1.1).  The cystic duct from the gallbladder meets the common hepatic duct to form 
the common bile duct.  The common bile duct meets the pancreatic duct near the 
duodenum and forms the Ampulla of Vater, regulated by the sphincter of Oddi 
(Dooley and Sherlock, 2011).   
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The internal structure of the liver tissue can be described as either a ‘lobule’; a 
hexagonal arrangement of cells centred on the hepatic vein, or as an ‘acinus’; a 
diamond-shaped region between two central vein branches (Dooley and Sherlock, 
2011). Figure 1.2 is a diagram illustrating the structures of the lobule and the acinus.  
Both functional units define zones of hepatocytes which have different metabolic 
properties as well as different susceptibilities to damage.  Zone 1 cells are closest to 
the arterioles and portal vein branches and therefore oxygen and nutrient supplies, 
but are more susceptible to injury from toxins (Dooley and Sherlock, 2011).  Zone 3 
cells are closest to the central veins and are therefore more susceptible to injury due 
to lack of oxygen (Dooley and Sherlock, 2011).  
Figure 1.1: A basic diagram of the liver and biliary system.  
Image taken from Wikimedia Commons. By Jiju Kurian Punnoose (Own work) [GFDL 
(http://www.gnu.org/copyleft/fdl.html) or CC-BY-SA-3.0-2.5-2.0-1.0 
(http://creativecommons.org/licenses/by-sa/3.0)]. 
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The liver tissue consists of a variety of cell types including hepatocytes (parenchymal 
cells), endothelial cells lining the sinusoids (vascular system), cholangiocytes 
(endothelial cells lining the bile ductules and ducts), Kupffer cells (phagocytic cells), 
pit cells (natural killer cells) and hepatic stellate cells (fat and retinoid storing cells) 
(Dooley and Sherlock, 2011). In addition, blood cells and blood vessels account for a 
significant proportion of cells. Figure 1.3 is a diagram showing the arrangement of 
cells in the liver in detail. 
 
 
 
 
 
Figure 1.2: A diagram of the internal structure 
of the liver. 
This shows the ‘lobule’ in orange with the 
portal vein in the centre. The red arrows 
outline the ‘acinus’ and show the flow of 
oxygen from the arteriole (red) to the portal 
vein past zone 1, 2 and 3 hepatocytes. The 
green arrows show the flow of bile from portal 
vein and hepatocytes towards the bile duct. 
Figure 1.3 A diagram showing the 
cellular structure of the liver. 
Image taken from Wikimedia 
Commons. By Zorn, A.M., Liver 
development (October 31, 2008), 
StemBook, ed. The Stem Cell 
Research Community, StemBook, 
doi/10.3824/stembook.1.25.1, 
http://www.stembook.org. [CC-BY-
3.0 (http://creativecommons.org 
/licenses/by/3.0)]. 
Image taken from Wikimedia Commons. "Liver scheme1". Licensed under Creative 
Commons Attribution-Share Alike 3.0 via -  http://commons.wikimedia.org/wiki 
/File:Liver_scheme1.jpg#mediaviewer/File:Liver_scheme1.jpg 
 
Kirsten McKay Bounford   
4 
 
1.1.2. Functions of the liver 
The functions of the liver are carried out by the hepatocytes and there are up 500 
separate functions known (Dooley and Sherlock, 2011).  Life is not possible without 
the liver as it is not currently possible to artificially replace all of these functions, and 
thus severe liver damage or disease may only be treated by liver transplantation 
(Wang et al., 2013).  Roles include synthesis of amino acids, carbohydrates, lipids, 
coagulation factors, red blood cells in the fetus, bile, insulin-like growth factor, 
albumin and thrombopoietin (Dooley and Sherlock, 2011).  Metabolism of hormones 
including insulin, bilirubin to bile, ammonia to urea, and of drugs by the cytochrome 
P450 proteins also occurs (Dooley and Sherlock, 2011).  Other functions of the liver 
include storage of glycogen, vitamins A, D, B12, K, iron and copper (Dooley and 
Sherlock, 2011). 
1.1.2.1. Bile production and secretion 
Bile is a dark green fluid made by the liver, temporarily stored in the gallbladder, and 
then released into the duodenum (Dooley and Sherlock, 2011).  Bile is composed of 
water, bile acids, bilirubin, cholesterol, phospholipids and electrolytes, and its two 
main functions are to aid the digestion of in food and to allow excretion of waste 
products via faeces.  Cholesterol is generally insoluble, however inside hepatocytes 
cholesterol is oxidised to form the bile acids cholic acid and chenodeoxycholic acid.  
Each of these can be conjugated with either taurine or glycine to produce a total of 
four types of conjugated bile acid.  Conjugated bile acids are soluble and are 
secreted into bile (via the bile salt export protein; BSEP) where they aid digestion by 
facilitating the emulsification of lipids. Bile allows the uptake of lipids and lipid-soluble 
vitamins from the GI tract into the bloodstream.  Bile also functions as the route by 
which bilirubin, a by-product of the breakdown of the haem molecule from red blood 
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cells, is excreted from the body. In hepatocytes, bilirubin becomes conjugated with 
glucuronic acid and it is in this conjugated form that is excreted via bile (via the 
MRP2 protein).  Bile acids are reabsorbed by the ileum into the portal bloodstream 
and then are very efficiently recycled by the hepatocytes (Dooley and Sherlock, 
2011). 
1.2. Infantile liver disease 
1.2.1. Overview of liver disease in infants 
Abnormal liver function in the neonatal period is initially suspected by the signs and 
symptoms of jaundice, dark coloured urine, pale coloured stools, and an enlarged 
liver.  Neonatal jaundice (or physiological jaundice) is common in neonates 
(approximately 60% of term babies and 80% of preterm babies) and is usually 
caused by unconjugated bilirubinaemia (NICE Guidelines, 2010).  Conjugated 
hyperbilirubinaemia is suspected if jaundice persists beyond 2 to 3 weeks; this 
occurs in around 1 in 2,500 births and indicates underlying liver disease (Mckiernan, 
2002).  Blood tests can determine the levels of bilirubin in serum, as well as 
differentiating between conjugated and unconjugated species.  Discolouration of 
urine and stools occurs because of disruption of bilirubin metabolism and 
transportation.  Conjugated hyperbilirubinaemia may be caused by cholestasis; 
defined as impaired bile flow.  Cholestasis can be associated with hepatomegaly and 
sometimes also splenomegaly.  Some babies with cholestasis recover with time, 
however all cases should be thoroughly investigated due to the possibility of a 
serious condition such as biliary atresia (see 1.2.3.1).  In addition, chronic liver 
failure may occur if persistent cholestasis is left untreated, due to fibrosis and 
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cirrhosis of the liver.  Acute liver failure (ALF) in infants is defined as severe 
impairment of liver function without a recognised chronic liver disease.  Infantile ALF 
is often a multi-system disorder and can occur with or without encephalopathy.  The 
underlying causes of infantile liver disease, and in particular cholestasis, are many 
and varied and will be discussed further (see 1.2.2). 
Routine investigations in infants with conjugated hyperbilirubinaemia aim to identify 
the underlying cause as this will influence management and likely prognosis.  Such 
investigations include blood tests to measure liver enzymes such as ALP, ALT, AST 
and GGT, screens for infectious causes, coagulation studies which will determine the 
level of liver function, and imaging techniques such as ultrasound to look for signs of 
structural abnormalities, such as biliary atresia or gallstones.  Liver biopsy is then 
considered and can uncover various abnormalities such as fibrosis, bile plugs, and 
hepatocyte or bile ducts abnormalities. 
Treatments for neonatal liver diseases vary depending on the underlying 
pathophysiology but will include promotion of growth and nutrition, such as vitamin 
supplementation.  Administration of ursodeoxycholic acid (UDCA) to reduce the 
effects of cholestasis is used as a treatment for gallstones and many types of 
cholestasis. The Kasai hepatoportoenteropathy is a surgical intervention used in 
cases of biliary atresia.  In other cases with acute or chronic liver failure, liver 
transplantation is required. 
1.2.2. Cholestasis in Infants 
Infantile cholestasis may be ‘obstructive’ or ‘metabolic’ in nature.  Obstructive 
cholestasis includes conditions such as biliary atresia and Alagille syndrome 
whereas metabolic cholestasis includes progressive familial intrahepatic cholestasis.  
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The most important causes of conjugated bilirubinaemia in neonates are listed in 
Table 1.1 and discussed below. 
Table 1.1: Known causes of infantile cholestasis.   
KEY; ALL=acute lymphoid leukaemia, AML=acute myeloid leukaemia, 
NHC=neonatal haemochromatosis. 
Cause Proportion of Neonatal Cholestasis 
Biliary Atresia ~35%  (Mieli-Vergani et al., 1989) 
Metabolic and inherited disorders, 
including: 
Up to 55% (De Bruyne et al., 2011a) 
          Alpha-1 anti-trypsin deficiency 5-15% (De Bruyne et al., 2011a) 
          Inherited forms of cholestasis 10-20% (De Bruyne et al., 2011a) 
          Inborn errors of metabolism 20% (De Bruyne et al., 2011a) 
Infectious disease 5% (De Bruyne et al., 2011a) 
Prematurity and/or parenteral nutrition Unknown  
Idiopathic cases (unspecified cause) Up to 15% 
Others  
         Chromosomal disorders, i.e. Trisomy         
          21, Trisomy 18, Turner’s syndrome 
Rare 
          Leukaemia, i.e. ALL or AML Rare 
          Immune system disorders i.e. NHC Rare 
 
 
1.2.3. Non-genetic causes 
1.2.3.1. Biliary atresia 
Biliary atresia (BA) is a rare disease affecting infants, which leads to progressive 
liver disease, liver failure and early death if untreated.  BA is caused by the absence 
of adequate biliary tree structures, leading to cholestasis, progressive fibrosis and 
portal hypertension.  It occurs in approximately 1 in 20,000 infants worldwide, but is 
more common in Asian populations, for example in 1 in 10,000 infants in Japan, or 1 
in 3,000 in French Polynesia (Moreira et al., 2012). 
There are three forms of BA; the first is isolated BA, also termed ‘perinatal’ or ‘non-
syndromic’, and accounts for 80-90% of cases (Moreira et al., 2012).  The second 
form is called ‘early’, ‘embryonic’ or ‘syndromic’, accounts for 10-20% of cases, and 
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is associated with other congenital malformations involving the spleen, intestines and 
heart (Moreira et al., 2012). The term ‘biliary atresia with splenic malformations’ 
(BASM) is sometimes used.  The third form is called cystic biliary atresia and 
accounts for only a very small proportion of syndromic BA cases.  There is no known 
cause for BA however, it is considered likely that non-syndromic and 
syndromic/cystic BA have different aetiologies.  The presence of other congenital 
malformations in syndromic BA suggests it may be a developmental disorder 
(Nakamura and Tanoue, 2013).  In comparison, bile duct remnants are detectable in 
patients with non-syndromic BA, indicating bile ducts had formed but have been 
destroyed and replaced by fibrous tissue.  BA has therefore been classified as a 
progressive obliterative cholangiopathy (Nakamura and Tanoue, 2013).  Many 
factors have been proposed to be contributors to BA, such as infection, aberrant 
immune-response and inflammation, and it is likely the answer will be multifactorial in 
nature (Hartley et al., 2013).  It is very unlikely that BA is a Mendelian condition; 
however NOTCH signalling and left-right patterning are pathways which may play a 
role in at least the syndromic BA cases (Nakamura and Tanoue, 2013). 
BA is suspected in infants with persistent neonatal jaundice, pale stools, dark urine 
or hepatomegaly.  Blood tests show conjugated hyperbilirubinaemia and elevated 
liver enzymes.  Diagnosis can be made by imaging of the liver such as ultrasound, 
magnetic resonance imaging or cholangiography or by liver biopsy.  Management of 
BA patients is different from other cholestatic infants as early surgical intervention is 
recommended in the form of the Kasai procedure or Kasai portoenterostomy.  BA 
initially affects the extrahepatic biliary structures and the Kasai procedure involves 
using a portion of the small intestine to connect the liver to the duodenum, allowing 
bile to drain via any remaining intraheptic bile ducts.  This procedure may be 
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successful in around 60% of cases (Hartley et al., 2013).  As the disease progresses 
the intraheptic biliary tree may also be obliterated and liver transplant is then 
required.   
1.2.3.2. Cholelithiasis 
Biliary sludge and resulting cholelithiasis (more commonly known as gallstones) has 
been described in children infrequently, with a prevalence ranging from 0.01 to 2% 
depending on population studied and method of identification.  As described by 
Svensson and Makin four types of gallstones have been observed in children 
(Svensson and Makin, 2011).  Gallstones consist of precipitated components of bile, 
which can block bile ducts leading to cholestasis.  Gallstones can result due to 
genetic defects in bile formation (see 1.3.1). 
1.2.3.3. Parenteral nutrition 
Parenteral nutrition (PN) is the administration of nutrients intraveneously, bypassing 
the processes of feeding and digestion. PN is used in infants who have undergone 
extensive gastrointestinal surgery or have congenital or acquired defects of the GI 
tract (Kelly, 2006).  PN in infants can be associated with serious hepatic 
complications including cholestasis (40-60%), biliary sludge and cholelithiasis and 
contributing factors are known, including prematurity, low birth weight, duration and 
composition of PN (Kelly, 2006). 
1.2.3.4. Congenital infection 
Congenital TORCH infections (toxoplasmosis, rubella, cytomegalovirus and herpes 
simplex) can present similarly with jaundice, hepatomegaly, splenomegaly and acute 
liver failure amongst other features (Roberts, 2003).   
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1.2.3.5. Neonatal haemochromatosis 
Neonatal haemochromatosis (NHC), also known as congenital alloimmune hepatitis, 
is a materno-fetal alloimmune disease which is characterised by severe liver disease 
in the neonate and extrahepatic siderosis (Whitington, 2007).  Untreated the 
prognosis is very poor, however a study in women who had suffered pregnancy or 
neonatal loss due to NHC and were treated with IgG from 18 weeks gestation, 
showed greatly improved outcomes for affected babies (Whitington and Kelly, 2008). 
1.3. Important genetic causes of cholestasis 
1.3.1. Progressive familial intrahepatic cholestasis (PFIC) 
Progressive familial intrahepatic cholestasis is a group of heterogeneous childhood 
liver diseases, which present with cholestasis of hepatic origin and death from liver 
failure in the first year or up to adolescence.  The incidence is estimated to be 
1/50,000 to 1/100,000 live births and account for 10-15% of neonatal cholestasis 
cases and 10-15% of childhood liver transplant indications (Davit-Spraul et al., 
2009).  PFIC affects all populations and is inherited in an autosomal recessive 
fashion.  PFIC is known to be caused by mutations in three genes; ATP8B1, 
ABCB11 and ABCB4 and so PFIC can be sub-classified according to the molecular 
diagnosis (see Table 1.2).  PFIC types 1 and 2 are unusual in that they are 
characterised by normal serum GGT levels, whereas other metabolic caused of 
cholestasis (including PFIC 3) are associated with high serum GGT levels (Davit-
Spraul et al., 2009).  
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Table 1.2:  A summary of some of the key features of PFIC types 1, 2 and 3 
(information drawn from Bull et al., 1998 and Davit-Spraul et al., 2009). 
Features PFIC1 PFIC2 PFIC3 
Cholestasis 
In first few 
months, 
becoming 
permanent later 
Becoming 
permanent in first 
few months 
Rare in neonates, 
1/3 of cases by 12 
months, rest in 
infancy, childhood 
or adolescence. 
Liver disease 
Liver failure and 
cancer 
Failure within first 
year.  High risk of 
liver cancer by 
age 1 year. 
Failure and 
transplant by 
average age of 7.5 
years.  No tumours 
associated. 
Extrahepatic 
findings 
Short stature, 
deafness, 
diarrhoea, 
pancreatitis. 
None None 
Ductules visible 
on liver biopsy 
Absent Absent Present 
Serum GGT Normal Normal High 
 
PFIC1 is caused by loss of function mutations in ATP8B1 (Bull et al., 1998), and it is 
allelic to the milder conditions benign recurrent intrahepatic cholestasis type 1 
(BRIC-1), Greenland familial cholestasis and intrahepatic cholestasis in pregnancy 
(ICP) (Mullenbach, 2005).  The gene encodes a P-type ATPase called FIC1, which is 
localised to the canalicular membrane in liver hepatocytes (Figure 1.4).  FIC1 protein 
function is not completely characterised, however it is known to be responsible for 
the translocation of aminophospholipids (e.g. phosphatidylserine, PS) from one side 
of the phospholipid bilayer of the plasma membrane to the other, causing an 
enrichment of PS on the inner layer.  This asymmetry is thought to protect the liquid-
ordered state of the outer leaflet of the membrane and thus protect against high bile 
salt concentrations in the canalicular lumen.  Loss of FIC1 protein function is thought 
to result in cholestasis at least partly because of decreased BSEP activity (see next 
paragraph), potentially as a result of disruption of membrane integrity (Paulusma et 
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al., 2009), or by downregulation of a nuclear receptor called Farnesoid X receptor 
(FXR) which is important in the bile salt signalling and regulation pathway (Chen and 
Chang, 2004).  It is likely that FIC1 has similar roles in maintaining membrane 
stability in other tissues in which it is expressed (inner ear, pancreas etc), loss of 
which should explain the extra-hepatic features involved in PFIC1 (Table 1.2).  
ATP8B1 mutations reflect a spectrum of phenotypes from mild BRIC1 to severe 
PFIC1 however; genotype-phenotype correlations are difficult due to compound 
heterozygosity.  It is likely that PFIC1 mutations completely disrupt the protein 
whereas BRIC1 mutations only partially disrupt the protein.  Heterozygous mutations 
in ATP8B1 have been identified in ICP patients (Mullenbach, 2005).   
PFIC2 is caused by mutations in the ABCB11 gene (Strautnieks et al., 1998), which 
encodes the ATP-dependent canalicular bile salt export protein (BSEP).  BSEP is 
the major exporter of primary bile acids at the hepatocyte canalicular membrane and 
functions in extreme concentration gradients (Figure 1.4).  Deficiency of BSEP 
directly leads to the accumulation of bile salts in hepatocytes and liver damage.  
BSEP deficiency also results in a spectrum of phenotypes from severe PFIC2 to mild 
BRIC2 (van Mil et al., 2004a).  PFIC2 mutations tend to result in prematurely 
truncated proteins and immunohistochemistry shows absence of protein (Jacquemin, 
2012).  Some missense mutations also lead to PFIC2 but show presence of BSEP 
protein.  These tend to be located in conserved regions of the gene; nucleotide 
binding fold containing the Walker A and B motifs and ABC signature ATP-binding 
motifs (Byrne et al., 2009).  In BRIC2, missense mutations are common and tend to 
be in less conserved regions of the gene.  Heterozygous mutations have also been 
detected in ICP2, drug induced cholestasis and transient neonatal cholestasis (Dixon 
et al., 2009). 
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PFIC3 differs from the other two phenotypes as it is associated with high serum GGT 
and ductule proliferation in the liver.  In addition, the age of onset tends to be later 
and more variable (Davit-Spraul et al., 2010).  PFIC3 is caused by mutations in the 
ABCB4 gene (De Vree et al., 1998), a member of the ABC transporter protein family 
similar in structure to ABCB11.  This encodes the MDR3 protein (Class III multidrug 
resistance P-glycoprotein) which is localised to canalicular membrane of hepatocytes 
(see Figure 1.4).  Similarly to FIC1, MDR3 is a phospholipid translocator, moving 
biliary phosphaditylcholine (PC) from the inner leaflet to the outer leaflet of the 
canalicular membrane, facing the lumen. PC is then extracted from the membrane 
by bile salts forming micelles.  Lack of PC leads to excess bile salts in the bile, which 
have a detergent effect on the canalicular membrane of hepatocytes and 
cholangiocytes, damaging the cells and resulting in cholestasis and cholangiopathy 
(Davit-Spraul et al., 2010).  The phenotype of PFIC3 ranges from neonatal 
cholestasis to cirrhosis in young adults (Davit-Spraul et al., 2010).  One third of 
mutations resulted in a truncated protein product with no detectable protein by 
immunostaining, presumably as a result of mRNA decay.  PFIC3 missense 
mutations are in highly conserved regions like Walker A and B motifs (ATP-binding).  
In addition, MDR3 mutations are involved in ICP3, cholesterol gallstone disease, 
drug induced cholestasis and transient neonatal cholestasis (TNC) (Jacquemin, 
2012; Mullenbach et al., 2003). 
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1.3.2. Niemann Pick disease type C 
Niemann-Pick disease type C (NPC) is caused by mutations in the genes NPC1 
(95% of cases) and NPC2 (5% of cases) (Carstea, 1997; Naureckiene, 2000a).  Both 
versions are autosomal recessively inherited.  The overall frequency is 1 in 150,000 
but this is likely to be an underestimate (Patterson, 2000).  NPC may present at any 
age, however three characteristic periods of onset exist, and may relate to different 
mutations, the gene affected or even modifier genes (Imrie et al., 2007).  Neonatal 
NPC in severe cases can sometimes be detected prenatally (Spiegel et al., 2009), 
and otherwise in the neonate with cholestatic liver disease, hepatomegaly and 
splenomegaly (Kelly et al., 1993).  The liver disease can be progressive at this stage 
leading to liver failure and death.  Those who survive are hypotonic (Kelly et al., 
1993).  Later on delayed motor development, neurological problems, enlarged liver 
and spleen, developmental delay and vertical supranuclear gaze palsy (VSGP) can 
also be observed (Kelly et al., 1993).  Death usually occurs by age 5 (Imrie et al., 
2007).  Childhood-onset NPC is the classical presentation of NPC affecting the vast 
Cholangiocytes 
Bile canaliculus 
Figure 1.4: A schematic of the PFIC proteins at the cellular level within the liver.  
The black arrow indicates bile flow.  
The blue transporter is FIC1. It translocates aminophospholipids, e.g. PS from the 
outer to the inner leaflet of the canalicular plasma membrane of hepatocytes.   
Yellow is BSEP which exports bile acids from hepatocytes into the canaliculus.   
Orange is MDR3 which translocates phosphatidylcholine from the inner to the outer 
leaflet of the canalicular plasma membrane of hepatocytes. 
Hepatocytes 
Bile 
duct 
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majority of patients (Vanier, 2010).  Initial symptoms are often clumsiness and gait 
disturbances and hepatomegaly or splenomegaly may be present upon examination 
(Vanier et al., 1988).  Typically VSGP occurs, there is progressive cognitive 
impairment and dyspraxia, often ataxia and dystonia involving the limbs, 
deterioration of speech and ability to feed, seizures and gelastic cataplexy (Imrie et 
al., 2007; Vanier et al., 1988).  Lifespan is variable and aspiration pneumonia is a 
common cause of death (Vanier, 2010).  With adolescent or adult-onset NPC, the 
presentation can be similar to the neurological disease in childhood NPC but with a 
slower rate of progression (Sevin et al., 2006).  Some adult-onset patients can 
present predominantly with psychiatric problems such as dementia, schizophrenia, 
delusions,hallucinations and paranoia (Sevin et al., 2006).  
NPC is an unusual lysosomal storage disorder that is caused by defective 
intracellular lipid trafficking rather than enzyme deficiency (Vanier, 2015).  The 
primary defect is accumulation of cholesterol from the late endosome/lysosome 
compartment.  Sphingomyelin accumulation also occurs; a feature shared with 
Niemann-Pick disease types A and B explaining the original grouping of these 
diseases together.  Accumulation of lipid-filled cells in the lungs leads to the lung 
impairment, in the liver the hepatomegaly, and in the neurons the neurological 
problems.  Purkinje cells in the cerebellum seem to be particularly affected by the 
accumulation of lipids in NPC (Ko et al., 2003); however it is not entirely clear how 
this is harmful to these cells (Vanier, 2015).   
The NPC1 gene (located on chromosome 18q11-q12) encodes the NPC1 protein; an 
integral membrane protein with 13 transmembrane domains that is targeted to the 
late endosome and lysosome (Ioannou, 2000).  It is known that NPC1 is involved in 
trafficking of cholesterol from the lysosome to the plasma membrane as part of the 
Kirsten McKay Bounford   
16 
 
usual distribution and cycling of lipids by the cell, how this happens is not fully 
understood.  It is likely that NPC1 has other functions or at least other downstream 
effects as defective cholesterol trafficking does not fully explain the pathogenesis of 
NPC, for example in the brain (Ioannou, 2000).  The NPC2 gene (located on 
chromosome 14q24.3) encodes the NPC2 protein (Naureckiene, 2000a).  NPC2 is 
widely expressed and is a soluble glycoprotein in the lumen of the late endosome 
and the lysosome (Naureckiene, 2000a).  NPC2 binds cholesterol, transporting it 
from internal vesicle membranes within the endosome to NPC1 on the endosome 
membrane (Ko et al., 2003).  High cholesterol levels are also likely to be responsible 
for reduced trafficking of other lipids, including sphingomyelin, leading to secondary 
accumulations (Vanier, 2010).  Miglustat (Zavesca® from Actelion Pharmaceuticals) 
has been shown to be an effective therapy for slowing the progression of the 
neurodegenerative effects of NPC in children and adults (Lyseng-Williamson, 2014).   
 
1.3.3. Citrin deficiency 
Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), failure to 
thrive and dyslipidaemia caused by citrin deficiency (FTTDCD) and citrullinaemia 
type II (CTLN2) are all caused by mutations in the SLC25A13 gene; also known as 
Citrin (Saheki and Kobayashi, 2002).  Previously it was thought that NICCD and 
CTLN2 were allelic conditions, however with the discovery of FTTDCD, it is now 
considered that these are all probably the same condition (termed Citrin Deficiency) 
with distinct symptomatic periods and clinical presentations.  It seems that not all 
patients with NICCD will go on to have CTLN2, and not all patients with CTLN2 will 
have had NICCD (Woo et al., 2014).   
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The symptoms of NICCD are prolonged intrahepatic cholestasis and metabolic 
abnormalities during the neonatal period, including amino acidaemia (especially 
citrulline) and galactosuria (Saheki and Kobayashi, 2002).  NICCD is usually 
relatively mild and symptoms disappear within a year with basic treatment; this might 
include lactose-free formula milk and fat-soluble vitamin supplements to combat the 
effects of prolonged cholestasis (Saheki and Kobayashi, 2002; Woo et al., 2014).  
There are infrequent NICCD cases with severe liver dysfunction and where liver 
transplants have been required in childhood (Tamamori et al., 2002). 
An apparently healthy phase was thought to follow the resolution of NICCD 
symptoms, however a new distinct phenotype has recently been described which 
includes failure to thrive, dyslipidaemia, echinosystosis and metabolic abnormalities 
(Song et al., 2011).  CTLN2 is characterised by recurrent periods of 
hyperammonaemia and neurological symptoms in adulthood.  The neurological 
symptoms are severe and usually sudden; these can include nocturnal delirium, 
behaviour changes, delusion, disorientation, drowsiness, loss of memory, tremor, 
seizures, coma and death (Kimura et al., 2013).  In addition, CTLN2 (and FTTDCD) 
patients are often thin or underweight, with a preference for lipid-rich and protein-rich 
foods and an avoidance of carbohydrate-rich foods (Saheki and Kobayashi, 2002).  
The most successful treatment for CTLN2 is liver transplant at the onset of 
symptoms (Kimura et al., 2013).     
The SLC25A13 gene is located at 7q21.3 and encodes a protein called citrin, 
specifically in the liver (Kobayashi et al., 1999).  The protein has a C-terminal region 
of the protein consists of 6 transmembrane domains, and the N-terminal region has 4 
calcium-binding EF-hand domains.  The protein is localised to the inner 
mitochondrial membrane with the N-terminal region in the mitochondrial lumen 
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between the two membranes.  The protein functions as part of the malate-aspartate 
NADH shuttle and is important for aerobic glycolysis and gluconeogenesis, as well 
as in the urea cycle and protein and nucleotide synthesis (see Figure 1.5).  Almost 
all reports of mutations in SLC25A13 have been reported in the Japanese 
population, where the frequency of carriers is estimated to be 1 in 65 and affected 
patients is 1 in 17,000 (Saheki and Kobayashi, 2002).  Mutations have now been 
found in patients from other populations, including the UK (Hutchin et al., 2009), 
although the carrier frequency and mutation spectrum are likely to be different.   
 
 
 
 
 
 
 
 
 
 
 
 
ASS enzyme
(Citrullinaemia
type 1)
Aspartate
Argininosuccinate
Citrulline
Urea 
Cycle
CITRIN 
Figure 1.5: A 
diagram showing 
the subcellular 
location of the 
citrin protein.  
Citrin (in red) 
exports 
aspartate (blue) 
out of the 
mitochondria, 
where it feeds 
into the urea 
cycle.  
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1.3.4. Alagille syndrome 
Alagille syndrome (AGS) is a multisystem disorder characterised by cholestasis in 
infancy, congenital heart defects, skeletal and eye malformations, renal 
abnormalities and distinctive facial features.  The incidence of AGS is at least 1 in 
70,000 births; however it is likely to be higher than this due to the widely variable 
expressivity of the condition (Turnpenny and Ellard, 2012).  The most clinically 
significant feature of AGS is cholestasis in infancy caused by bile duct paucity, which 
occurs in over 90% of cases (Emerick et al., 1999).  Left untreated, cholestasis in 
AGS may lead to fibrosis and liver failure in around 15% of cases (Emerick et al., 
1999), however it is not yet possible to predict which children will require liver 
transplant and when.  Cholestasis can be treated using ursodeoxycholic acid, partial 
external biliary diversion (PEBD) and liver transplant if required (Hartley et al., 2013).  
Cardiac abnormalities in AGS occur in over 90% of cases (Emerick et al., 1999).  
Most commonly these are outflow tract defects such as peripheral pulmonary 
stenosis, tertralogy of Fallot, atrial septal defect and ventricular septal defect 
(Turnpenny and Ellard, 2012).  A distinctive feature of AGS is the presence of 
butterfly vertebrae, a congenital malformation of the spine which occurs in over 60% 
of cases with no associated morbidity (Emerick et al., 1999).  Other skeletal 
complications of AGS can be clinically significant, such as craniosynostosis, 
osteoporosis and fractures (Turnpenny and Ellard, 2012).  Posterior embryotoxon is 
an ocular feature which occurs in around 80% of AGS cases, but also in 15% of the 
normal population and up to 70% of patients with 22q11.2 deletion syndrome 
(McDonald-McGinn et al., 1999).  Renal tubular acidosis may occur in around 70% of 
cases and structural abnormalities of the kidney are also common (Emerick et al., 
1999).  AGS is associated with distinctive facial features such as wide prominent 
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forehead, deep set eyes, long mandible and pointed chin, giving an overall 
appearance of an inverted triangular shape (Krantz et al., 1997). 
AGS is caused by mutations in the JAG1 gene in 90% of families and hundreds of 
different mutations have been described (Li et al., 1997; Oda et al., 1997).  The 
majority are small-scale insertions, deletions or base substitutions, however whole 
gene deletions have been reported in around 7% of cases (Turnpenny and Ellard, 
2012).  DNA sequencing can be used to detect the sequence changes as these are 
spread throughout the gene.  Multiplex ligation-dependent probe amplification 
(MLPA), fluorescent in situ hybridisation (FISH), array comparative genome 
hybridisation (aCGH) or other quantitative methods can be used to detect exonic 
deletions and duplications as well as whole gene deletions.  Deletions of larger 
regions including this gene have been reported and are associated with extra 
phenotypes including mental retardation (Turnpenny and Ellard, 2012).  A smaller 
group of AGS families have been shown to carry mutations in the NOTCH2 gene 
(McDaniell et al., 2006).  These are clinical indistinguishable from JAG1-associated 
AGS patients, however there may be a higher incidence of renal disease in 
NOTCH2-AGS patients (McDaniell et al., 2006). 
The genes JAG1 and NOTCH2 encode the Jagged-1 receptor and Notch-2 ligand 
proteins, respectively.   AGS mutations in both genes are consistent with 
haploinsufficiency as they are heterozygous protein-truncating mutations, deletions 
or other predicted loss of function mutations (Li et al., 1997; Oda et al., 1997).  Jag-1 
and Notch-2 are components of the NOTCH signalling pathway, an essential cellular 
mechanism during development, explaining the multi-system features of AGS.  
Mouse and zebrafish models have shown NOTCH signalling to be essential for both 
the formation of the ductal plate and tubulogenesis processes during development of 
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the intrahepatic biliary tree, corresponding to the paucity of bile ducts phenotype 
observed in AGS patients (Lorent, 2004). 
AGS is inherited in an autosomal dominant fashion with reduced penetrance and 
variable expressivity observed within families (Kamath et al., 2003).  Many 
apparently healthy parents have been identified as a consequence of investigations 
into a more severely affected child.  Often these individuals do not meet the clinical 
diagnostic criteria for AGS or have only mild clinical features; however they carry the 
same genetic lesion as their child (Kamath et al., 2003).  A proportion of AGS 
mutations are have occurred de novo in the child (up to 60% of cases), or within the 
parental gonad and therefore germline mosaicism is a real possibility (Turnpenny 
and Ellard, 2012).  These complex genetic issues can result in difficult decisions 
regarding prenatal diagnosis for future pregnancies.  As a result genetic diagnosis of 
AGS and access to appropriate genetic counselling is recommended for these 
families. 
1.3.5. Alpha-1 anti-trypsin deficiency (AATD) 
AATD is characterised by lung disease in adults and liver disease in children and 
adults. Chronic obstructive pulmonary disease (COPD), specifically emphysema, is 
the most common manifestation of AATD in the lung.  Presenting features include 
breathlessness, coughing and wheezing, typically for a significant period of time 
before diagnosis (American Thoracic Society/European Respiratory Society, 2003).  
Cigarette smoking is the biggest lifestyle factor influencing lung disease in AATD, 
with the age of onset being 30-50 years in smokers, and over age 50, or sometimes 
not at all, in never-smokers (American Thoracic Society/European Respiratory 
Society, 2003).  Some individuals present with asthma or chronic bronchitis 
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(American Thoracic Society/European Respiratory Society, 2003).   Liver disease in 
AATD has two clinical phases.  Firstly, some children with AATD present with 
neonatal cholestasis and usually this resolves spontaneously (Sveger, 1976).  
Outcomes following neonatal presentation vary from some children having 
progressive liver damage, cirrhosis and requiring liver transplantation, to some being 
seemingly healthy into adulthood (Sveger and Eriksson, 1995).  Secondly, adults 
with AATD present with fibrosis, cirrhosis and have an increased risk of 
hepatocellular carcinoma (Fairbanks and Tavill, 2008).   Other rare features found in 
AATD include kidney disease, rheumatoid arthritis, panniculitis and necrotizing 
vasculitis (Fregonese and Stolk, 2008).   
The prevalence of AATD is around 1 in 2,500 in Western Europe (Fregonese and 
Stolk, 2008), with the Z allele being mostly found in patients of Scandinavian descent 
and the S allele being more common in the Southern European population (see 
dbSNP:rs28929474, (Fregonese and Stolk, 2008)) .  PI*ZZ homozygotes account for 
95% of all AATD cases.  AATD is inherited in an autosomal recessive fashion and 
shows both reduced penetrance and variable expressivity (Fregonese and Stolk, 
2008).   
AATD is caused by mutations in the SERPINA1 gene which encodes the protease 
inhibitor Alpha-1 anti-trypsin (AAT) (Yamamoto et al., 1986).  AAT is produced and 
secreted by hepatocytes into the bloodstream and is detectable in all tissues 
(Carlson et al., 1988).  Deficiency of AAT leads to cell damage by protease activity, 
for example by neutrophil elastase, and the alveolar tissue of the lungs appear to be 
particularly affected.   The most common mutation in SERPINA1 is c.1096G>A 
p.Glu342Lys (NM000295.4) and results in the production of the Pi*Z protein variant 
(Jeppsson, 1976).  This forms polymers and insoluble aggregates that are retained 
Kirsten McKay Bounford   
23 
 
within the endoplasmic reticulum of hepatocytes rather than being excreted 
(Fairbanks and Tavill, 2008).  Other protein variants, such as S, may result in 
reduced serum AAT, but not the formation of polymers and damage to hepatocytes.  
Individuals with rarer null alleles are likely to have earlier onset of lung damage than 
individuals with S or Z alleles, which have some residual AAT activity (Ferrarotti et 
al., 2014). 
1.3.6. Other genetic causes 
1.3.6.1. Cystic fibrosis 
Cystic fibrosis (CF) is the most common autosomal recessive condition in patients of 
Northern European origin and is caused by mutations in the CFTR gene (Riordan et 
al., 1989).  It is characterised by meconium ileus, chronic obstruction of the lungs, 
recurrent lung infections, pancreatic insufficiency and infertility (Moskowitz et al., 
1993).  Some CF patients have chronic liver disease, and severe disease involving 
cirrhosis and portal hypertension occurs in 3 to 5% of CF patients (Lindblad et al., 
1999).  Liver involvement is a feature which varies between patients with the same 
CFTR genotype. Known genetic factors which contribute to this variation include 
mutations in the MBL2 gene (Gabolde et al., 2001) and the Z-allele of the SERPINA1 
gene (Bartlett, 2009).  CF is commonly diagnosed by a newborn screening 
programme in the UK. 
1.3.6.2. Galactosaemia 
Galactosaemia is a defect in galactose metabolism that usually presents in the first 
few weeks of life with jaundice, hepatomegaly, hepatic and renal dysfunction, and 
cataract (Bosch, 2006).  The defect is in the GALT gene which encodes a crucial 
enzyme for galactose metabolism (Reichardt and Woo, 1991).  Galactosaemia can 
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be diagnosed biochemically and may be treated by dietary restriction of galactose 
(Bosch, 2006). 
1.3.6.3. Tyrosinaemia type 1 
Tyrosinaemia type 1 (TYRSN1) is caused by mutations in the FAH gene which 
encodes the last enzyme in the tyrosine metabolism pathway; fumarylacetoacetase 
(Phaneuf et al., 1991).  Acute cases of TYRSN1 will present in infancy with 
hepatomegaly, acute liver failure and cirrhosis (Laberge, 1969).  TYRSN1 may be 
diagnosed using biochemical measurements. 
1.3.6.4. Hereditary fructose intolerance 
Hereditary fructose intolerance is caused by mutations in the ALDOB gene (Cross et 
al., 1988).  In infants, this condition tends to present at weaning when fructose is 
introduced to the diet.  Clinical features can include vomiting, failure to thrive and 
hepatomegaly (Baerlocher et al., 1978).  Long term exposure to fructose in 
undiagnosed children can lead to cirrhosis (Ali et al., 1998). 
1.3.6.5. Congenital bile acid synthesis defects 
Congenital bile acid synthesis defects cause progressive liver disease, presenting 
with neonatal cholestatic jaundice, hepatomegaly, splenomegaly, and giant cell 
hepatitis and inflammation on biopsy (Cheng et al., 2003).  Mutations have been 
identified in four genes known to be responsible for the different subtypes; HSD3B7 
(Schwarz et al., 2000), AKR1D1 (Setchell et al., 1988), CYP7B1 (Setchell et al., 
1998) and AMACR (Ferdinandusse et al., 2000). The genes encode enzymes 
responsible for catalysing steps in the synthesis of bile acids.  Deficiency of these 
enzymes leads to low levels of bile acids in the duodenum and associated problems 
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absorbing fats and fat-soluble vitamins in the gut.  Patients generally respond well to 
bile acid replacement therapy; in comparison to PFIC patients (Cheng et al., 2003). 
1.3.6.6. ARC syndrome 
Arthrogryposis, renal abnormalities and cholestasis (ARC) syndrome is a rare 
disease characterised by the named features presenting in infancy.  Liver-specific 
features include paucity of bile ducts, giant cell hepatitis and portal tract fibrosis 
(Gissen et al., 2006). It has been shown to be caused by mutations in one of two 
genes, VPS33B (Gissen et al., 2004) and VIPAS39 (Cullinane et al., 2009).   
1.3.6.7. NISCH syndrome 
Neonatal icthyosis-sclerosing cholangitis syndrome (NISCH) is a very rare 
autosomal recessive condition caused by mutations in the CLDN1 gene (Hadj-Rabia 
et al., 2004).  It is characterised by hypotrichosis, scalp alopecia and scarring, 
sparse eyebrows, jaundice, pruritis, hepatomegaly and cholestasis (Hadj-Rabia et 
al., 2004).  CLDN1 encodes claudin-1; a tight junction protein. 
1.3.6.8. Wolman disease 
Lysosomal acid lipase deficiency (LALD) is a lysosomal storage disorder caused by 
mutations in the LIPA gene (Aslanidis et al., 1996).  LALD is responsible for two 
phenotypes in humans; Wolman disease is a rare, infantile-onset form of LALD with 
feeding difficulties, diarrhoea and vomiting, hepatomegaly and splenomegaly.  
Cholesterol ester storage disease (CESD) is later-onset form which is more variable 
in presentation and progression.  It is thought that Wolman disease results from 
complete loss of function mutations in LIPA whereas CESD mutations have some 
residual protein function (Aslanidis et al., 1996).   
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1.3.6.9. Caroli disease 
Caroli disease is a congenital condition characterised by cystic dilation of 
intrahepatic bile ducts.  Jandice, cholestasis, cholangitis, hepatomegaly and liver 
cirrhosis can occur.  There is an association and overlap with autosomal recessive 
polycystic kidney disease (ARPKD).  Mutations in the PHKD1 gene cause ARPKD, 
congenital hepatic fibrosis and at least some cases of Caroli disease, in an 
autosomal recessive inheritance pattern (Adeva et al., 2006; Hao et al., 2014).  
1.3.6.10. North American Indian childhood cirrhosis 
North American Indian childhood cirrhosis (NAIC) is a disorder of isolated liver 
cirrhosis, predominantly affecting the bile ducts, found in Ojibway-Cree families in 
Quebec, Canada.  Mutations in the CIRHA1 gene encoding the cirhin protein have 
been identified as the cause of the disorder in these patients; however the incidence 
of NAIC in other ethnic groups is not known (Chagnon et al., 2002). 
1.3.6.11. Familial hypercholanaemia 
Familial hypercholanaemia is characterised by raised serum bile acid concentrations, 
fat malabsorption and pruritus.  Originally associated with the Lancaster County Old 
Order Amish population, its incidence in other ethnic groups is not known.  A 
missense mutation in the TJP2 gene and a missense mutation in the BAAT gene 
were identified as the cause of disease in the majority of cases (Carlton et al., 2003).   
1.3.6.12. Zellweger syndrome 
Peroxisomal biogenesis disorders (PBDs) present as a spectrum of phenotypes 
including Zellweger syndrome (ZS). ZS is a neonatal-onset condition with jaundice 
and liver dysfunction as well as hypotonia, seizures and distinctive facial features.  
One of two common mutations in the PEX1 gene is identified in about 80% of all 
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PBD patients (Waterham and Ebberink, 2012).  Sequencing of the coding regions of 
PEX1 will detect around 50% of all mutations, however the rest are distributed 
throughout at least 14 different genes; with PEX6, PEX10, PEX12 and PEX26 genes 
being the most common after PEX1 (Waterham and Ebberink, 2012). 
1.3.6.13. Gaucher disease 
Gaucher disease (GD) is another autosomal recessive condition that may present as 
liver disease in infancy; typically hepatosplenomegaly (Jmoudiak and Futerman, 
2005).  Type I GD patients also have cytopenia, bone disease and lung disease, and 
type II and III patients also have CNS involvement.  GD is a lysosomal storage 
disease cause by mutations in the GBA gene leading to deficiency of the 
glucocerebrosidase enzyme (Tsuji et al., 1987). 
1.3.6.14. Mitochondrial DNA Depletion 
Mitochondrial DNA Depletion syndrome is a group of disorders characterised by 
reduced copy number of mtDNA in one or more tissues.  It can be caused by biallelic 
mutations in one of several nuclear genes; including DGOUK, POLG, C10orf2, 
MPV17 and RRMB2 (Nogueira et al., 2014).   Patients with DGOUK mutations may 
present with an early-onset multisystem disease including cholestasis, progressive 
liver dysfunction and liver failure, or isolated liver disease later in childhood.  
1.3.6.15. Dubin-Johnson syndrome 
Dubin-Johnson syndrome is a relatively mild condition characterised by conjugated 
hyperbilirubinaemia and darkly stained deposits in an otherwise normal liver.  It is 
caused by biallelic mutations in the ABCC2 gene which encodes the MRP2 protein 
(Wada et al., 1998).  MRP2 (also known as cMOAT) is expressed in the canalicular 
membrane of hepatocytes where is functions as an exporter of conjugated bilirubin.   
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1.3.6.16. Rotor syndrome 
Rotor syndrome (RS) is a disease manifesting as mild conjugated and unconjugated 
bilirubinaemia.  RS is an unusual autosomal recessive condition that requires 
complete loss of function mutations to be present on both alleles of two closely 
located genes; SLCO1B1 and SLCO1B3 (van de Steeg et al., 2012).  These genes 
encode the proteins OATP1B1 and OATP1B3 respectively, which are hepatocyte 
membrane transporters responsible for uptake of bilirubin from sinusoidal blood.  
1.3.6.17. Cholestasis-Lymphedema syndrome 
Cholestasis-Lymphedema syndrome (also known as Aagenaes syndrome) is likely to 
be a genetic condition, with features of neonatal cholestasis and recurring cholestatic 
episodes. So far the gene responsible has not been identified but a region on 
chromosome 15 has been mapped (Bull et al., 2000). 
1.4. Diagnostic genetic testing  
Diagnostic genetics laboratories carry out genetic testing on samples from patients 
suspected of being affected by, or at risk of, or with a family history of, genetic 
disease.  Various molecular or cytogenetic methods might be employed to look for 
specific genetic lesions that might be responsible.  Ideal characteristics for a test to 
be used for diagnostic testing are that it should be accurate, robust, reproducible, 
amenable to up-scaling or automation, allow turnaround targets to be met and be 
cost effective whilst maintaining reasonable standards.  These characteristics can be 
considered in the context of the ACCE framework for the evaluation of genetic tests; 
consisting of Analytical validity, Clinical validity, Clinical utility and Ethical, social and 
legal issues (Grosse and Khoury, 2006). 
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1.4.1. Inheritance patterns and pathogenic mechanisms 
Autosomal recessive genetic conditions are those in which affected individuals 
inherit mutations on both alleles of a gene, and are typically caused by mutations 
that result in absence or reduction in protein or protein function; ‘loss of function’.  
Those individuals with only a single loss of function allele are usually not affected by 
the condition and are often called ‘carriers’.  Autosomal dominant genetic conditions, 
in contrast, are those in which affected individuals have inherited a defective copy of 
a gene from one parent only, and this is sufficient to cause disease.  The mechanism 
of pathogenicity for dominantly inherited conditions varies, and includes ‘gain of 
function’ and ‘dominant negative’ mutations; however loss of function mutations can 
also result in dominant disorders where there is ‘haploinsufficiency’ (T. Strachan, 
2011).  Haploinsufficiency results when one loss of function mutation leads to 
reduced levels of the protein product and this reduction is sufficient to cause the 
symptoms of the disease (T. Strachan, 2011).  Not all individuals with one dominant 
mutation will manifest the disease.  Often ‘dominant’ disorders show variability 
between individuals with mutations in the same gene; observed as variable 
expressivity, reduced penetrance, genetic predisposition effects, etc (T. Strachan, 
2011).  Mutations which have not been inherited from either parent are presumed to 
have occurred in the germline of a parent or during fetal development and are called 
de novo mutations (T. Strachan, 2011).  Other modes of inheritance not discussed 
further include X-linked, mitochondrial and imprinting. 
1.4.2. Types of mutation 
There are a variety of types of mutations known to cause disease in humans and 
include small changes at the nucleotide level (such as base substitutions and 
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deletions, insertions and duplications of small numbers of bases), copy number 
changes (deletions and duplications ranging from a few hundred bases to millions of 
bases) and rearrangements (mutations which are copy number neutral but are 
aberrantly located in the genome and can result in disruption of gene sequences at 
the breakpoints).  Other types of mutation include microsatellite repeat expansion 
mutations and mitochondrial DNA mutations. The vast majority of variation in the 
human genome does not cause disease (T. Strachan, 2011). 
1.4.3. Testing strategy 
In the six genes of interest; NPC1, NPC2, ATP8B1, ABCB11, ABCB4 and 
SLC25A13, there is a large degree of allelic heterogeneity in terms of known 
disease-causing mutations. Variation in any part of a gene can result in loss of 
function alleles; however the vast majority of known disease-causing mutations in 
humans are located within the coding exons and the exon boundaries of the genes 
(T. Strachan, 2011).  Therefore, an efficient testing strategy for these genes is 
mutation scanning of the coding exons and traditionally, this has been done using 
Sanger sequencing; dideoxy-sequencing (Sanger et al., 1977).  Other mutation 
scanning methods are possible (for example high resolution melt curve analysis and 
denaturing high performance liquid chromatography); however the resources 
required were not available for this project and these techniques are not discussed 
further. 
1.4.4. Sanger sequencing 
Over the years since Sanger initially reported this method (Sanger et al., 1977), it 
has been developed to increase throughput and turnaround, utilising several 
commonly used modifications, robotics and sequencing analysis software (Wilson et 
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al., 1990).  Fluorescent capillary Sanger sequencing (FS) has revolutionised 
diagnostic molecular genetics services and become the ‘gold standard’ method, 
however there are two major limitations.  Firstly, costs are high for reagents, 
machinery and staff to carry out the work; it typically costs clinicians hundreds of 
pounds to sequence one gene in their patient, compared with much cheaper 
biochemical tests (De Leeneer et al., 2011).  Secondly, throughput is limited; 
increasing demand for gene sequencing means that many diagnostic genetics 
laboratories are reaching saturation point in their FS capacity (De Leeneer et al., 
2011).  These two factors have a significant impact on the service that a typical 
laboratory can offer patients, for example a neonate presents with a severe but 
undefined phenotype whose management would benefit from a rapid molecular 
diagnosis but requires several genes to be sequenced.  Even such an urgent sample 
might take a few months to be processed.  Another example would be when a 
patient has been given a definite clinical diagnosis of an autosomal recessive 
condition, but only one mutation is identified by the FS test; the second mutation 
might be far into the intron or in the promoter region or indeed in another gene, 
however these are not often screened due to the constraints of finance and capacity.  
There are many further examples of how patient care can be improved by faster, 
cheaper and more extensive sequencing.  When this work began in 2009, alternative 
methods for DNA sequencing other than FS were being considered by diagnostic 
labs. 
1.4.5. Microarray sequencing  
Microarray sequencing (MS) is a technology that has evolved from SNP genotyping 
arrays and array CGH (comparative genome hybridisation) (Hacia, 1999).  DNA 
probes are designed to cover the target regions.  In total, there are eight probes for 
Kirsten McKay Bounford   
32 
 
each base of target DNA on the array, which differ in their central base (A, C, G and 
T, forward and reverse strands).  DNA from the test sample is labelled with a 
fluorescent dye and hybridised to the array.  The array is then washed and scanned 
and the fluorescence measured.  Bioinformatics is then used to interpret the pattern 
of hybridisation at each base and read the DNA sequence. The method relies on the 
principle that the test DNA sequence will hybridise most strongly to the version of the 
probe that is complementary (see example in Figure 1.6).  For heterozygous base 
changes, hybridisation will occur at two probe sites.  In this way, sequencing 
microarrays can detect single nucleotide variation in the heterozygous or 
homozygous state.  Insertions, deletions and duplications are not well detected by 
this technology because the wild-type allele always gives a normal hybridisation 
pattern, and this is especially true for such mutations in the heterozygous state.  
Homozygous mutations of this type may be suspected by regions of low 
hybridisation (deletions) or apparent base substitutions (insertions).  To improve the 
detection of these mutations, extra probes can be added to the design, which are 
complementary to DNA with known insertions and deletions.  
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Figure 1.6: A diagram showing 
the principle involved in 
hybridisation-based sequencing. 
This sketch illustrates how the 
fluorescently tagged sample DNA 
hybridises most strongly to the 
complementary resequencing 
array probe, and this is translated 
into the brightness of the 
fluorescent signal emitted from 
each feature (spot) on the array.  
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1.4.6. Next Generation Sequencing 
The last few years has seen the advent of Next Generation Sequencing (NGS; also 
known as massively parallel sequencing).  This umbrella term encompasses several 
different methods and combinations of technologies from different companies; 
however it generally refers to the significant advancements made in increasing the 
capacity of sequencers and reducing the costs of sequencing per base (Metzker, 
2010).  Within NGS technology, second generation sequencing (SGS) refers to 
technologies which rely on a two-step sequencing (clonal amplification and then 
sequencing) whereas third generation sequencers are sensitive enough that they do 
not require the amplification step, and so are sometimes called Single Molecule 
Sequencers.  As mentioned, SGS techniques have two steps; a PCR step to amplify 
the DNA fragment library, and then a combined sequencing and detection step 
(Metzker, 2010).  Fragment library is a term used to describe the starting DNA that is 
to be sequenced and the production of this will be described later.  454 sequencing 
was the first method to be published and is the method used in this project.  Illumina 
(Solexa) sequencing was next on the market and over-time has become the 
dominant method used for both research and diagnostic sequencing of human DNA.  
Life Technologies’ SOLiD sequencing method was next to be launched but has 
largely failed to compete with the earlier established methods.  Life Technologies 
hoped to regain its place in the DNA sequencing market by taking over Ion Torrent 
and acquiring its promising cheaper technology. These four technologies will be 
discussed in turn and criteria important to diagnostic laboratories are compared in 
Table 1.3.  
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Table 1.3: A comparison of capacity, read length and run time of commercially 
available second generation sequence platforms with Sanger sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
Company Method Machine Capacity Read length Run time 
Applied 
Biosystems 
Sanger 3730xl 
96 samples 
~86kb 
approx. 
Up to 900bps 
60-120 
minutes 
Roche 454 
GS Junior+ 70Mb Up to 700bps 18 hours 
GS FLX+ 700Mb 
Up to 700 
bps 
23 hours 
Illumina Solexa 
MiSeq (v3 
kit) 
3.3-15Gb 75-300bps 21-55 hours 
NextSeq 
(High output 
kit) 
25-120Gb 75-150bps 11-29 hours 
HiSeq 2500 
(High output 
mode) 
128 Gb – 
1Tb 
36-125bps 
29 hours - 6 
days 
Applied 
Biosystems 
SOLiD 5500 W 120Gb 75bps 7 days 
Ion Torrent 
Ion PGM 30Mb-2Gb 200-400bps 3-8 hours 
Ion Proton Up to 10Gb 200 bps 2-4 hours 
Capacity is a measure of the amount of bases sequenced in one run and should 
be divided by the depth of coverage required and the fragment length being 
sequenced, ie 70Mb from a GS Junior run = 100,000 reads of 700bps long at 
minimum 30x coverage = approximately 3,300 PCR fragments per run.  This is not 
directly comparable for Sanger sequencing as each PCR fragment is sequenced 
individually.   
Read length is important for sequence alignment with longer sequencing reads 
being more easily aligned, especially when aligning to the human genome 
reference.   
Run time varies considerably between machines with Ion Torrent being the 
fastest chemistry, this is because it does not rely on capturing light released by 
the reactions, ie post-light chemistry.  Sanger sequencing using the latest 
machines can allow 384-well setup and automated plate loading, however the 
amount of time to sequence a plate is limited by the number of capillaries on the 
machine and remains constant. 
 
Numbers taken from Roche 454, Illumina and Applied Biosystems (Thermofisher) 
websites, June 2016. 
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1.4.6.1. 454 Sequencing 
454 Sequencing uses emulsion PCR for its amplification step followed by 
pyrosequencing in its two platforms; GS FLX and GS Junior (Roche Diagnostics™).  
For the emulsion PCR (emPCR) the fragment library (see 1.4.6.5) is mixed with 
beads, which have DNA sequences complementary to the adaptor sequence 
attached, and a water-and-oil emulsion.  These are mixed in the correct proportion to 
achieve one bead and one DNA molecule in one microreaction (or micelle; see 
Figure 1.7a).  A PCR is carried out to clonally amplify the DNA fragment on the 
surface of the bead (see Figure 1.7a).  The emulsion is broken and the beads are 
isolated and spread out on a picotitre plate so that one bead (with its clonally 
amplified DNA fragments attached) fits into each well on the plate (see Figure 1.7b).  
A massively parallel pyrosequencing reaction is then carried out and detected in 
real-time by the sequencer; nucleotides of known type are added to the plate and if 
incorporated emit light, and no light is emitted if the nucleotide is not incorporated 
(Figure 1.7c).  The sequencer detects which areas of the plate emit light in response 
to addition of which nucleotides and the sequence is built up (Figure 1.7 d).   
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Figure 1.7: A diagram showing the steps involved in 454 sequencing. 
a) emPCR b) beads in picotitre plate c) pyrosequencing reaction d) read is produced 
Images taken from (Metzker, 2010) 
 
 
 
 
 
 
 
 
 
1.4.6.2. Illumina Sequencing 
The strategy utilised by Illumina’s various sequencing platforms involves bridge 
amplification PCR and reversible chain-terminating sequencing (Metzker, 2010).  
Bridge amplification is shown in Figure 1.8.  Then is reversible chain-terminating 
sequencing, which uses four types of fluorescently-tagged chain terminating 
nucleotides (ddNTPs).  A mix of fluorescent nucleotides is washed over the slide, 
one nucleotide is incorporated per DNA fragment, the fluorescence is detected by 
the machine and the fluorescent tag is cleaved off allowing extension from the 3’ end 
possible again.  This process is repeated many times and the nucleotide 
incorporated is identified by the colour emitted from each cluster.   
 
 
a) b) 
c) 
d) 
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1.4.6.3. SOLiD sequencing 
Applied Biosystems (ThermoFisher Scientific, previously Life Technologies) produce 
the SOLiD™ 4 system and the SOLiD™ PI system, which work using the same 
chemistries; emulsion PCR and fluorescent ligation-based sequencing.  The 
emulsion PCR step is very similar to what happens with the Roche system (see 
Figure 1.7a). Later SOLiD machines utilise an alternative to emPCR called ‘template 
walking’ which has been packaged into the Wildfire™ chemistry and offers increased 
speed and automation. 
Beads (with clonally amplified DNA fragments attached) are spread onto a glass 
slide. The sequencing reaction is complicated compared to the other chemistries as 
it requires several reads for each fragment to be overlaid or combined to obtain the 
sequence of the DNA, see Figures 1.9a and b (Metzker, 2010).   
Figure 1.8: A diagram showing the principles of bridge amplification PCR. 
A fragment library is hybridised to a glass slide covered in a ‘lawn’ of adaptor primers 
(blue or green).  DNA extension occurs across the bridge between the two fixed 
adapters (dotted line). Once ligated, the double-stranded DNA is melted into two 
strands, which are each free to fold over to hybridise to another adaptor.  In this way 
clusters of clonally amplified DNA fragments are produced at a high density across the 
glass slide (flow cell).   
Image taken from (Bentley et al., 2008) 
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Figure 1.9: A diagram showing the principles of SOLiD sequencing chemistry. 
a) A sequencing primer is hybridised to the DNA fragment attached to the bead, then 
a set of fluorescently labelled probes are added.  The probes are hybridised to the 
DNA fragment and then ligated (if next to the primer).  Un-ligated primers are washed 
off and the fluorescence is detected across the slide by the machine.  The DNA tail 
and fluorescent tag is cleaved off and the cycle is repeated many times.  In this way, 
two bases at a time are interrogated, with three uninterrogated bases in between.  
The extended primer is removed and a second primer is added, this time n-1 for the 
adaptor sequence, and the whole process is repeated again.  This is done for a total 
of 5 different primer starting points so that each base is interrogated twice.   
 
Images taken from (Valouev et al., 2008). 
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1.4.6.4. Ion Torrent Sequencing 
Ion Torrent sequencing marketed by Applied Biosystems (ThermoFisher Scientific, 
previously Life Technologies) also uses emulsion PCR as a first step (see Figure 
1.7a) but the sequencing technology is different again (see Figure 1.10). 
 
 
 
 
 
 
 
 
 
b) The fluorescent label is red, green, 
yellow or blue and is determined by the 
first two bases (3’end) of the probe. The 
probe consists of two interrogating 
bases, followed by 3 degenerate bases, 
a non-complementary DNA tail and 
fluorescent label.  The individual reads 
are then overlaid or combined by the 
software to determine the DNA 
sequence using the 2-base decoding 
algorithm.  
Images taken from (Valouev et al., 
2008). 
 
Figure 1.10: A diagram showing the steps involved in Ion Torrent sequencing. 
a) The sequencing reactions are carried out on a microchip containing a high density 
array of wells.  In each well, the incorporation of a nucleotide to a growing DNA 
strand fixed to a bead releases a hydrogen ion (H+).  
b) This change in pH is detected by a sensor below the well.   
c) One type of base is flooded onto the chip and the change in pH for each well is 
measured before the process is repeated with another type of base.  In this way the 
DNA sequence in each well is recorded.  
Images taken from (Rothberg et al., 2011). 
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1.4.6.5. Fragment library preparation 
Fragment library preparation (FLP) is the DNA template preparation stage which is 
used for all of the SGS technologies.  Sequencing of the whole genome or the whole 
transcriptome is perversely a more straightforward workflow that that required for 
targeted sequencing.  The whole gDNA or cDNA sample is fragmented to the 
required length for PCR amplification and sequencing, and then adapter sequences 
added on to the fragments to allow binding to beads of plates. Alternatively, 
particular regions of the genome may be targeted or selected for sequencing.  The 
strategy employed for this can vary and factors influencing the choice include the 
size of the target to be amplified, the number of samples to be tested in a batch, the 
time for the process, the scope for automation and the cost (see 1.4.6.6).   
1.4.6.6. Target enrichment methods 
Traditionally in diagnostic genetics, DNA sequencing is targeted to regions of interest 
(ROI), which is the gene or genes known to be involved in a particular phenotype or 
syndrome, most usually by polymerase chain reaction (PCR).  Straightforward PCR 
is possible for SGS technologies, however thousands or more individual PCR 
reactions are required to fill one such run because of the machines’ enormous 
capacities.  To minimise the number of PCRs performed long PCR or multiplex PCR 
can be used.  Other strategies are available from commercial companies that aim to 
solve this ‘PCR bottleneck’ and are collectively known as target enrichment methods 
(TEM). TEMs that have been developed are based upon PCR, hybridisation or a 
combination of both strategies (Mamanova et al., 2010).  
Array capture technology is available from commercial companies including Agilent 
(SureSelect™ products) and Roche Nimblegen (SeqEZ™ products).  Long 
oligonucleotide probes complementary to the regions of interest are synthesised 
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attached to a glass slide.  These probes are then used to hybridise to, and draw out, 
the target regions from a solution containing fragmented sample DNA.  This can 
either be performed in solution or on the glass slide.  
Automated PCR strategies have been developed by Fluidigm Corporation and 
RainDance Technologies.  Fluidigm produce an array system that allows the setup of 
48 different PCRs for 48 different samples, a total of 2,304 PCR reactions, in 
nanolitre volumes.  This open platform allows incorporation of adaptor sequences 
and molecular barcodes, and is flexible in terms of which sequences are to be 
amplified.  RainDance Technologies utilise the ability to produce thermodynamically 
stable microdroplets.  They synthesise a custom designed primer library covering the 
target regions, this is a pool of primer sets in a tube, each microdroplet containing 
one set.  They also produce a machine onto which the primer library and the 
samples are loaded and the PCR reactions are carried out.  The machine produces 
microdroplets from the sample DNA and then fuses them with primer microdroplets, 
creating picolitre sized PCR reactions.  This technology allows the production of up 
to 2 million PCR reactions and amplification using up to 20,000 different primers 
sets.   
Technologies which combine PCR and hybridisation include Haloplex™ (Agilent 
Technologies) and TruSeq™ and TruSignt™ Rapid Capture methods (both by 
Illumina). Figure 1.11 illustrates the steps involved in these processes.   
All TEMs involve selection of specific regions of DNA and therefore bias of selection 
towards wild type sequences is always possible.  PCR in particular is sensitive to 
sequence changes under the primer binding sites, and similarly Haloplex™ is 
sensitive to sequence changes within restriction enzyme cleavage sites.  The use of 
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long probes and multiple probes can help to overcome some of these issues.
Figure 1.11: (next page) Target enrichment methods involving PCR and hybridisation. 
a) TruSeq™.  Probes targeted to the regions of interest (ROI) are hybridised with 
genomic DNA.  Extension of the bases between the probes, and ligation, occurs if both 
probes are hybridised.  PCR using primers complementary to the probes is then used to 
amplify the ROIs.  
b) TruSight™ Rapid Capture.  Transposons are used to randomly fragment gDNA and 
add primer sequences.  PCR is used to amplify all of the DNA fragments.  Biotinylated 
probes are then used to pull out the fragments containing the ROIs using streptavidin 
coated magnetic beads.  
c) Haloplex™.  gDNA is digested using restriction enzymes.  Biotinylated probes 
designed to be complementary to the digested ends of the ROIs are added.  
Hybridisation with the probes causes the DNA fragments to circularise, and then ligation 
occurs.  Streptavidin coated magnetic beads are used to select the ROIs.  PCR primers 
are added allowing amplification of the selected DNA fragments. 
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1.4.6.7. Molecular barcodes 
Many applications of SGS require the combining of several samples onto one 
sequencing run and therefore require the addition of molecular barcodes.  Molecular 
barcodes are also known as molecular indices, tags or MIDs.  These are short 
stretches of unique DNA sequence which are incorporated into the sample fragment 
library, either before, during or after the TEM. Barcodes are usually incorporated 
using PCR or ligation strategies.  These barcodes are recognised by computer 
algorithms early in the bioinformatics process and allow reads, and therefore results, 
from individual samples to be separated out (Oliver et al., 2015). 
1.4.6.8. Data processing 
Data is outputted from NGS machines in various forms however the most basic and 
useful are the .fasta and .fastq files.  These files contain hundreds of thousands to 
billions of reads of DNA sequence (.fasta) and with associated quality scores (.fastq).  
These files can then be processed in order to identify sequence variants in the 
samples and the steps are summarised in Figure 1.12.  Usually reads of poor quality 
are trimmed to improve quality or discarded.  The remaining good quality reads are 
aligned against a reference sequence; this may be for individual genes or the entire 
human genome.  Good alignment is crucial to avoid mutant reads being mapped 
incorrectly and therefore missed.  The aligned reads are then interrogated to identify 
bases which differ from the reference.  Usually a minimum threshold is required in 
order to confidently call variants, as there is usually a low level of miscalled bases 
across the sequencing reads. Annotation of the variant calls is required in order to 
determine where the calls are in relation to genes and mRNA transcripts.  A variant 
call file is produced called .vcf which is an annotated list of all the sequence changes 
called.  Filtering strategies may be employed to the .vcf at this stage and may 
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include, for example, only listing variants within genes of interest, or only listing 
variants resulting in severe consequences to the protein. 
These processes can be carried out as individual steps or sequentially in what is 
known as a bioinformatics pipeline (Oliver et al., 2015).  Computer software options 
are available which can perform some or all of these steps (e.g. SoftGenetics 
NextGene).   
 
 
 
 
 
 
 
1.4.7. Interpretation of sequence variants 
There is variation in DNA sequence of humans compared to the reference human 
genome sequence, and much of this variation is ‘benign’; that is it has no adverse 
impact on the health or fitness of those individuals.  Therefore, it cannot be 
presumed that any sequence variant identified when testing a patient is definitely 
causative of their disease; ‘pathogenic’.  The first step to ascertaining the relevance 
of a sequence variant is to predict the effect on the protein product of the gene.   
1.4.7.1. Categories of sequence variant 
Variants that lead to premature termination codons (PTCs) are usually presumed to 
be pathogenic, because mRNA transcripts containing PTCs are subject to nonsense-
.fasta .fastq 
Alignment 
Variant Calling 
Annotation 
Filtering 
.vcf 
Figure 1.12: The basic steps involved in a 
bioinformatics pipeline for the processing 
of data from next generation sequencers. 
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mediated decay or NMD (Miller and Pearce, 2014).  These would be nonsense, 
frameshift and conserved splice-site mutations (nucleotides at positions -2, -1, +1 
and +2 from the exon).  Exceptions to this are PTCs which occur in the last exon or 
the last 30 bases of the penultimate exon, as these are likely to avoid the nonsense-
mediated decay machinery (Miller and Pearce, 2014).  In addition, the destruction of 
a splice-site would usually lead to a frameshift and therefore a PTC, however care 
with interpretation should be taken when there is a possibility of in-frame deletions or 
intron inclusions, especially when these consist of small numbers of nucleotides.  In 
addition to PTCs, sequence variants that severely disrupt the gene would also be 
predicted to be pathogenic, for example whole exon deletions. 
The predicted effect of missense changes are much more difficult to predict.  Some 
missenses change crucial amino acids that are important for ligand binding or protein 
structure and are thus pathogenic, whereas others have no effect on the production 
and function of the protein and are thus benign.  Similarly, silent variants (or non-
synonymous variants) are not predicted to change the amino acid sequence but can 
affect the processing of the mRNA, therefore again these may be pathogenic or 
benign, depending upon their position in the gene.  When sequence variants like 
these are detected in a patient, it is important to gather as much information as 
available to determine the clinical significance of the variant.  Guidelines have been 
published by the Association for Clinical Genetic Science in the UK and the 
American College of Medical Genetics and Genomics in order to standardise the 
classification of sequence variants (Deans et al., 2015; Richards et al., 2015). 
1.4.7.2. Methods for classification 
Firstly, an important part of the classification process is to determine whether a 
sequence variant has been identified before, and then to establish whether this was 
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seen in a patient or in a healthy population. This can be done using literature and 
database searching.  If identified in a patient population, it is important to ascertain 
whether any evidence other than co-occurrence with disease has been found.  This 
evidence might be segregation with disease in a large family, mRNA, protein or 
functional studies to look at the downstream effects of the variant, or multiple reports 
in the literature by several different groups.  In general, absence of a variant in a 
healthy population is evidence for pathogenicity; however care must be taken 
regarding the size and ethnic make-up of the healthy population tested.  Datasets 
such as 1000Genomes and Exome Variant Server provide good sources of ‘normal’ 
variation however; absence of a variant from these datasets does not prove 
pathogenicity, as the variant may just be very rare, or even unique.  
Secondly, in silico tools exist that can provide some information for classification of 
sequence variants.  Tools to evaluate missense changes by analysing the 
conservation of nucleotides and amino acids between species, the physiochemical 
properties of the amino acids involved and the structure of the protein domains 
(Williams, 2012). The most commonly used are SIFT, PolyPhen, AlignGVGD and 
MutationTaster.  The results produced can only be used as a guide as there are 
examples of well-known pathogenic missense changes and benign polymorphisms 
that give erroneous results using these tools.  
 There are also splicing prediction tools that can measure the effect of exonic and 
intronic changes on the strength of surrounding splice sites.  Splicing tools have 
been shown to have a high degree of accuracy when used to assess the effect of 
variants on wild-type splice-sites in positions between +3 to +7 and -3 to at least -10 
from the exon (Hellen, 2009), and similarly can predict the creation of alternative 
splice-sites at any position.   
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Thirdly, other circumstantial evidence might exist that can shed light on a particular 
variant.  Examples might be a different change at the same amino acid position as 
the missense in question which has been causally linked to the disease. Another 
example could be a missense occurring in a particular mutation hotspot region in a 
gene, or within a known functional domain of the protein.  A good example would be 
in Alport syndrome where mutations involving the glycine residues of the 
collagenous domain of the type α5 chain collagen subunit are always pathogenic 
(Hertz, 2009). 
 
1.5. Aims of the thesis 
 To investigate new sequencing methods for the diagnosis of genetic causes 
of cholestasis 
 To determine to incidence of known genetic disorders in infants presenting 
with cholestasis 
 To determine the mutation spectrum in the ATP8B1, ABCB11, ABCB4, NPC1, 
NPC2 and SLC25A13 genes in the UK population 
 To investigate genotype-phenotype correlations in these genes, especially 
regarding novel genetic findings. 
  
Kirsten McKay Bounford   
49 
 
Chapter 2 – 
MATERIALS AND METHODS 
2. Materials 
2.1.1. Patient Material 
The patient materials varied so are described within each results chapter.  All 
references to blood can be assumed to be venous blood in EDTA tubes. 
2.1.2. DNA extraction kits 
Autopure extractions and Puregene manual extractions; RBC Lysis Solution, Cell 
Lysis Solution, Precipitation Solution, DNA Hydration Solution (all Gentra Puregene 
Bloodkit components from Qiagen). 
QiaSymphony DSP DNA Midi kit (96) (Cat: 937255 Qiagen) 
Phenol chloroform reagents; Phenol solution saturated with 100mM Tris-HCl 
(pH8.0), Phenol/Chloroform 5:1 solution, Chloroform/Isoamyl alcohol 24:1 mix,  
100% Ethanol, 70% Ethanol, 3% Virkon, Salt/EDTA solution (4.39g of NaCl, and 
50mls of 0.5M EDTA (pH 7.5) made up to 1 litre with distilled water), Proteinase K 
solution (10mg/ml), 10x Lysis buffer (41.45g ammonium chloride (NH4CL), 4.6g 
potassium hydrogen carbonate (KHCO3) and 20ml 0.5M EDTA (pH 7.5) made up to 
1 litre with distilled water). 
Distilled water (pure filtered water from Elga Veolia Water filtration system) 
100% Isopropanol   
70% Ethanol  
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2.1.3. PCR solutions 
MegaMix PCR mastermix (Cat: 2MM-1 Microzone) 
BioMix™ Red PCR mastermix (Cat: BIO-25006 Bioline) 
Long PCR kit reagents; Long PCR Enzyme Mix (5 U/µL) and 10X Long PCR Buffer 
with 15 mM MgCl2 (Fermentas). 
FastStart HiFidelity PCR kit reagents; FastStart High Fidelity Enzyme Blend, (5 U/µl), 
FastStart High Fidelity Reaction Buffer 10x with 18 mM MgCl2 (Roche). 
dNTP 100mM stock (Cat: U1330 Promega) 
1x Tris EDTA buffer (10nM Tris-HCL (pH 8.0) and 0.1 mM EDTA; ThermoFisher 
Scientific Cat: 12090-015). 
PCR grade sterile water (Sigma-Aldrich Cat: 03315959001)  
PCR primers are described in 2.1.12. 
2.1.4. MLPA reagents 
MLPA probe sets for NPC1 and NPC2 (P193-A2) and for ABCB4 (P109-B1) 
(MRCHolland) 
SALSA® MLPA® reagents (MRCHolland). 
Mineral oil (Cat: M5904 Sigma) 
Hi-Di™ Formamide (ThermoFisher Scientific Cat: 4311320) 
GeneScan™ 600 LIZ® dye Size Standard v2.0 (Cat:4408399) 
2.1.5. FS reagents 
ExoSap IT (GE Healthcare) 
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BigDye 3.1 (Life Technologies Inc) 
1x BigDye buffer (Life Technologies Inc) 
Agencourt CleanSEQ magnetic beads (Beckman Coulter Inc) 
2.1.6. Gel electrophoresis 
Agarose Multipurpose (Cat:  BIO-41025 Bioline) 
Orange G loading dye (Sigma) 
10 mg/ml ethidium bromide solution made from powdered stock (Cat: E8751 Sigma) 
10x Tris borate EDTA buffer (Severn Biotech) 
1kb plus DNA ladder (Invitrogen) 
2.1.7. Capiliary electrophoresis 
FS; DNA analyzer 3730xl (Life Technologies Inc) 
MLPA products; DNA analyser 3130xl (Life Technologies Inc) 
2.1.8. Picogreen reagents 
100ng/ul λ standard DNA, 20X TE buffer and PicoGreen reagent from Quant-iT™ 
PicoGreen® dsDNA Assay Kit (Cat: P7589 Invitrogen) 
2.1.9. MS reagents 
All kits provided by Affymetrix for use with GeneChip® Resequencing chips.  
In addition;  
5 M Tetramethylammonium chloride solution (TMAC; Sigma) 
Tween-20 (10% solution): Pierce, P/N 28320 
Acetylated Bovine Serum Albumin (BSA) solution conc. 50μg/μL (Invitrogen)  
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Herring sperm DNA (Promega Corp) 
Tris-HCl, 1 M, pH 7.8 (Sigma) 
Molecular Biology Grade Water (Fisher Bioreagents BP2819-10) 
SAPE (Molecular Probes) 
Anti-streptavidin antibody (goat), biotinylated (Vector Labs) 
20X SSPE solution (3 M NaCl, 0.2M NaH2 PO4, 0.02 M EDTA) (Cambrex) 
Denhardt’s Solution, 50X concentrate (Sigma) 
MES hydrate (Sigma-Aldrich) 
MES Sodium Salt (Sigma-Aldrich) 
5 M NaCl, RNase-free, DNase-free (Ambion) 
2.1.10. NGS kits 
All kits provided by Roche 454 for use with the GS Junior sequencer. 
Sodium hydroxide solution 50% (Merck Millipore Cat: 158793). 
2.1.11. M13 primer tags 
Forward primer tag sequence TGTAAAACGACGGCCAGT 
Reverse primer tag sequence CAGGAAACAGCTATGACC 
2.1.12. PCR primers 
Primers were Invitrogen Custom DNA Oligos synthesised by Thermo Fisher 
Scientific.  The standard synthesis was 50 nanomoles and they were rehydrated in 
Tris EDTA buffer to a stock concentration of 200 nanograms per micolitre. 
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2.1.12.1. PCR primer sequences 
Table 2.1: PCR primer sequences. 
Note these sequences include the M13 universal sequences. 
 
Gene Exon Direction Primer sequences Other Info 
ATP8B1 01 
F TGTAAAACGACGGCCAGTGCATGCAGGCAGTATTCAAC Sanger + NGS 
R CAGGAAACAGCTATGACCAGACCGATCATCTTTGGCAC Sanger + NGS 
ATP8B1 02 
F TGTAAAACGACGGCCAGTCAACATTTGAATCTGGGGAAG Sanger + NGS 
R CAGGAAACAGCTATGACCAGGCAGGTGTAGCATGAAGG Sanger + NGS 
ATP8B1 03 
F TGTAAAACGACGGCCAGTCTGTAAGCTGTGGGACTTGTG Sanger + NGS 
R CAGGAAACAGCTATGACCTGTGTCTACAGCTTAAATGTTATCGAG Sanger + NGS 
ATP8B1 04_05 
F TGTAAAACGACGGCCAGTTTAGCAAGCTTAGAATTAGCAATAAG Sanger only 
R CAGGAAACAGCTATGACCTCTGAATGTGTTTCTAGGCAGAG Sanger only 
ATP8B1 04 
F TGTAAAACGACGGCCAGTTGATGACGGTGATGAGACTTG NGS only 
R CAGGAAACAGCTATGACCGAAGGAAGATGGGGAAATGC NGS only 
ATP8B1 05 
F TGTAAAACGACGGCCAGTAATCAAAGACCTGGTGGACG NGS only 
R CAGGAAACAGCTATGACCGAACCTGGGAGGTGGAAG NGS only 
ATP8B1 06_07 
F TGTAAAACGACGGCCAGTAAAGAATAGTAATTCCCTTGCCTG Sanger + NGS 
R CAGGAAACAGCTATGACCTTCAGTGGAATGAATGTGCC Sanger + NGS 
ATP8B1 08_09 
F TGTAAAACGACGGCCAGTTCATGTCCAGGTATGGCTAATG Sanger only 
R CAGGAAACAGCTATGACCGACAGAAAAGCAATCCCCTC Sanger + NGS 
ATP8B1 08 
F TGTAAAACGACGGCCAGTCCAAACCTGAAGTTCCAAGG NGS only 
R CAGGAAACAGCTATGACCGGGTTCTTCACATTCAATAAAACC NGS only 
ATP8B1 09 F TGTAAAACGACGGCCAGTTTTTAGTTGCTTGGTTCAATTCC NGS only 
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ATP8B1 10 
F TGTAAAACGACGGCCAGTAGGCGTAAGCCACCATGC Sanger + NGS 
R CAGGAAACAGCTATGACCTTCCACCTAAAGAGGTAAGATTTTG Sanger + NGS 
ATP8B1 11 
F TGTAAAACGACGGCCAGTGAAATGCAAGAGGTTGGAAATC Sanger + NGS 
R CAGGAAACAGCTATGACCAAATGAAGGCACTATGTTGGG Sanger + NGS 
ATP8B1 12 
F TGTAAAACGACGGCCAGTTCTCTACTACTTGCCACTCGTATCC Sanger + NGS 
R CAGGAAACAGCTATGACCAGTAATGACCTGCACACGGC Sanger + NGS 
ATP8B1 13 
F TGTAAAACGACGGCCAGTAGCAAAGCCAGGTAAGGAGG Sanger only 
R CAGGAAACAGCTATGACCTGCTGGGACCCTGACATC Sanger only 
ATP8B1 13 
F TGTAAAACGACGGCCAGTAGACCAGGGGTCATCTAACG NGS only 
R CAGGAAACAGCTATGACCCCAAGTCTCCAAGCCAAGG NGS only 
ATP8B1 14 
F TGTAAAACGACGGCCAGTGAAAAGTTCATGTCATTTGTTAAGTC Sanger + NGS 
R CAGGAAACAGCTATGACCCCATAAGCAGGAGTTACCTGG Sanger + NGS 
ATP8B1 15 
F TGTAAAACGACGGCCAGTGGCCTCAACAATGAGCTCTG Sanger + NGS 
R CAGGAAACAGCTATGACCTCAATACAATGGGCACAAGC Sanger + NGS 
ATP8B1 16 
F TGTAAAACGACGGCCAGTTCTAGAGGAACTGATGGTTTTAAGC Sanger only 
R CAGGAAACAGCTATGACCTATCCCAGGAAGTCAGTGGC Sanger only 
ATP8B1 16 
F TGTAAAACGACGGCCAGTTGGACAACAGAGCAAGACCC NGS only 
R CAGGAAACAGCTATGACCGGTCAGCAGTTAACATACAGCTTTC NGS only 
ATP8B1 17 
F TGTAAAACGACGGCCAGTTCAAAGTAAAATTTCAGACTTGATCC Sanger + NGS 
R CAGGAAACAGCTATGACCTCTTCCATTGTGCCAGTGTC Sanger + NGS 
ATP8B1 18 
F TGTAAAACGACGGCCAGTAGGAGAGCAGCAACCAGG Sanger only 
R CAGGAAACAGCTATGACCTCATCTTGGGCAAAGGAAAC Sanger only 
ATP8B1 19 
F TGTAAAACGACGGCCAGTCTAGGCAGTGGGAGTGAGATG Sanger + NGS 
R CAGGAAACAGCTATGACCTCTTCTACAGACAGTCTTGCATTTG Sanger only 
 ATP8B1 19 R CAGGAAACAGCTATGACCAAGTGACACATCGTAACCCC NGS only 
ATP8B1 20 
F TGTAAAACGACGGCCAGTAAAGTTATCTCAGAGTCAAGGGC Sanger + NGS 
R CAGGAAACAGCTATGACCCATCTAAAAGTGGCTCCAAATG Sanger + NGS 
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ATP8B1 21 
F TGTAAAACGACGGCCAGTCTTGGGAATGGTACTCCTGG Sanger + NGS 
R CAGGAAACAGCTATGACCCATTCCAGCCATTTCTCCTC Sanger + NGS 
 ATP8B1 21A R CAGGAAACAGCTATGACCACCATGGCCTTCTGCTTG NGS only 
ATP8B1 21B F TGTAAAACGACGGCCAGTAAGAAAGACGGATGCGGAC NGS only 
ATP8B1 22 
F TGTAAAACGACGGCCAGTGATGTTTTGCCTCACAATCG Sanger + NGS 
R CAGGAAACAGCTATGACCCTGTAAGGAGACACAGCCCC Sanger + NGS 
ATP8B1 23 
F TGTAAAACGACGGCCAGTGCTAACTAGGCTGGCATGTG Sanger only 
R CAGGAAACAGCTATGACCTTGAAACGTTTGCTTGGGAC Sanger only 
ATP8B1 23 
F TGTAAAACGACGGCCAGTGCTTAAGGCCAGGAGTTCG NGS only 
R CAGGAAACAGCTATGACCGACCCTTGATGCCTGACAAC NGS only 
ATP8B1 24 
F TGTAAAACGACGGCCAGTAACATATCTCTGACTGCTTTGACC Sanger + NGS 
R CAGGAAACAGCTATGACCGTGCAGTGGGAGTCAGGTG Sanger + NGS 
ATP8B1 25 
F TGTAAAACGACGGCCAGTCAAGCCACATCATGCCTAAC Sanger + NGS 
R CAGGAAACAGCTATGACCCACTGTGCCCAGCCATTC Sanger + NGS 
ATP8B1 26 
F TGTAAAACGACGGCCAGTCCACACCTGGCGAAATATTAAC Sanger + NGS 
R CAGGAAACAGCTATGACCGAAACGCTTTGGTTTCTGTG Sanger + NGS 
ATP8B1 27 
F TGTAAAACGACGGCCAGTCCTCCTCCCTGGTGTGG Sanger + NGS 
R CAGGAAACAGCTATGACCCACACACACAAAGTCCTGAGAG Sanger + NGS 
ABCB11 02 
F TGTAAAACGACGGCCAGTCAAATTGTTCTTTCGTTTGGC Sanger + NGS 
R CAGGAAACAGCTATGACCTGCTCCTTGAAACTTGACCAG Sanger + NGS 
ABCB11 03 
F TGTAAAACGACGGCCAGTTGAGCAGGAAGAAAGAAAAGG Sanger only;  
R CAGGAAACAGCTATGACCCCTAGAAGGGATATTCCAAAAGG Sanger only;   
ABCB11 04 
F TGTAAAACGACGGCCAGTGCCAGTGGGGATTTTCTTTC Sanger only 
R CAGGAAACAGCTATGACCAACACTCCCCTCATGATCTAAAC Sanger only 
ABCB11 04 
F TGTAAAACGACGGCCAGTAGGTTTGGCCAGAATTTTCC NGS only 
R CAGGAAACAGCTATGACCGGATAGGATTTGTATGCTTTATGAGC NGS only 
ABCB11 05 F TGTAAAACGACGGCCAGTAGTCCTCCTACCTCTCCTGC Sanger + NGS 
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R CAGGAAACAGCTATGACCTCAGCCAGTAAAATCCCCTC Sanger + NGS 
ABCB11 06 
F TGTAAAACGACGGCCAGTAATCTCTGGTGGCTTGATCC Sanger only 
R CAGGAAACAGCTATGACCGTGGCAACACATTGCATCTC Sanger only  
ABCB11 07 
F TGTAAAACGACGGCCAGTCCCCTTTTCTCAACTGTTGTATTG Sanger + NGS 
R CAGGAAACAGCTATGACCAATTTAGAAACAAGGGTTTTATTATCC Sanger + NGS 
ABCB11 08 
F TGTAAAACGACGGCCAGTGAGAGATGGGAATGTTTAAAAGG Sanger + NGS 
R CAGGAAACAGCTATGACCTCAGGAAAAGGGACTCAAGC Sanger + NGS 
ABCB11 09 
F TGTAAAACGACGGCCAGTGACAGACTGACTTACCTAATTTCTTGG Sanger + NGS 
R CAGGAAACAGCTATGACCCCGCTTTGCACAAACTGAG Sanger + NGS 
ABCB11 10 
F TGTAAAACGACGGCCAGTGTAAAACCACTGCATCACGG Sanger + NGS 
R CAGGAAACAGCTATGACCCCTGAAGGCACCAAAGTAATAAAC Sanger + NGS 
ABCB11 11 
F TGTAAAACGACGGCCAGTTGCGTTAACATGGAAGACCC Sanger + NGS 
R CAGGAAACAGCTATGACCGAGTTCATTCTGTGCCCCAC Sanger + NGS 
ABCB11 12 
F TGTAAAACGACGGCCAGTGCAGAGATACGCCAAAGATG Sanger + NGS 
R CAGGAAACAGCTATGACCGGAAACAGAGTCAGGCTTCAG Sanger + NGS 
ABCB11 13 
F TGTAAAACGACGGCCAGTAAGCATCTGCACCTGTAGCC Sanger + NGS 
R CAGGAAACAGCTATGACCCTGCCATTTGCACTTTACTG Sanger + NGS 
ABCB11 14 
F TGTAAAACGACGGCCAGTTGCCCATTGGTCAAGTATG Sanger only 
R CAGGAAACAGCTATGACCCTAAAACATGGCTTAAGAATTTAATG Sanger only 
ABCB11 14A 
F TGTAAAACGACGGCCAGTCCCATTGGTCAAGTATGAC NGS only 
R CAGGAAACAGCTATGACCAAGTTGTAGGCATTGGCCTC NGS only 
ABCB11 14B 
F TGTAAAACGACGGCCAGTTGGCTTAGAGATCAGATTGGG NGS only 
R CAGGAAACAGCTATGACCAATTTAATGACTTGGGAATCATAC NGS only 
ABCB11 15 
F TGTAAAACGACGGCCAGTTTATAGTGGATCACTGTCAGAAGC Sanger + NGS 
R CAGGAAACAGCTATGACCAGCAGCACAAGCATTTCCAC Sanger + NGS 
ABCB11 16 
F TGTAAAACGACGGCCAGTTGATGCAAAGGTCAGTGTCAG Sanger + NGS 
R CAGGAAACAGCTATGACCCATAGAAAACCGTAAAGCACTATAGAC Sanger + NGS 
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ABCB11 17 
F TGTAAAACGACGGCCAGTGTAAAGAATTCTACTTGGATATGGTTC Sanger only 
R CAGGAAACAGCTATGACCCAGAGTTTCCTTGTTGTACCTGAG Sanger + NGS 
ABCB11 17 F TGTAAAACGACGGCCAGTGAATGTTTTGGCATTTGACATAG NGS only 
ABCB11 18 
F TGTAAAACGACGGCCAGTACACCAGTTGATCCTGCTCC Sanger only 
R CAGGAAACAGCTATGACCAAAGGGTACCCAACAGTCCC Sanger only 
ABCB11 18 
F TGTAAAACGACGGCCAGTCCATGTGACCTACCAAACATTTC NGS only 
R CAGGAAACAGCTATGACCTTTTAGTCTGACTTGAAACACTGC NGS only 
ABCB11 19 
F TGTAAAACGACGGCCAGTTGTGAATGCCAAAGGATCTG Sanger + NGS 
R CAGGAAACAGCTATGACCCATGAAAACAAAGAGCGGAC Sanger + NGS 
ABCB11 20_21 
F TGTAAAACGACGGCCAGTCCCACCAGAATGATACATTTCC Sanger only 
R CAGGAAACAGCTATGACCATCCCACTGGTCCCTATTCC Sanger + NGS 
ABCB11 20 
F TGTAAAACGACGGCCAGTAGGGTTCACTCTTGGTGTTG NGS only 
R CAGGAAACAGCTATGACCAGGAGCTCCCCAGATTTAGC NGS only 
ABCB11 21 F TGTAAAACGACGGCCAGTTCTTTTCACCCAATTTCTACAGG NGS only 
ABCB11 22 
F TGTAAAACGACGGCCAGTTGGTAATTGGTAAAAGCGACTG Sanger only  
R CAGGAAACAGCTATGACCGGCTGACAGCTTCCTTCAGT Sanger only   
ABCB11 23 
F TGTAAAACGACGGCCAGTGCCACTGAAATGTCACGAAAG Sanger + NGS 
R CAGGAAACAGCTATGACCCAGAACCAGGCTATTCCTTCC Sanger + NGS 
ABCB11 24 
F TGTAAAACGACGGCCAGTATCACACCAACCACGCC Sanger only 
R CAGGAAACAGCTATGACCCAACCTTACCCCTCATCAATAC Sanger only 
ABCB11 24 
F TGTAAAACGACGGCCAGTTCTGCCTTCAGGTCATCACA NGS only 
R CAGGAAACAGCTATGACCCCCTGTGTCCATGTGTTCTG NGS only 
ABCB11 25 
F TGTAAAACGACGGCCAGTAAACTCAAGATTTAGGTGTGTTTTC Sanger + NGS 
R CAGGAAACAGCTATGACCAGGGGTTGGAAATACTCTGC Sanger + NGS 
ABCB11 26 
F TGTAAAACGACGGCCAGTAAGCAAACCAAATGTCCTGC Sanger + NGS 
R CAGGAAACAGCTATGACCTGCTCAACCTGTACACTCTGG Sanger + NGS 
ABCB11 27 F TGTAAAACGACGGCCAGTGAGTTCAGTACAGCACAGGAGC Sanger + NGS 
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R CAGGAAACAGCTATGACCTTGAAAATAGTGCCATTTTATTAAGG Sanger + NGS 
ABCB11 28 
F TGTAAAACGACGGCCAGTTTGTTATTCAGGTCGTGTTAACTG Sanger only 
R CAGGAAACAGCTATGACCTGGTGGCTGAGCTGCCACTTG Sanger only;   
ABCB4 02 
F TGTAAAACGACGGCCAGTCTGGCCTCGAAGGGAGAC Sanger + NGS 
R CAGGAAACAGCTATGACCAAGGGTGAACTTAGTCCTGCTG Sanger + NGS 
ABCB4 03 
F TGTAAAACGACGGCCAGTATTTTGTGAACATCACTCTTATATTTG Sanger + NGS 
R CAGGAAACAGCTATGACCGGATTACAAGTATGAGTCAGCTCG Sanger + NGS 
ABCB4 04 
F TGTAAAACGACGGCCAGTTGAAGGCCTCCTTTTCTAAGAC Sanger + NGS 
R CAGGAAACAGCTATGACCAATGAATAGCAAAATCAACTCCC Sanger + NGS 
ABCB4 05 
F TGTAAAACGACGGCCAGTACTTAACAATAGCATCTTCTAGCTTTC Sanger + NGS 
R CAGGAAACAGCTATGACCTGGGTAAAGAGTACACGTTATTTG Sanger + NGS 
ABCB4 06 
F TGTAAAACGACGGCCAGTCTGAGATGGTGCCACTGC Sanger + NGS 
R CAGGAAACAGCTATGACCTTTCCTTGACATATTTTCACACAG Sanger + NGS 
ABCB4 07 
F TGTAAAACGACGGCCAGTTTTGTTGGATGTCTACTTCATCTTTC Sanger + NGS 
R CAGGAAACAGCTATGACCGAACAGGTACAAGTACGAGACTTCTG Sanger + NGS 
ABCB4 08 
F TGTAAAACGACGGCCAGTAAAGGAGAGGGTTTGGGAAG Sanger + NGS 
R CAGGAAACAGCTATGACCGGGTTAATATTAGGAAAGGGAAGG Sanger + NGS 
ABCB4 09 
F TGTAAAACGACGGCCAGTGTGTGACTCGGACTATGGATTG Sanger + NGS 
R CAGGAAACAGCTATGACCGCGATATCAAAGAAAAGAGAAGG Sanger + NGS 
ABCB4 10 
F 
TGTAAAACGACGGCCAGTGGATAAACCTAAACTTAATCCTTTATGT
A Sanger + NGS 
R CAGGAAACAGCTATGACCAAAAATATGCAAACTAAAGCCAGA Sanger + NGS 
ABCB4 11_12 
F TGTAAAACGACGGCCAGTGATTGTGACATTCCAGGTCC Sanger + NGS 
R CAGGAAACAGCTATGACCTTACCAAAACTGGATTCACACG Sanger + NGS 
    R CAGGAAACAGCTATGACCCCCCAAAGGAAAAGGCAC NGS only 
ABCB4 12 F TGTAAAACGACGGCCAGTTTATGTGCCTTTTCCTTTGG NGS only 
ABCB4 13 F TGTAAAACGACGGCCAGTTTCTTGCATATTGCTGTTTATTTC Sanger only 
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R CAGGAAACAGCTATGACCCAGGGGACTTATCTAGCAAAGTTGGAC Sanger only 
ABCB4 13 
F TGTAAAACGACGGCCAGTTGAATGGTCCTGATACTTCAGC NGS only 
R CAGGAAACAGCTATGACCCAAAGTTGGACAATCTTGCATC NGS only 
ABCB4 14 
F TGTAAAACGACGGCCAGTCAAAGCTCCATGTTGTCTTTATG Sanger + NGS 
R CAGGAAACAGCTATGACCCAGCCCAGACTCCGGAAGCAC Sanger + NGS 
ABCB4 15 
F TGTAAAACGACGGCCAGTTGCATGTTAATTGACAGTGTGC Sanger + NGS 
R CAGGAAACAGCTATGACCTTTCTTCTTGCTCAGTATAGCATTC Sanger + NGS 
ABCB4 16 
F TGTAAAACGACGGCCAGTTCCTTGATTGAGAAGCAGTTAGG Sanger + NGS 
R CAGGAAACAGCTATGACCAAAGAGTATGGCTCATAGTAGCAGTC Sanger only 
ABCB4 16A R CAGGAAACAGCTATGACCGGTTTCCACATCAAGGCTCT NGS only 
ABCB4 16B 
F TGTAAAACGACGGCCAGTTGTCTTGATATTCTTTCAGACATCAG NGS only 
R CAGGAAACAGCTATGACCAAAGAGTATGGCTCATAGTAGCAGTC NGS only 
ABCB4 17 
F TGTAAAACGACGGCCAGTATGGCCATGCCTTTTCTATG Sanger + NGS 
R CAGGAAACAGCTATGACCGGCTGCTTAATCCCAGAATG Sanger + NGS 
ABCB4 18 
F TGTAAAACGACGGCCAGTAAACATGTGACACTCAAGCCAC Sanger + NGS 
R CAGGAAACAGCTATGACCAGCAGAGCCTTATGCCAATC Sanger + NGS 
ABCB4 19 
F TGTAAAACGACGGCCAGTGCTACATAAAAGTTGAACATGATTGG Sanger + NGS 
R CAGGAAACAGCTATGACCTGCAGGACTCTGCCCCATCC Sanger + NGS 
ABCB4 20 
F TGTAAAACGACGGCCAGTGCTCAGAGCAAGGCCAGGGAC Sanger only 
R CAGGAAACAGCTATGACCTCTGGAGGGGGCAGTGGGTC Sanger only 
ABCB4 20 
F TGTAAAACGACGGCCAGTAATTTCCTCAGCATTGGAGC NGS only 
R CAGGAAACAGCTATGACCCATCTTAACAAGTGTGGGTATGC NGS only 
ABCB4 21 
F TGTAAAACGACGGCCAGTGGAGCGCATGCATTTGG Sanger + NGS 
R CAGGAAACAGCTATGACCGCTCAACGTTTTATGTTAATCACC Sanger only 
ABCB4 21A R CAGGAAACAGCTATGACCTCTCTTTTGGCATTTCCAGC NGS only 
ABCB4 21B 
F TGTAAAACGACGGCCAGTCAGGAACCAGGTTGGCTTTA NGS only 
R CAGGAAACAGCTATGACCAGTTGTAGTGGGCACAAACATT NGS only 
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ABCB4 22 
F TGTAAAACGACGGCCAGTACCTTCAGGATACTTTTGACAGAGCCC Sanger + NGS 
R CAGGAAACAGCTATGACCTCATATCATTGTTTGGAGCAGCAGAGC Sanger + NGS 
ABCB4 23 
F TGTAAAACGACGGCCAGTGGCCAGACTTAGAAGCCGTGCTC Sanger + NGS 
R CAGGAAACAGCTATGACCGACCTCATCTTTGGACACAGG Sanger + NGS 
ABCB4 24 
F TGTAAAACGACGGCCAGTGGGATGATTAAGGAGTAAAGGG Sanger + NGS 
R CAGGAAACAGCTATGACCAATCTAGCAGACAGCAAACCTTAG Sanger + NGS 
ABCB4 25 
F TGTAAAACGACGGCCAGTCAGTCTTTGGTAAAGTTTCCTTG Sanger + NGS 
R CAGGAAACAGCTATGACCCCATTATGACAATATTGGTTGGG Sanger + NGS 
ABCB4 26 
F TGTAAAACGACGGCCAGTGGAGGGTTGTTGTTTTGAAGC Sanger + NGS 
R CAGGAAACAGCTATGACCTGTTGGCATAACTTTGGTAATTG Sanger + NGS 
ABCB4 27 
F TGTAAAACGACGGCCAGTTGTAAATAGAACTGTCAACTGTTAAGC Sanger + NGS 
R CAGGAAACAGCTATGACCATGGTTGACAGCAAAATCCC Sanger + NGS 
ABCB4 28 
F TGTAAAACGACGGCCAGTAGCATGGGAACCCATTTGTG Sanger only 
R CAGGAAACAGCTATGACCAGGGAGAGCTAGCCTGTTGT Sanger only 
ABCB4 28A R CAGGAAACAGCTATGACCCCTGGACACTGACCATTGAA NGS only 
SLC25A13 01 
F TGTAAAACGACGGCCAGTGACTAGAAGTGAGCCGCCC Sanger only   
R CAGGAAACAGCTATGACCACCAACCCAGACACGTGAG Sanger only 
SLC25A13 02 
F TGTAAAACGACGGCCAGTCGGCTAGCTTGATTTCTCAGC Sanger only 
R CAGGAAACAGCTATGACCGGGCTGACACTTTGGGAC Sanger + NGS 
SLC25A13 02 F TGTAAAACGACGGCCAGTTGGGGCAACATGGTATTTAAG NGS only 
SLC25A13 03 
F TGTAAAACGACGGCCAGTGAACTGTTGGGAGATAATGGTC Sanger + NGS 
R CAGGAAACAGCTATGACCGGTCCTAAGAGATGGGAAGG Sanger + NGS 
SLC25A13 04 
F TGTAAAACGACGGCCAGTTTTGTATATGCTTCTGTTTTCCAC Sanger + NGS 
R CAGGAAACAGCTATGACCAAATGCTCACACAAGTCCACA Sanger only 
SLC25A13 04 R CAGGAAACAGCTATGACCTCAAAACTACTAAGCCAGAAACTTG NGS only 
SLC25A13 05 
F TGTAAAACGACGGCCAGTAAGCGATATCCATTCAATAACAG Sanger + NGS 
R CAGGAAACAGCTATGACCATCTCCTGACCTCGTCATCC Sanger + NGS 
Kirsten McKay Bounford   
61 
 
SLC25A13 06 
F TGTAAAACGACGGCCAGTGGCAGATGAGGGCTTGTTAG Sanger + NGS 
R CAGGAAACAGCTATGACCAAAACACACTCTTTGTTTGAGTTTAG Sanger + NGS 
SLC25A13 06 
F TGTAAAACGACGGCCAGTAAACTCTCTTTCTTCAGTCTGATTTT NGS only 
R CAGGAAACAGCTATGACCCCAAAACACACTCTTTGTTTGA NGS only 
SLC25A13 07 
F TGTAAAACGACGGCCAGTTCATGATTAGTTGCAGTTGCTTC Sanger only 
R CAGGAAACAGCTATGACCTGGTGAAGATTGTTTTGTTTGC Sanger only 
SLC25A13 07 
F TGTAAAACGACGGCCAGTTCATGATTAGTTGCAGTTGCTTC NGS only 
R CAGGAAACAGCTATGACCACACCACAATACTTGCAGGC NGS only 
SLC25A13 08 
F TGTAAAACGACGGCCAGTTCACTCATTCCAGTGCCTTG Sanger + NGS 
R CAGGAAACAGCTATGACCATTGCTGCCCTCCTCCTAAC Sanger only 
SLC25A13 08 R CAGGAAACAGCTATGACCTTCAGTATAGCCTTCAGTTTGGC NGS only 
SLC25A13 09 
F TGTAAAACGACGGCCAGTGGCAGCAATCAGGAGAAAAA Sanger + NGS 
R CAGGAAACAGCTATGACCGGAACAGGGTTGGGGTATC Sanger + NGS 
SLC25A13 10 
F TGTAAAACGACGGCCAGTCATGGATTTAGAACCCAATGAG Sanger + NGS 
R CAGGAAACAGCTATGACCTGATAACTGGCATTGGGAAAG Sanger + NGS 
SLC25A13 11 
F TGTAAAACGACGGCCAGTTTGTCCTTGACTTTAACTACCTTCTTC Sanger + NGS 
R CAGGAAACAGCTATGACCTCTTGCTAATTCATGTCAGGC Sanger + NGS 
SLC25A13 12 
F TGTAAAACGACGGCCAGTTTGCAGCAGAGATTAAGCAG Sanger + NGS 
R CAGGAAACAGCTATGACCTCCCCTGCTTTCAAATTAGC Sanger + NGS 
SLC25A13 13 
F TGTAAAACGACGGCCAGTTTGACAGATGCATATTTATAAGTGTTT Sanger + NGS 
R CAGGAAACAGCTATGACCTTCCACCTCTGGAATGGTTC Sanger + NGS 
SLC25A13 14 
F TGTAAAACGACGGCCAGTTCATCTCTTCCTGACCCACC Sanger + NGS 
R CAGGAAACAGCTATGACCTGTTGAAGAATAGTTTCTGCATTAGG Sanger + NGS 
SLC25A13 15 
F TGTAAAACGACGGCCAGTAGCTTGATCTCCTCAATGGG Sanger + NGS 
R CAGGAAACAGCTATGACCTAGCATGCAGCTAGGGAAGG Sanger + NGS 
SLC25A13 16_17 
F TGTAAAACGACGGCCAGTACGGCCAGCAGTTCAAAG Sanger only 
R CAGGAAACAGCTATGACCCCTTTCCCTACGACAACAGAG Sanger only 
Kirsten McKay Bounford   
62 
 
SLC25A13 16 
F TGTAAAACGACGGCCAGTGAGGACAGCAAAATAGGCATT NGS only 
R CAGGAAACAGCTATGACCGGGGTGAGGATCGAAATACA NGS only 
SLC25A13 17 
F TGTAAAACGACGGCCAGTGCTGGTGGTATGGAAATAATGTG NGS only 
R CAGGAAACAGCTATGACCTGAGGTACCTTTCCCTACGAC NGS only 
SLC25A13 18 
F TGTAAAACGACGGCCAGTTGATGAGAATGTATCAACTCCTTTAC Sanger + NGS 
R CAGGAAACAGCTATGACCCATTGCTTCATTCCCAGGAG Sanger + NGS 
NPC1 01 
F TGTAAAACGACGGCCAGTAACAGCCCGGGGAAGTAG Sanger only;   
R CAGGAAACAGCTATGACCCTCCATCGCCAGACCAAC Sanger only;   
NPC1 02 
F TGTAAAACGACGGCCAGTTGAGTGGGCACTTCTTGTTG Sanger + NGS 
R CAGGAAACAGCTATGACCCACCTCCACCCTGCAATAAC Sanger + NGS 
NPC1 03 
F TGTAAAACGACGGCCAGTTGAATGAATGTGTCTTAGTTCACTG Sanger + NGS 
R CAGGAAACAGCTATGACCCAAAGAATAAATGGAAAGCTGAG Sanger + NGS 
NPC1 04 
F TGTAAAACGACGGCCAGTTTTAAAATCGTTCTTGCTGGC Sanger + NGS 
R CAGGAAACAGCTATGACCCAATTTGCTCTGCTGTCCTG Sanger + NGS 
NPC1 05 
F TGTAAAACGACGGCCAGTTCTTGCCTCGTGAATTACAGC Sanger + NGS 
R CAGGAAACAGCTATGACCACTGTGCCCAGCCAGTTC Sanger + NGS 
NPC1 06 
F TGTAAAACGACGGCCAGTGTTGTTTTATGTATTTCAGTGGGC Sanger only 
R CAGGAAACAGCTATGACCTGGAGGTATTTGTTTCTTGTCC Sanger only 
NPC1 06 
F TGTAAAACGACGGCCAGTTTCAGTGGGCTTTTCTTTGAG NGS only 
R CAGGAAACAGCTATGACCGAAAGCTCAAAGTGCCAGTG NGS only 
NPC1 07 
F TGTAAAACGACGGCCAGTGCCAGGAGGAGGAAGAAAG Sanger + NGS 
R CAGGAAACAGCTATGACCCACACCACCTCACCCACTG Sanger + NGS 
NPC1 08 
F TGTAAAACGACGGCCAGTACTTTCAGGAACGGCTTGG Sanger only 
R CAGGAAACAGCTATGACCCATGTAAAAGCCAGCAAACC Sanger only 
NPC1 08A 
F TGTAAAACGACGGCCAGTACGGCTTGGCTCTTAACCTC NGS only 
R CAGGAAACAGCTATGACCGAAGAAAGGCCCAAAGTGC NGS only 
NPC1 08B F TGTAAAACGACGGCCAGTTCATTACTGCGTGTTCGTCAG NGS only 
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R CAGGAAACAGCTATGACCCAGCAAACCACAAGGTCATC NGS only 
NPC1 09 
F TGTAAAACGACGGCCAGTTGACCCTCAGGGCAATG Sanger only 
R CAGGAAACAGCTATGACCTTTGCTCACCTCTGGGTTATG Sanger only 
NPC1 09 
F TGTAAAACGACGGCCAGTACCCTCAGGGCAATGCTG NGS only 
R CAGGAAACAGCTATGACCTGCCCATGTACCCTAAGTCAG NGS only 
NPC1 10 
F TGTAAAACGACGGCCAGTAGGGCCCATGTTGTCCTTAG Sanger + NGS 
R CAGGAAACAGCTATGACCGGTAAGAAATTAACAAAACTGCCC Sanger + NGS 
NPC1 11 
F TGTAAAACGACGGCCAGTGAGCCCAGAGATACAGTCCATAG Sanger + NGS 
R CAGGAAACAGCTATGACCCGTAACTCAGATCTGCCATTG Sanger + NGS 
NPC1 12 
F TGTAAAACGACGGCCAGTAAAACGTGGCCTTTGTATCG Sanger only   
R CAGGAAACAGCTATGACCTGAAGAAAATAGATGTAGGCAACAG Sanger only 
NPC1 13 
F TGTAAAACGACGGCCAGTGGAGGACCTTTTAGTAACAAGTGG Sanger + NGS 
R CAGGAAACAGCTATGACCTCACACTCACGAATGCGG Sanger + NGS 
NPC1 14 
F TGTAAAACGACGGCCAGTGCTTAGAAGACACTGCTAATCGTC Sanger + NGS 
R CAGGAAACAGCTATGACCAAAGGAAGCAACACAAAGGG Sanger + NGS 
NPC1 15_16 
F TGTAAAACGACGGCCAGTCATGAACATAAGACCTGCAGAGAG Sanger + NGS 
R CAGGAAACAGCTATGACCTCTTAGAAGGCATGTGATAATCTG Sanger only 
NPC1 15 R CAGGAAACAGCTATGACCATACCCGCTAGCTGCTTCC NGS only 
NPC1 16 
F TGTAAAACGACGGCCAGTAGAGGTAAGTTGGTGCCAGG NGS only 
R CAGGAAACAGCTATGACCAATCTCCTTCCCAGGCTGTC NGS only 
NPC1 17 
F TGTAAAACGACGGCCAGTGCCCTGTACTCCCTATTAGCC Sanger + NGS 
R CAGGAAACAGCTATGACCGGAAACCCTGTCACCATTTG Sanger + NGS 
NPC1 18 
F TGTAAAACGACGGCCAGTGGGAAGACTGGTGGTGTTAGG  Sanger only 
R CAGGAAACAGCTATGACCTTTTCAGTGAGACATTTCAGGC Sanger only 
NPC1 18 
F TGTAAAACGACGGCCAGTGATCCTCGCCTTGCTTAGTTAC NGS only 
R CAGGAAACAGCTATGACCGACTGCCTGGCTGAGAGC NGS only 
NPC1 19 F TGTAAAACGACGGCCAGTTGAAACTAAAGACTTCCTCCCTG Sanger + NGS 
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R CAGGAAACAGCTATGACCCAAATAGGTATAAACTGAGGCACG Sanger + NGS 
NPC1 20 
F TGTAAAACGACGGCCAGTAAGAAAGTAATGCCCCTCACTG Sanger + NGS 
R CAGGAAACAGCTATGACCCCATGCAACTGTCTTAGCCC Sanger + NGS 
NPC1 21 
F TGTAAAACGACGGCCAGTTTTGCTTAGCCTCAAGTGCTC Sanger + NGS 
R CAGGAAACAGCTATGACCACCCAGTGTAGGCCCTTTG Sanger + NGS 
NPC1 22 
F TGTAAAACGACGGCCAGTGTGACAGGATGAACACGCAG Sanger + NGS 
R CAGGAAACAGCTATGACCTCTAAGACAGCCAATTCCCC Sanger + NGS 
NPC1 23 
F TGTAAAACGACGGCCAGTCTTGGCCTCCTCTAGCACC Sanger + NGS 
R CAGGAAACAGCTATGACCAGAAGCTGCTTTGTAAGTACAGG Sanger + NGS 
NPC1 24 
F TGTAAAACGACGGCCAGTctggggcaggagaatcactt Sanger + NGS 
R CAGGAAACAGCTATGACCtgaaaagaatgcctcaggataga Sanger + NGS 
NPC1 25 
F TGTAAAACGACGGCCAGTGCTGGTCTCAAGCAATTCTC Sanger + NGS 
R CAGGAAACAGCTATGACCTCCGGTGTTCAACTTGGC Sanger + NGS 
NPC2 01 
F TGTAAAACGACGGCCAGTTGGTTACTGGTGACAGGTCG Sanger only  
R CAGGAAACAGCTATGACCCAGTTAGGTAGGGTCCAAGGC Sanger only   
NPC2 02 
F TGTAAAACGACGGCCAGTGGGAGAGCAGAGCACCTTC Sanger + NGS 
R CAGGAAACAGCTATGACCATTCATGACTGCCAATTCCC Sanger + NGS 
NPC2 03 
F TGTAAAACGACGGCCAGTGACCCTAGGAATGCTGTTGC Sanger + NGS 
R CAGGAAACAGCTATGACCCCCATCTCTGCTTCTTGCC Sanger + NGS 
NPC2 04 
F TGTAAAACGACGGCCAGTTAAGGCTGTAAGCTGTGCCC Sanger only 
R CAGGAAACAGCTATGACCCTCCACTGTCAGGGCAATAACCC Sanger only 
NPC2 04 
F TGTAAAACGACGGCCAGTAGGATTCATAGTTAAACCAATTATGG NGS only 
R CAGGAAACAGCTATGACCCAGCAGTCTTGAAATTCCTTTTATC NGS only 
NPC2 05 
F TGTAAAACGACGGCCAGTAGGAAGGTCCAGCCAGACAGGA Sanger + NGS 
R CAGGAAACAGCTATGACCAACCAGCCACCCGGAGCTCA Sanger + NGS 
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2.1.12.2. MID primer sequences 
Table 2.2 MID primer sequences 
MID  Forward Primer Reverse Primer 
MID-1 CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGTGGTCATAGCTGTTTCCTG 
MID-2 CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACAACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACAGGTCATAGCTGTTTCCTG 
MID-3 CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTCACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTCGGTCATAGCTGTTTCCTG 
MID-5 CGTATCGCCTCCCTCGCGCCATCAGATCAGACACGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGATCAGACACGGGTCATAGCTGTTTCCTG 
MID-6 CGTATCGCCTCCCTCGCGCCATCAGATATCGCGAGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGATATCGCGAGGGTCATAGCTGTTTCCTG 
MID-7 CGTATCGCCTCCCTCGCGCCATCAGCGTGTCTCTAACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCGTGTCTCTAGGTCATAGCTGTTTCCTG 
MID-8 CGTATCGCCTCCCTCGCGCCATCAGCTCGCGTGTCACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCTCGCGTGTCGGTCATAGCTGTTTCCTG 
MID-10 CGTATCGCCTCCCTCGCGCCATCAGTCTCTATGCGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCTCTATGCGGGTCATAGCTGTTTCCTG 
MID-11 CGTATCGCCTCCCTCGCGCCATCAGTGATACGTCTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTGATACGTCTGGTCATAGCTGTTTCCTG 
MID-13 CGTATCGCCTCCCTCGCGCCATCAGCATAGTAGTGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCATAGTAGTGGGTCATAGCTGTTTCCTG 
MID-14 CGTATCGCCTCCCTCGCGCCATCAGCGAGAGATACACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCGAGAGATACGGTCATAGCTGTTTCCTG 
MID-15 CGTATCGCCTCCCTCGCGCCATCAGATACGACGTAACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGATACGACGTAGGTCATAGCTGTTTCCTG 
MID-16 CGTATCGCCTCCCTCGCGCCATCAGTCACGTACTAACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCACGTACTAGGTCATAGCTGTTTCCTG 
MID-17 CGTATCGCCTCCCTCGCGCCATCAGCGTCTAGTACACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCGTCTAGTACGGTCATAGCTGTTTCCTG 
MID-18 CGTATCGCCTCCCTCGCGCCATCAGTCTACGTAGCACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCTACGTAGCGGTCATAGCTGTTTCCTG 
MID-19 CGTATCGCCTCCCTCGCGCCATCAGTGTACTACTCACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTGTACTACTCGGTCATAGCTGTTTCCTG 
MID-20 CGTATCGCCTCCCTCGCGCCATCAGACGACTACAGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACGACTACAGGGTCATAGCTGTTTCCTG 
MID-21 CGTATCGCCTCCCTCGCGCCATCAGCGTAGACTAGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCGTAGACTAGGGTCATAGCTGTTTCCTG 
MID-22 CGTATCGCCTCCCTCGCGCCATCAGTACGAGTATGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTACGAGTATGGGTCATAGCTGTTTCCTG 
MID-23 CGTATCGCCTCCCTCGCGCCATCAGTACTCTCGTGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTACTCTCGTGGGTCATAGCTGTTTCCTG 
MID-24 CGTATCGCCTCCCTCGCGCCATCAGTAGAGACGAGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTAGAGACGAGGGTCATAGCTGTTTCCTG 
MID-25 CGTATCGCCTCCCTCGCGCCATCAGTCGTCGCTCGACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCGTCGCTCGGGTCATAGCTGTTTCCTG 
MID-26 CGTATCGCCTCCCTCGCGCCATCAGACATACGCGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACATACGCGTGGTCATAGCTGTTTCCTG 
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MID-27 CGTATCGCCTCCCTCGCGCCATCAGACGCGAGTATACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACGCGAGTATGGTCATAGCTGTTTCCTG 
MID-28 CGTATCGCCTCCCTCGCGCCATCAGACTACTATGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACTACTATGTGGTCATAGCTGTTTCCTG 
MID-29 CGTATCGCCTCCCTCGCGCCATCAGACTGTACAGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACTGTACAGTGGTCATAGCTGTTTCCTG 
MID-30 CGTATCGCCTCCCTCGCGCCATCAGAGACTATACTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGAGACTATACTGGTCATAGCTGTTTCCTG 
MID-31 CGTATCGCCTCCCTCGCGCCATCAGAGCGTCGTCTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGAGCGTCGTCTGGTCATAGCTGTTTCCTG 
MID-32 CGTATCGCCTCCCTCGCGCCATCAGAGTACGCTATACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGAGTACGCTATGGTCATAGCTGTTTCCTG 
MID-33 CGTATCGCCTCCCTCGCGCCATCAGATAGAGTACTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGATAGAGTACTGGTCATAGCTGTTTCCTG 
MID-34 CGTATCGCCTCCCTCGCGCCATCAGCACGCTACGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCACGCTACGTGGTCATAGCTGTTTCCTG 
MID-35 CGTATCGCCTCCCTCGCGCCATCAGCAGTAGACGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCAGTAGACGTGGTCATAGCTGTTTCCTG 
MID-36 CGTATCGCCTCCCTCGCGCCATCAGCGACGTGACTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGCGACGTGACTGGTCATAGCTGTTTCCTG 
MID-37 CGTATCGCCTCCCTCGCGCCATCAGTACACACACTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTACACACACTGGTCATAGCTGTTTCCTG 
MID-38 CGTATCGCCTCCCTCGCGCCATCAGTACACGTGATACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTACACGTGATGGTCATAGCTGTTTCCTG 
MID-39 CGTATCGCCTCCCTCGCGCCATCAGTACAGATCGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTACAGATCGTGGTCATAGCTGTTTCCTG 
MID-40 CGTATCGCCTCCCTCGCGCCATCAGTACGCTGTCTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTACGCTGTCTGGTCATAGCTGTTTCCTG 
MID-42 CGTATCGCCTCCCTCGCGCCATCAGTCGATCACGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCGATCACGTGGTCATAGCTGTTTCCTG 
MID-43 CGTATCGCCTCCCTCGCGCCATCAGTCGCACTAGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCGCACTAGTGGTCATAGCTGTTTCCTG 
MID-44 CGTATCGCCTCCCTCGCGCCATCAGTCTAGCGACTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCTAGCGACTGGTCATAGCTGTTTCCTG 
MID-45 CGTATCGCCTCCCTCGCGCCATCAGTCTATACTATACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTCTATACTATGGTCATAGCTGTTTCCTG 
MID-46 CGTATCGCCTCCCTCGCGCCATCAGTGACGTATGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTGACGTATGTGGTCATAGCTGTTTCCTG 
MID-47 CGTATCGCCTCCCTCGCGCCATCAGTGTGAGTAGTACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGTGTGAGTAGTGGTCATAGCTGTTTCCTG 
MID-48 CGTATCGCCTCCCTCGCGCCATCAGACAGTATATAACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACAGTATATAGGTCATAGCTGTTTCCTG 
MID-49 CGTATCGCCTCCCTCGCGCCATCAGACGCGATCGAACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACGCGATCGAGGTCATAGCTGTTTCCTG 
MID-50 CGTATCGCCTCCCTCGCGCCATCAGACTAGCAGTAACTGGCCGTCGTTTTACA CTATGCGCCTTGCCAGCCCGCTCAGACTAGCAGTAGGTCATAGCTGTTTCCTG 
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2.1.13. Software 
Mutation Surveyor version 2.2 (SoftGenetics) 
GeneMarker version 1.7 (SoftGenetics) 
GSEQ version 4.1 (Affymetrix) 
NextGENe version 2.16 (SoftGenetics) 
Alamut v2.1 (Interactive Biosoftware) 
2.1.14. On-line bioinformatics tools 
Primer3 via Broad Institute http://bioinfo.ut.ee/primer3/ 
Exon-Primer via UCSC genome browser https://genome.ucsc.edu/ 
Primer Blast via NCBI genome browser 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome 
SNPCheck via NRGL Manchester https://secure.ngrl.org.uk/SNPCheck/snpcheck.htm 
PolyPhen-2 http://genetics.bwh.harvard.edu/pph2/ 
1000 Genomes Project Browser http://browser.1000genomes.org/index.html 
Exome Variant Server (browser for the NHLBI GO Exome Sequencing Project data) 
http://evs.gs.washington.edu/EVS/ 
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2.2. Methods 
2.2.1. Extraction of genomic DNA from whole blood 
2.2.1.1. Autopure method 
This method was performed using the Autopure LS machine according to the 
manufacturer’s instructions. 
2.2.1.2. Qiasymphony SP method 
This method was performed using the QiaSymphony SP machine according to the 
manufacturer’s instructions. 
2.2.1.3. Manual PureGene method 
A minimum of 0.3ml of blood is required for a small-scale extraction or 3ml of blood for a 
medium-scale extraction.  The blood is transferred to a 1.5ml Eppendorf tube (small) or 
a 15ml Falcon tube (medium). 0.9ml or 9ml of red cell lysis solution is added, 
respectively.  The tube is incubated at room temperature for 10 minutes on a rotator 
then centrifuged (1 minute at 13,000rpm in a microfuge or 10 minutes at 3200 rpm in a 
bench top centrifuge) to pellet the white blood cells. The supernatant is poured off and 
cell pellet re-suspended in the remaining supernatant. 0.3ml or 3ml of cell lysis solution 
is added, respectively, and the tube is mixed thoroughly by vortexing.  2ul or 15ul of 
RNAse A solution is added and mixed by vortexing.  Then 0.1ml or 1ml of protein 
precipitation solution and mixed thoroughly by vortexing.  The tube is incubated for 15 
minutes on a rotator to allow protein precipitation.  Further protein precipitation solution 
can be added if required.  The tube is centrifuged to pellet the protein (5 minutes at 
13000 rpm in a microfuge or 20 minutes at 3600 rpm in a bench top centrifuge). The 
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supernatant is transferred to a 1.5 ml Eppendorf containing 300ul of 100% isopropanol 
or 15ml tube containing 3ml of 100% isopropanol.  The tube is gently inverted to 
precipitate the DNA then centrifuged for 2 minutes at 13000 rpm in a microfuge or 5 
minutes at 2000 rpm in a bench top centrifuge.  The supernatant is poured off and the 
pellet washed using 70% ethanol (0.5ml or 2ml).  After centrifuging again the 
supernatant is poured off, the pellet air dried at room temperature for a few minutes and 
then re-suspended in hydration solution. 
2.2.1.4. Phenol Chloroform method 
4ml of blood is transferred to a 15 ml falcon tube.  An equal volume of cold 2x lysis 
buffer is added and the tube sealed with parafilm.  This is left on ice for 10 minutes then 
mixed on a rotator rack for 10 minutes. Centrifuge at 3600 rpm for 20 minutes at 4°C to 
pellet the cell nuclei. The supernatant is poured off and the pellet is resuspended by 
gentle vortexing in 3ml of Salt/EDTA buffer. 300 μl of 10% SDS and 20 μl of 10mg /ml 
proteinase K is added before leaving overnight at 37C or at 55C for 3 hours.  After 
incubation, 3 ml of phenol solution is added.  This is mixed on a rotator rack for 10 
minutes, centrifuged at 3600 rpm for 5 minutes at room temperature, and then the 
aqueous layer is carefully removed and transferred to a new 15 ml falcon tube. 3 ml of 
phenol/chloroform solution is added to the tube.  This is mixed for on a rotator rack for 
10 minutes, centrifuged at 3600 rpm for 5 minutes at room temperature, and then the 
aqueous layer is carefully removed and transferred to a new 15 ml falcon tube.  3 ml of 
chloroform solution is added to the tube.  This is mixed on a rotator rack for 10 minutes, 
centrifuged at 3600 rpm for 5 minutes at room temperature, and then the aqueous layer 
is carefully removed and transferred to a new 15 ml falcon tube.  Twice that volume of 
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chilled 100% ethanol is added to the aqueous layer, gently mixing by hand until DNA 
strands appear.  The tube is centrifuged at 2000 rpm for 5 minutes at room temperature 
to pellet the DNA and the ethanol is poured off.  The pellet is washed by adding 2 ml of 
70% ethanol.  The DNA is transferred into a 1.5 ml Eppendorf tube using a plastic 
inoculation loop, where it is allowed to air dry at room temperature for a few minutes.  
100-400 ul of hydration solution is added, depending upon the size of the pellet.  The 
tube is incubated at 65oC on the Thriller Thermoshaker for 1 hour, then at 37oC 
overnight to allow the DNA to be fully resuspended. 
2.2.2. DNA quantification 
2.2.2.1. Nanodrop method 
All DNA samples were assessed for concentration and purity using a NanoDrop ND-
µ000 machine and associated software.  Using the software ‘nucleic acid’ was selected 
as the sample type.  The pedestal was washed using sterile water and then 70% ethanol 
prior to use and between samples.  Sterile water was used as a blank control, followed 
by TE buffer, followed by each DNA sample.  For each measurement 2µl is added to the 
pedestal using a pipette, the measurement is taken, the sample is wiped off with a tissue 
and the pedestal washed as described before.  The DNA concentration in ng/µl and 
260/230and 260/280 ratios were recorded. 
2.2.3. PCR amplification 
Megamix, BioMix Red and Long PCR reactions were performed in 0.5 ml thin-walled 
Eppendorf tubes in a final volume of 25 µl. 
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2.2.3.1. Megamix method 
The PCR reaction used 50 ng of DNA, 0.5 μM each primer and 23 µl of Megamix PCR 
buffer in a final volume of 25.  The thermocycling conditions were as follows; 95oC for 5 
minutes, 20 cycles of; 95oC for 1 minute, 65oC for 1 minute (reducing by 0.5oC per 
cycle), 72oC for 1 minute, followed by 10 cycles of; 95oC for 1 minute, 55oC for 1 minute, 
72oC for 1 minute, followed by 72oC for 10 minutes. 
2.2.3.2. BioMix™ Red method 
The PCR reaction used 50 ng of DNA, 0.5 μM each primer, 0.25 mM dNTPs and 2 units 
of Taq DNA polymerase in 1x PCR buffer.  The thermocycling conditions were as 
follows; 95oC for 5 minutes, 30 cycles of 95 oC for 1 minute, 60 oC for 1 minute, 72 oC for 
1 minute, and 72 oC for 10 minutes. 
2.2.3.3. Long PCR method 
The PCR reaction used 2µl of 50 ng/µl DNA, 1.25µl of each primer (stock at 20nM), 5µl 
of dNTP mix (each at 2 mM), 5 µl of 10x Long PCR buffer with 15 mM MgCl2, 0.3 µl of 
Long PCR enzyme mix and made up to 50 µl with molecular grade water. 
2.2.3.4. AA method 
PCR products were generated using the 48.48 Access Array™ system (Fluidigm Inc.) 
according to the manufacturer’s instructions.   
Sample-specific pools containing 138 PCR products per sample were generated using 
three arrays and pooling of equal volumes of the products.  All PCR primers were 
tagged at the 5’ end with M13 sequences (see 2.1.1) to allow incorporation of MID 
primers during a second round of PCR (see 2.1.12.2). The second round PCR 
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components used were as follows; 2µl of 10x PCR buffer*, 3.6µl of 25mM MgCl2*, 1µl of 
DMSO*, 0.4µl of 10mM dNTPs, 0.2µl of Taq*, 7.8µl of PCR grade sterile water, 4 µl of 
MID primer mix, and 1 µl of first round PCR product (diluted 1:1000); in 0.2ml thin-walled 
Eppendorf tubes with a final volume of 20 µl.  The thermocycling conditions were as 
follows; 95oC for 10 minutes, 15 cycles of 95 oC for 15 seconds, 60 oC for 30 seconds, 
72 oC for 1 minute, and 72 oC for 3 minutes.  Equal volumes of second round PCR 
products, which had MID primers incorporated, were pooled. 
2.2.4. PCR Cleanup 
2.2.4.1. ExoSap method 
5µl of PCR product was transferred to a new tube or 96-well plate.  0.5µl of ExoSAP-IT 
and 0.5µl of water per reaction were mixed and 1µl of the mix was added to each 
reaction. The reactions are then incubated on a PCR machine at 37oC for 15 mins 
followed by µ0ºC for 15 mins. 
2.2.4.2. AMPure bead method 
PCR cleanup of the library (final pool), was done using AMPure beads (Beckman 
Coulter Inc) adding the following components to an Eppendorf tube; 36µl of Agencourt 
AMPure beads, 24µl of 1xTE buffer and 12µl of library.  The library was mixed and 
incubated at room temperature with the beads for 10 minutes, then placed on a 
Magnetic Particle Concentrator (MPC; Life Technologies Inc) for 5 minutes.  The 
supernatant was removed and the pellet was twice washed with 170µl of 70% ethanol 
before returning the tube to the MPC for 5 minutes.  The pellet was allowed to air dry at 
room temperature for a few minutes then resuspended in 40µl of TE buffer. 
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2.2.5. Fragment Library Quantification 
Quantification of the library was done using the PicoGreen ® dsDNA quantitation assay.  
In a black 96-well flat bottom plate (obtained from ThermoFisher Scientific, catalogue 
number 611F96BK), a serial dilution of standard λ DNA 2ng/µl was done over wells A1 
to A10 to generate a standard curve in a volume of 50µl per well.  Well A11 was 
designated a ‘no DNA’ control and 50µl of water was added.  25µl of library was added 
to wells C1-C3, diluted 1 in 10, 1 in 20 and 1 in 40, respectively.  The PicoGreen ® 
reagent was diluted 1 in 200 and 50µl was added to wells A1 to A11.  After each 
addition, 50µl of mix was transferred to the row below B1 to B11. 25µl of diluted 
PicoGreen ® reagent was added to wells C1 to C3.  The plate was transferred to the 
DTX 880 Multimode Detector (Beckman Coulter Inc).  The fluorescence from each well 
was detected and used to determine the double stranded DNA concentration in well C1 
to C3 by plotting the readings against the standard curve; an average of A1 to A10 and 
B1 to B11 serial dilutions. The DNA concentration and average amplicon length was 
used to calculate the number of molecules per µl.  This allowed the volume of library to 
be added to the emulsion PCR reaction downstream to be calculated. 
 
2.2.6. Sequencing methods 
2.2.6.1. FS method 
Sequencing primers (at a final concentration of 0.3μM) was added to 1μl of BigDye 3.1 
and 1x BigDye buffer (Life Technologies Inc) in a final volume of 10μl. The sequencing 
programme was thermal cycling for 30 cycles of denaturing at 95oC for 30 seconds, 
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annealing 50oC for 10 seconds and extension at 60oC for 4 minutes. Resulting products 
were purified using Agencourt CleanSEQ magnetic beads according to the 
maufacturer’s instructions.  Sequencing products were separated and detected using a 
DNA analyzer 3730xl (Life Technologies Inc).  
2.2.6.2. MS method 
PCR product quantitation by PicoGreen, pooling, fragmentation, labelling and 
hybridisation and was performed according to the GeneChip Custom Resequencing 
Array Protocol V2.1 (Affymetrix). Arrays were washed and stained using a FS450 
fluidics station before being scanned with a GCS3000 7G scanner (Affymetrix).  
Fluorescence at each probe spot was measured using AGCC software (Command 
Console V1.0, Affymetrix) and intensity files were generated (CEL file).   
2.2.6.3. NGS method 
The emulsion PCR and sequencing reactions for the GS Junior system (Roche) were 
carried out according to the manufacturer’s instructions.  For the emPCR reaction a ratio 
of 1 molecule per bead was used (5x106 molecules of library were added to each of the 
A and B beads).  Consistently, these libraries resulted in enrichment between 5% and 
8%, by visual judgement.  Around 5-6% was loaded onto the picotitre plate for 
sequencing.   
2.2.7. MLPA 
DNA is diluted to a final volume of 2.5µl in a 0.2ml Eppendorf tube using TE buffer and 
including 25ng to 125ng of DNA per reaction.  A drop of mineral oil is added to each 
tube to prevent evaporation of the small volume.  The tubes are heated to 98oC for 5 
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minutes then cooled to 25oC for 30 minutes using a PCR machine.  0.75µl of MLPA 
probe and 0.75µl per reaction are mixed together and aliquoted into each tube on the 
PCR machine below the mineral oil.  Hybridisation occurs overnight on the PCR 
machine using the following program; 1 minute at 95°C, then 16 hrs at 60°C. Following 
hybridisation, the PCR machine temperature is changed to 54oC. 1.5µl of Ligase Buffer 
A, 1.5µl of Ligase Buffer B, 0.5µl of Ligase-65 enzyme and 12.5µl of water per reaction 
are mixed together and aliquoted into each PCR tube. The tubes are incubated for 10-
15 minutes at 54°C, then 5 minutes at 98°C then stored 40C until required.  A PCR 
master mix is made consisting of 1µl of PCR primers, 0.25µl of Polymerase and 3.75µl 
of Water per reaction.  At room temperature 5µl of the mix is added to each tube. The 
PCR program is as follows; 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 
minute, for 33 cycles, then 72°C for 20 minutes. 
1µl of PCR product, 1µl of size standard and 8µl of HiDi formamide are mixed together 
in a 96-well plate prior to analysis using a DNA analyzer 3130xl (Life Technologies Inc). 
 
2.2.8. Data analysis 
2.2.8.1. FS analysis 
Analysis of the Sanger sequencing data was done using Mutation Surveyor™ version 
3.2 (SoftGenetics®). .seq files were aligned against GenBank reference sequences and 
variants called.  Sequence quality and variant calls were checked and manually 
recorded by two independent scorers. 
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2.2.8.2. MLPA analysis 
MLPA analysis was done using GeneMarker software.  The raw .fsa files for the run 
were loaded into a new GeneMarker project and run with pre-set parameters for the 
relevant MLPA kit.  The peaks were sized and labelled automatically according to the kit 
instructions and the size standard peaks.  The settings were as follows; AutoRange, 
Smooth, Peak Saturation, Baseline Subtraction, Pull-up Correction and Spike Removal 
were all selected, Size Call was Local Southern, Allele Call was Auto Range 120 to 
1000, Peak Detection Threshold was >100 intensity, >1% of the maximum, >5% of the 
local maximum and with a maximum intensity of 30,000.  The Plus A Filter and Stutter 
Peak Filter were selected and set to 25% for the Left and 25% for the Right.  Population 
Normalisation was selected. The MLPA analysis module was used to perform a dosage 
quotient calculation for each probe, using internal control probes and three normal 
control samples on the run.  The following settings were used; the Analysis Method was 
MLPA Ratio, the Quantification used Peak Height and the ratios were adjusted using the 
control probes.  In addition to the normal controls, a sample with trisomy of chromosome 
13 was included on the NPC runs to mimic a whole gene duplication. Ratios of 0.75 to 
1.3 are considered in the normal range, below 0.75 indicates a heterozygous deletion, 
and above 1.3 indicates a heterozygous duplication.  All positive results were repeated. 
2.2.8.3. MS analysis 
GeneChip Sequence Analysis Software (GSEQ 4.1, Affymetrix) was used to interrogate 
the CEL files for base calling and variant calling. Base calling assumed the diploid model 
and a quality score threshold of 2 (default settings were used for all other parameters).  
A list of software-generated variant calls were transferred into a Microsoft Excel 
Kirsten McKay Bounford   
77 
 
document, manually checked and decisions recorded.  Any calls that were deemed not 
to be benign polymorphisms or sequencing artefacts were confirmed using FS. 
2.2.8.4. tNGS analysis 
Analysis of the NGS data for coverage and variant calling was done using NextGENe™ 
version 2.16 (SoftGenetics®).  The GS Junior generated .sff file was converted to .fna 
using the Format Conversion tool and these settings; Median Score Threshold >=20, 
Called Base Number of Each Read >= 100, max # of uncalled bases <=2, Trim or Reject 
Read when >=3 Bases with Score <=16. The Barcode Sorting tool was used to 
interrogate the run .fna for reads corresponding to all the barcodes used in the 
laboratory to detect contamination.  The AutoRun tool was used to perform three tasks; 
1) splitting of the .fna file according to the barcodes used in the particular run to 
generate individual .fna files for each patient, 2) alignment of the reads against GenBank 
files and 3) variant calling using these settings (Matching requirement >=100 Bases and 
85% homology, Remove Ambiguously Mapped Reads, Detect Large Indels, Rigorous 
Alignment, Hide Unmatched Ends, Mutation Percentage <=15%, SNP Allele <=3 
Counts, Total Coverage <=15 reads, Except for Homozygous) .  The Variant 
Comparison tool was used to generate a list of all the variants called by the software for 
all of the patients on the run.  This was saved as a text file and imported into a Microsoft 
Excel template to allow scoring of the variants by two independent scorers.  Mutation 
reports (detailing variant calls) and Expression reports (detailing Coverage) were 
generated for each patient from NextGene Viewer.  
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2.2.9. Mutation nomenclature 
GenBank reference files were used for both sequencing methods and for the six genes 
were as follows;  NM_000271 (NPC1), NM_006432.3 (NPC2), NM_005603.3 (ATP8B1), 
NM_003742.2 (ABCB11), NM_018849.2 (ABCB4) and NM_014251.2 (SLC25A13).  
Mutation nomenclature was done according to HGVS guidelines. 
2.2.10. Variant interpretation 
Variant interpretation was done using Alamut software.  This allowed checking of variant 
nomenclature, literature searching, presence or absence on the HGMD database, and 
predictions of the effect on protein structure (using Align GVGD, SIFT and PolyPhen 
tools) and mRNA splicing (using SpliceSiteFinder-like, MaxEntScan, NNSPLICE, 
GeneSplicer and Human Splicing Finder tools).  In addition, a search of dbSNP Build 
138 was done and the 1000Genomes project data and Exome Sequencing Project data 
was used as a source of presumed normal variation (see 2.1.14).  All sequence variants 
identified were investigated using this pipeline and classified into the following groups 
‘pathogenic’, ‘possibly pathogenic’, ‘uncertain significance’, ‘likely benign’ and ‘benign’.  
It is important to note that these classifications are based on available information, and 
may change in response to additional information, i.e. a new publication of mutation data 
or case studies. 
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Chapter 3 – EVALUATION OF 
MICROARRAY SEQUENCING AND 
TARGETTED NEXT GENERATATION 
SEQUENCING FOR THE GENETIC 
INVESTIGATION OF CHOLESTASIS 
3.1. Introduction 
3.1.1. Diagnostic genetic testing 
Accurate genetic diagnosis can be essential to inform decisions on treatment and 
management of many genetic conditions.  As an example, progressive familial 
intrahepatic cholestasis type 1 (PFIC type 1) caused by mutations in ATP8B1 (FIC1 
protein deficiency) and PFIC type 2 caused by mutations in ABCB11 (BSEP deficiency) 
may present with the same clinical features, however liver transplantation is indicated 
for severe PFIC type 2 than and not for type 1 (Pawlikowska et al., 2010).  Genetic 
testing provides definitive diagnoses and allows accurate assessment of the genetic risk 
of cholestasis in families.  Fluorescent capillary Sanger sequencing (FS) has been the 
gold standard method for diagnostic laboratories for the detection of unknown 
mutations, because of its high specificity and developments in automation.  However, 
FS is limited by machine capacity and relatively high consumables costs.  In this 
chapter microarray sequencing (MS) is evaluated and a targeted next generation 
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sequencing (tNGS) assay is designed, optimised and evaluated, as alternative methods 
for the diagnosis of genetic cholestasis disorders.   
3.1.2. Microarray sequencing 
Initial testing of a 300kb custom-designed microarray (Birmingham ReseqUencing 
Microarray; BRUM1) was done previously using patients with known mutations (Bruce et 
al., 2010).  BRUM1 includes probes to sequence ATP8B1 and ABCB11.  In this chapter 
further evaluation of the BRUM1 microarray using samples simultaneously tested by FS 
and MS in patients without previously known mutations is described and the advantages 
and disadvantages of MS for clinical laboratory use are discussed.  
This work has been published and the paper is included in Appendix I: Mutation 
detection in cholestatic patients using microarray resequencing of ATP8B1 and 
ABCB11 (McKay et al., 2013). 
3.1.3. Targeted Next Generation Sequencing 
The combination of 48.48 Access Array (Fluidigm), GS Junior (Roche 454) and 
NextGene (SoftGenetics) analysis software were selected as the methods for a custom-
designed tNGS assay to sequence six genes, ATP8B1, ABCB11, ABCB4, NPC1, NPC2 
and SLC25A13.  This assay was to be transferred to clinical service at a future date 
therefore the considerations for assay design at the time were as follows;  
 The combined size of the target regions was too small (23.7Kb) for commercially 
available TEMs, leaving PCR-based enrichment as the only option. 
 Runs were required to be at the rate of one per month at least to ensure timely 
reporting of results. 
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 The target size and number of patients expected per month (12-20) meant that a 
small-scale sequencer was required.  High capacity machines would not be cost 
effective to run. 
 No bioinformatics expertise was readily available. 
The main reasons for selecting the components of the assay were as follows; 
 48.48 Access Array was selected as the TEM as it offered automation, 
reproducibility and flexibility.   
 The GS Junior was selected as the sequencer as it was compatible with the 
Access Array method, it produced long reads in order to make downstream data 
analysis simpler, and it had a short run time. 
 NextGene was selected as the analysis software as it offered a simple user 
interface and automated sequence alignment and variant calling algorithms. 
The design and optimisation of this assay will be described as well as an evaluation of 
the advantages and disadvantages of tNGS for use in clinical laboratories. 
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3.1.4. Chapter 3 Objectives 
 To evaluate MS as an alternative sequencing method to FS for diagnosing 
genetic cholestasis conditions. 
 To design and optimise a tNGS assay to sequence six genes involved in 
cholestasis 
 To evaluate the tNGS assay as an alternative sequencing method to FS for 
diagnosing genetic cholestasis conditions.  
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3.2. Methods 
3.2.1. Patients for evaluation of MS 
DNA samples from twenty nine individuals with intrahepatic cholestasis, low-normal 
range GGT activity without ARC syndrome or defects in bile acid biosynthesis were 
used.  ARC syndrome was excluded by clinical examination (Gissen et al., 2006) and 
bile acid biosynthesis disorders were excluded by determination of urinary bile acid 
profile by electrospray ionisation mass spectrometry.  Thus there was a high likelihood 
of detecting mutations in ATP8B1 and ABCB11 in these samples. 
3.2.2. Patients for evaluation of tNGS 
Seventy four DNA samples from patients known to carry mutations and polymorphisms 
in the six genes of interest.  Twenty three DNA samples from clinically unaffected 
controls which had previously been anonymised.  Thirty nine DNA samples consented 
for research in which no mutations in the genes of interest had previously been found. 
3.2.3. Fluorescent Sanger sequencing 
PCR amplification of the coding exons and boundaries of the ATP8B1, ABCB11, 
ABCB4, NPC1, NPC2 and SLC25A13 genes according to method described (2.2.3.1).   
PCR clean up, sequencing, sequencing clean up, capillary electrophoresis and data 
analysis was done according to methods described (2.2.4.1, 2.2.6.1 and 2.2.8.1). 
3.2.4. Microarray sequencing 
PCR amplification of the coding exons and boundaries of the ATP8B1 and ABCB11 
genes according to the method described (2.2.3.2).  Quantification and pooling of the 
PCR products was done according to the method described (2.2.5).  Quantification and 
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pooling of the PCR products, the MS method and data analysis was done according to 
the methods described (2.2.6.2 and 2.2.8.3). 
3.2.5. Targeted NGS 
The methods for this process are discussed in the Results section.  
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3.3. Results 
3.3.1. Evaluation of Microarray Sequencing (MS) 
The coding regions of the ATP8B1 and ABCB11 genes were analysed using FS and 
MS in twenty nine patients with increased likelihood of carrying mutations.  The 
sequence variants detected in thirteen of the samples (44.5% detection rate) are listed 
in Table 3.1.  Eight variants had previously been described in association with PFIC and 
ten variants were novel.  Four of the variants were nonsense mutations (22%), two were 
splice site changes (11%) and the rest were missense (67%).  No insertions or deletions 
were detected using the specifically designed probes.  No mutations were detected by 
either technique in the remainder of the patients and therefore the cause of ‘low-normal 
GGT’ cholestasis remains undetermined in these cases.  The negative results in these 
cases may be explained by whole exon deletions or duplications, intronic mutations 
affecting splicing, or promoter region mutations in ATP8B1 and ABCB11; as such 
mutations would not be detected by either strategy. In addition, it is possible that further 
genes are involved in the phenotype of neonatal cholestasis with low GGT. 
In sample 17, MS detected a variant not confirmed by FS, constituting a false positive 
result.  Two samples (6 and 22) had compound heterozygous changes in ATP8B1 
detected by FS but not by MS. Both samples had two variants in close proximity; 
therefore we speculate that these are in cis and that each sequence variant has 
impaired the hybridisation of surrounding probes.  Our experience of testing patients for 
mutations in these genes suggests that false negative results arising in this manner are 
likely to be uncommon.  However, in this cohort they occurred in 7% of samples. 
Kirsten McKay Bounford   
86 
 
Table 3.1:  Mutations detection by MS and FS. 
a - Variant was not confirmed by FS and is therefore a false positive finding.  b - DNA changes were experimentally determined by 
sequencing.  c - Protein changes are predicted rather than experimentally determined.  d - Novel missense changes are of unclear 
pathogenicity. 
 
 
Sample 
Gene DNA change 
b
 
Protein 
change 
c
 
Zygosity 
 
 
 
Predicted effect 
Previously 
reported? 
Microarray 
Sequencing 
Fluorescent 
Sanger 
sequencing 
2 ABCB11 c.850G>C p.V284L Heterozygous Missense (Byrne et al., 
2009) 
Y Y 
4 ABCB11 c.2178+1G>T  Heterozygous Altered splicing (van Mil et al., 
2004b) 
Y Y 
6 ATP8B1 c.1010T>G  p.M337R Heterozygous Missense Novel 
d
 N Y 
ATP8B1 c.1018A>G p.M340V Heterozygous Missense Novel 
d
 N Y 
7 ATP8B1 c.208G>A  p.D70N Heterozygous Missense (Klomp et al., 
2004) 
Y Y 
9 ABCB11 c.2170G>A  p.D724N Heterozygous Missense Novel 
d
 Y Y 
12 ABCB11 c.2611-2A>T  Heterozygous Altered splicing (Strautnieks et 
al., 2008) 
Y Y 
17 ATP8B1 c.1660G>A  p.D554N Homozygous Missense (Klomp et al., 
2000) 
Y Y 
ATP8B1 c.1564G>A 
a
 p.D522N 
a
 Heterozygous
a
 Missense Novel 
d
 Y    N  
a
 
18 ABCB11 c.290T>G  p.L97* Homozygous Truncated protein Novel Y Y 
19 ATP8B1 c.3040C>T  p.R1014* Heterozygous Missense (Klomp et al., 
2004) 
Y Y 
22 ATP8B1 c.1014C>G  p.N338K Heterozygous Missense Novel 
d
 N Y 
ATP8B1 c.1018A>G  p.M340V Heterozygous Missense Novel 
d
 N Y 
ABCB11 c.1636C>A  p.Q546K Heterozygous Missense Novel 
d
 Y Y 
25 ABCB11 c.499G>A  p.A167T Heterozygous Missense (Liu et al., 2009) Y Y 
ABCB11 c.3458G>A  p.R1153H Heterozygous Missense (Strautnieks et 
al., 2008) 
Y Y 
26 ABCB11 c.3484G>T  p.E1162* Homozygous Truncated protein Novel Y Y 
29 ABCB11 c.483C>A  p.C161* Homozygous Truncated protein Novel Y Y 
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3.3.2. tNGS Design  
3.3.2.1. PCR design 
According to the manufacturer’s guidelines for assay design, the size range of the 
PCR products to be amplified in one assay was less than 150 base pairs, to avoid 
disparate levels of amplification between long and short products during the emPCR 
step of the GS Junior protocol.  In addition, the maximum read length of the 
sequencer was around 500 bases and PCR products of this size or less would allow 
bi-directional sequencing of the fragments. 
PCR primers covering the ROIs were already available in the laboratory for FS and 
included M13 tag sequences allowing universal sequencing primers to be used.  The 
primer sequences and their product sizes are listed in chapter 2 (2.1.12.1, Table 
2.1).  The FS primers including M13 tags, amplified products ranging from 279 to 
894 bases with an average of 574 bases, therefore some redesign of primers was 
required to achieve and optimal design.   The size range of 364 to 514 bases was 
selected for the tNGS design to minimise the number of amplicons requiring 
redesign.  46 primers sets (25% of total) were redesigned to this size range using the 
Primer3 and Primer-BLAST tools and avoiding polymorphisms of more than 1% 
frequency using the SNPCheck tool (see 2.1.14). 
3.3.2.2. Modified TEM - 3AA-2 step amplification 
The capacity of one 48.48 Access Array (AA) was 48 PCR reactions and 47 samples 
(plus a negative control).  Since 134 PCRs were required to cover the ROIs in the six 
genes of interest, three AAs were required to amplify all the fragments.  These are 
shown in 96-well plate layout in Figure 3.1.  The standard protocol for the AA method 
involved adding CS-tagged sequencing primers in with the DNA samples, each 
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containing a unique MID sequence for each DNA (2.1.12.2, Table 2.2).  This allows 
PCR amplification of the ROIs and incorporation of the MID and sequencing primers 
into the PCR products in one-step.  Since the M13 tags already incorporated in the 
primers were untested in this assay, a more flexible and less competitive two-step 
protocol was used, which also allowed for the potential of multiplexing PCR reactions 
at a later date.  A modified protocol was devised that involved three separate AA set-
ups, pooling of patient-specific products, followed by a second round of PCR 
incorporating the M13-tagged MID primers (see Figure 4.4). 
3.3.2.3. PCR Clean-up and Quantification 
The clean-up of the fragment library was done using AMPure beads as described 
(2.2.4.2).  The quantification and dilution of the fragment library was done using the 
PicoGreen protocol previously described in Chapter 2 (2.2.5).  
3.3.2.4. Sequencing method 
The emPCR set-up, emPCR breaking, enrichment, clean-up, quantification, PTP 
loading and sequencing protocols are described in Chapter 2 (2.2.6.3).   
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Figure 3.1: The PCR primer layouts for the 3AA-2 step protocol. 
 
These primers were used as the TEM for the tNGS assay.  AA1 and AA2 contained 
the FS primers and AA3 contained the newly designed primers. 
 
AA1 primers 
 1 2 3 4 5 6 
A NPC1 Ex01 NPC1 Ex13 NPC1 Ex24 ATP8B1 Ex03 ATP8B1 Ex18 ABCB11 Ex03  
B NPC1 Ex02 NPC1 Ex14 NPC1 Ex25 ATP8B1 Ex06_07 ATP8B1 Ex20 ABCB11 Ex05  
C NPC1 Ex03 NPC1 Ex17 NPC2 Ex01 ATP8B1 Ex10 ATP8B1 Ex22 ABCB11 Ex07  
D NPC1 Ex04 NPC1 Ex19 NPC2 Ex02 ATP8B1 Ex11 ATP8B1 Ex24 ABCB11 Ex08  
E NPC1 Ex05 NPC1 Ex20 NPC2 Ex03 ATP8B1 Ex12 ATP8B1 Ex25 B l a n k  
F NPC1 Ex07 NPC1 Ex21 NPC2 Ex05 ATP8B1 Ex14 ATP8B1 Ex26 B l a n k  
G NPC1 Ex10 NPC1 Ex22 ATP8B1 Ex01 ATP8B1 Ex15 ATP8B1 Ex27 B l a n k  
H NPC1 Ex11 NPC1 Ex23 ATP8B1 Ex02 ATP8B1 Ex17 ABCB11 Ex02 B l a n k  
 
 AA2 primers 
 
AA3 primers 
 1 2 3 4 5 6 
A NPC1 Exon06 NPC2 Exon04 ATP8B1 Exon21A ABCB11 Exon18 ABCB4 Exon16A SLC25A13 Exon04 
B NPC1 Exon08A ATP8B1 Exon04 ATP8B1 Exon21B ABCB11 Exon20 ABCB4 Exon16B SLC25A13 Exon06 
C NPC1 Exon08B ATP8B1 Exon05 ATP8B1 Exon23 ABCB11 Exon21 ABCB4 Exon20 SLC25A13 Exon07 
D NPC1 Exon09 ATP8B1 Exon08 ABCB11 Exon04 ABCB11 Exon24 ABCB4 Exon21A SLC25A13 Exon08 
E NPC1 Exon12 ATP8B1 Exon09 ABCB11 Exon06 ABCB11 Exon28 ABCB4 Exon21B SLC25A13 Exon16 
F NPC1 Exon15 ATP8B1 Exon13 ABCB11 Exon14A ABCB4 Exon11 ABCB4 Exon28A SLC25A13 Exon17 
G NPC1 Exon16 ATP8B1 Exon16 ABCB11 Exon14B ABCB4 Exon12 ABCB4 Exon28B B l a n k 
H NPC1 Exon18 ATP8B1 Exon19 ABCB11 Exon17 ABCB4 Exon13 SLC25A13 Exon02 B l a n k 
 
 
 
 
 
 
 1 2 3 4 5 6 
A ABCB11 Ex09 ABCB11 Ex22 ABCB4 Ex05 ABCB4 Ex17 ABCB4 Ex27 SLC25A13 Ex13 
B ABCB11 Ex10 ABCB11 Ex23 ABCB4 Ex06 ABCB4 Ex18 SLC25A13 Ex01 SLC25A13 Ex14 
C ABCB11 Ex11 ABCB11 Ex25 ABCB4 Ex07 ABCB4 Ex19 SLC25A13 Ex03 SLC25A13 Ex15 
D ABCB11 Ex12 ABCB11 Ex26 ABCB4 Ex08 ABCB4 Ex22 SLC25A13 Ex05 SLC25A13 Ex18 
E ABCB11 Ex13 ABCB11 Ex27 ABCB4 Ex09 ABCB4 Ex23 SLC25A13 Ex09 B l a n k 
F ABCB11 Ex15 ABCB4 Ex02 ABCB4 Ex10 ABCB4 Ex24 SLC25A13 Ex10 B l a n k 
G ABCB11 Ex16 ABCB4 Ex03 ABCB4 Ex14 ABCB4 Ex25 SLC25A13 Ex11 B l a n k 
H ABCB11 Ex19 ABCB4 Ex04 ABCB4 Ex15 ABCB4 Ex26 SLC25A13 Ex12 B l a n k 
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Figure 3.2: Schematic showing the modified target enrichment protocol used for the 
tNGS assay (3AA-2-step protocol).  
 
   
5. 3 x AA setups with different primer sets; AA1, AA2 and AA3 
6. Patient-specific PCR 
products pooled for 3 AAs 
into tubes/96 well plate 
7. Sequencing 
primers containing 
unique MIDs 
8. Second round of PCR to 
incorporate MIDs and 
sequencing primers into PCR 
products 
9. Patient-specific MID-tagged 
pools are themselves pooled 
10. Fragment library ready for 
clean-up and quantification 
1. Up to 47 DNA 
samples plus negative 
control are added 
3. Array of 
nanolitre-sized 
chambers where 
2,304 individual 
PCRs performed 
2. 44-46 ROI-
specific primer 
pairs are added 
4. Patient-specific pools 
containing 44-46 PCR 
products are harvested 
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3.3.3. tNGS Optimisation 
3.3.3.1. PCR validation 
All PCR primer sets including the 46 redesigned sets were tested using the Roche 
Hi-Fidelity PCR kit and cycling conditions reflecting the 48.48 Access Array protocol 
(described in 2.2.3.4).  The volumes were proportionally increased to a final volume 
of 8µl and set up in 96-well plates, as shown in Table 3.2.  Please note the amplicon-
specific primers were added upfront, instead of by the AA machine at a later point, 
and therefore the final volume of the PCR is increased from 4 µl to 8 µl.  
Table 3.2: The recipe used for the PCR validation of the amplicon-specific primers 
using the Roche High-Fidelity kit.  Those components with an asterisk were provided 
with the kit.  The AA loading reagent was provided with the AA kit. 
PCR Component Validation PCR volume 
(µl) 
10x Buffer (without 
MgCl2)* 
0.5 
25mM MgCl2* 0.9 
DMSO* 0.25 
10mM nucleotides* 0.1 
Taq (5U/µl) * 0.05 
20x AA loading reagent 0.25 
Genomic DNA (50ng/µl) 0.8 
Water 1.15 
1µM M13 tagged 
amplicons-specific primers 
(F+R) 
4 
Total 8 
 
PCR products were visualised using gel electrophoresis (see Chapter 2.1.6) and 
examples of gel pictures are shown in Figure 3.3.  128 of the 134 possible PCR 
products amplified well and only 6 showed potential problems for sequencing.  For 
each gene a summary of the PCR results was as follows; 
NPC1 - Exons 4 and 17 have weak products 
ABCB11 – Exons 22 and 28 have weak products, Exon 6 has an extra band 
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ABCB4 - Ex28A has a weak product 
NPC2, ATP8B1, SLC25A13 - All OK 
Figure 3.3 Gel picture from PCR validation 
A typical gel picture from PCR validation step showing a selection of NPC1 exons. 
The vast majority of primer pairs generated single strong bands; however Ex17 
shows a clearly weaker product in comparison. 
 
 
 
3.3.3.2. Assay validation 
It was not practical to validate each component of the assay individually, therefore 
the TEM, sequencing and data analysis methods were validated together by looking 
at the end point of the assay; the sequencing data.  4 validation runs were performed 
and optimisation continued on subsequent live runs whilst testing new research 
patients.  Here is an outline of the runs; 
1. AA1 primer sets and 46 DNA samples (9 anonymised ‘normal’ DNAs, 19 
research samples with no known mutations and 18 with known 
mutations/polymorphisms from FS data).  Done in duplicate. 
2. AA2 primer sets and 46 DNA samples (4 normals, 10 research samples with 
no known mutations and 30 with known mutations/polymorphisms from FS 
data; 2 of these were run in duplicate). 
3. AA3 primer sets and 46 DNA samples (10 normals, 10 research samples with 
no known mutations and 26 with known mutations/polymorphisms from FS 
data). 
Ex11 Ex13 Ex19 Ex14 Ex17 Ex20 Ex21 
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4. The products from 12 MIDs from Runs 1-3 were combined to produce 
pseudo-samples and sequenced. 
5-7. 46 samples containing a mixture of samples run on Runs 1-3 and new 
research patients were enriched using the 3AA-2step protocol and the 
products were split into 3 GS Junior runs. 
8.  ‘Live’ run of new research patients. 
The objectives of the optimisation were; 
 to check performance of GS Junior sequencer 
 to check the performance of the MIDs 
 to test reproducibility of the test between  and within runs 
 to test PCR primers amplification within AA system and downstream 
sequencing 
 to optimise the depth of coverage across ROIs 
 to establish optimum number of patients on a run 
 to check assay can detect all known sequence variants including 
polymorphisms. 
3.3.3.2.1. GS Junior performance 
Roche 454 provides various parameters against which data from the GS Junior may 
be measured.  The most useful and relevant of those are shown in Table 3.3.   
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Table 3.3:  GS Junior run metrics 
Run 
Total raw 
wells 
≤ 250,000 
Total key 
pass/Total 
raw well 
>90% 
Total pass 
filtering/Total 
key pass 
25-50% 
Mix&Dots/ 
Total key 
pass 
<20% 
Trimmed too 
short quality 
reads 
30-55% 
Number of 
passed filter  
(PF) reads 
50-80,000 
1A 218745 97.00% 44.00% 11.80% 44.30% 93305 
1B 226761 96.30% 53.57% 8.26% 38.16% 116971 
2 236377 97.88% 45.17% 17.37% 37.45% 104506 
3 227232 97.41% 48.79% 6.84% 44.36% 107990 
4 215435 97.38% 58.29% 7.18% 34.52% 122297 
5 220307 97.40% 40.15% 14.56% 45.28% 86119 
6 205250 96.88% 59.32% 5.01% 35.66% 117968 
7 219522 97.37% 49.63% 5.25% 45.11% 106091 
8 203877 96.50% 60.67% 4.74% 34.47% 119335 
 
Run metrics from assay validation showing the numbers advised by Roche in the 
header and the numbers achieved on each validation run.  The most important 
column is the number of passed filter reads (PF) as this is the number of reads 
useable for analysis.  Note that the PF numbers achieved are significantly higher 
than the number Roche considered as an adequate run.  This is because Roche are 
conservative in order to reduce customer expectations of machine capacity.  In our 
hands with well-optimised assays the machine can routinely produce around 
120,000 passed filter reads (60MB compared to the 40MB advertised for GS Junior 
with standard chemistry). 
 
3.3.3.2.2. MID validation 
It was important to exclude the MID primer pairs as variable factors in the assay and 
therefore the total number of reads per MID was compared against Runs 1-3 in 
which 3 different sets of sample DNAs were amplified.  This found that whilst there 
were some poor samples on each run, no MID set performed badly in all runs and 
therefore the problems were caused by the DNA or the preparation rather than the 
MID primers.   
In runs 5-8 the total number of reads per MID was compared across each run to look 
for over or under-representation of MIDs.  The results for Run 5 are shown in Figure 
3.4. 
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3.3.3.2.3. Reproducibility 
Run 1 was performed in duplicate by running the same fragment library on two 
different machines (1A and 1B).  Run 1B was a better performing run than 1A and as 
a result average numbers of reads per amplicon were slightly higher for 1B.  Overall 
the numbers of reads per amplicon and per sample correlated well and 
demonstrated that the sequencer will reproducibly sequence the material in the 
fragment library (see Figure 3.5). 
In order to evaluate the reproducibility between runs, two samples were run in 
duplicate on Run 2 using two different MIDs.  The comparison was measured using 
total number of reads and average reads per amplicon (see Table 3.4).  Both 
measurements showed considerable variation and the effect of MIDs and TEM 
preparation was considered as possible reasons for this.  However as discussed in 
0
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Figure 3.4: Total matched 
reads per MID 
 A graph showing the total 
number of matched reads for 
Run 5 by MID.  The reads are 
evenly split between MIDs 
and a similar pattern was 
seen for Runs 6-8 where the 
3AA-2step method was used.  
This shows that the AA TEM 
is effective in producing even 
PCR amplification between 
samples.  In addition, it shows 
that the subsequent pooling of 
equal volumes of sample-
specific second round PCR 
products is sufficient to 
prevent uneven distribution of 
reads between 
samples/MIDs. 
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section MID validation, both factors were shown to have minimal effects when 
compared across the validation runs.    
Table 3.4: Inter-run comparison for two samples 
Inter-run comparison between samples 1 and 2 using two different MIDs.  There was 
considerable variation between the samples for both measurements. 
Sample 
Total number 
of reads 
Average 
reads per 
amplicon 
1 MID 003 2950 61 
1 MID 007 1465 31 
2 MID 033 4151 86 
2 MID 036 8465 176 
  
3.3.3.2.4. Coverage of ROIs 
In order to evaluate the ability of the AA TEM to enrich for the ROIs in the target 
genes, the total number of reads per amplicon in Runs 1-3 was measured, see 
Figure 3.6. There were 9 amplicons identified as fails (less than 10 reads on average 
per sample).  Of these ABCB11 exons 6, 22 and 28 were all identified as problem 
amplicons at the PCR validation stage.  In addition, three amplicons had high GC 
content (NPC1 exon 1 at 71%, NPC2 exon 1 at 67%and SLC25A13 exon 1 at 75%) 
and one had high AT content (ABCB11 exon 3 at 70%), both of which are known to 
reduce efficiency of PCR reactions performed using standard conditions such as the 
emPCR step of the tNGS assay (Metzker, 2010). These amplicons were removed 
from the assay.  Lastly, ATP8B1 exon 18 and NPC1 exon 12 produced very few 
reads however no obvious reason for this was identified.  These amplicons were 
included in Runs 5-7 to rule out loading errors or random dropout, however the 
sequencing results did not improve therefore they were also removed from the assay 
at a later date.   
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3.3.3.2.5. Assay balancing 
A minimum of 30 reads covering each ROI was the target for this assay in order to 
ensure a high probability of sequencing both alleles in a heterozygote (De Leeneer 
et al., 2011). As highlighted in Figure 3.7 several amplicons in Runs 1 to 3 were not 
reaching the minimum of 30 reads on average (these runs were based on 46 
samples and 44 to 46 amplicons).  In order to increase the number of reads per 
sample, the number of samples per run for runs 5 to 7 was reduced to ten samples, 
from the equivalent of sixteen samples per run in Runs 1 to 3.  In addition, 
underperforming amplicons (10 to 30 reads on average) were added to the AA plate 
layout twice, in order to boost the amount of PCR product and increase the 
proportion of reads.  In order to free up space on the 3 AAs, over-performing 
amplicons (more than 70 reads on average) were di-plexed together.  Two rounds of 
assay balancing were performed; round one before Runs 5 to 7, and round two 
before Run 8, see Figure 3.7.  Lastly, over the course of the optimisation of the 
assay the protocol for the GS Junior was optimised and this lead to an increase in 
the number of reads produced.  Overall these measures increased the average 
number of reads per amplicon from 42 in Runs 1 to 3, to 114 in Run 8. 
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Figure 3.5 Comparison of Run 1A and Run 1B. 
These runs were the same fragment library run on two different GS Junior machines.  This graph compares the 
average number of reads for each amplicon and shows good correlation between the runs. 
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Run 1 - Reads per amplicon (on average per sample) 
Figure 3.6 This graph shows the average number of reads across samples for each amplicon in Run 1.   
It shows significant variation between amplicons, ie NPC1_Ex01 and NPC1_Ex02 for example. In addition, it shows several 
amplicons that are below 30 reads on average, and this was replicated across Runs 2 and 3.   
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Amplicons in coverage order 
Assay balancing - average number of reads per amplicon 
Run 1-3 Run 4 Run 5-7 Run 8
Figure 3.7 This graph shows the average number of reads for amplicons.   
The results for Runs 1-3 were adjusted for total numbers of reads on the run.  Runs 5-7 were averaged.  The improvements 
between Run 1-3 and Run 4 were achieved by decreasing the number of patients on a run from 16 to 10.  The improvement to 
Runs 5-7 were achieved by amplicon balancing as described in the text.  The improvements seen in Run 8 were as a result of 
further amplicon balancing and increased reads from the GS Junior. 
Kirsten McKay Bounford   
101 
 
3.3.3.2.6. Mutation detection 
Runs 1 to 3 were used to test the mutation detection capabilities of the tNGS assay.  
This was done by including samples with known mutations in the six genes.  Since 
mutations were not available for all the amplicons in the assay, polymorphism data 
from samples previously tested using FS was also used to establish whether 
sequence changes were reliably detected.  The majority of sequence variants not 
detected were in Run 3 because they were present in regions detected by the FS 
primers but were outside of the newly designed tNGS primers.  The next most 
common reason was that the amplicon containing the variant failed to amplify (less 
than 10 reads) and some variants were not detected because of low coverage on 
Runs 1-3 (less than 30 reads).  Excluding exon failure, sample failure and variants 
being outside of new primer sets, a total of 326 variants were tested (103 being 
unique). 321 of them were detected by the tNGS assay and 5 were not correctly 
called. Of the 5, 3 were the same polymorphism in ATP8B1, therefore there were 3 
unique variants incorrectly called. A breakdown of the detection of previously known 
sequence variants across the 3 runs is shown in Table 3.5.    
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Table 3.5: Summary of the sequence variants detected. 
A summary of the sequence variants during the evaluation of the tNGS assay. Three 
unique variants were not correctly identified by the assay. 
Run 
Number 
of 
unique 
variants 
Total 
number 
of 
variants 
Number 
correctly 
identified 
Number 
not 
correctly 
identified 
Comments 
1 36 97 96 1 
Variant 1 was within a 
homopolymer tract. 
2 25 89 89 0  
3 42 140 136 4 
Variant 2 was seen 3 times 
and was within a homopolymer 
tract. 
Variant 3 was in an exon with 
two overlapping amplicons. 
Total 103 326 321 5  
 
Variant 1 was a polymorphism present at one end of a homopolymer stretch of DNA; 
ATP8B1 c.2931+59T>A.  Sequencing of homopolymer stretches is a known problem 
for 454 sequencing (Loman 2012, see sections 3.3.3.3.6 and 3.3.3.3).  The sample 
in Run 1 was previously shown to be homozygous for this polymorphism, however 
the allele was only detected in 83% of reads, and the remainder of the reads were 
showing a deletion of a T.  This is because a deletion artefact was introduced when 
the homopolymer stretch increased from 5 adenines to 6 adenines (see Figure 3.8). 
Variant 2 resulted from a similar scenario.  It was a polymorphism present in a 
homopolymer stretch of DNA; ATP8B1 c.1820-54T>A.  c.1820-54T>A creates a 
poly-adenine stretch of 8 bases. 6 samples tested were known to have this 
polymorphism, 2 heterozyotes and 4 homozygotes.  3 homozygotes had low 
coverage, therefore the remaining 1 homozygote and 2 heterozygotes were 
incorrectly called.  Variation was identified by the pipeline at this position for all 3 
samples, although this was a deletion of a T rather than a T to A substitution. 
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Variant 3 was a homozygous missense mutation c.1766C>T p.Ser589Phe in 
SLC25A13 which had been called as heterozygous by the software in one patient.  
This was present in an exon containing two overlapping PCR fragments and was 
located within a primer sequence.  Therefore the primer sequence was contributing 
wild-type bases to the number of bases at that position and resulting in a 
heterozygous rather than a homozygous call.  The risk was another such mutation 
could be missed in the future, see 3.3.3.3.7.   
Although there were no true misses, as Variants 1 to 3 were called incorrectly rather 
than missed, there were three possible risks to missing a sequence variant identified 
by this analysis, and these were; 
1. variant is not covered adequately by assay, 
2. variant is in region overlapped by primer sequence, 
3. and, variant is located within a homopolymer stretch. 
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Figure 3.8 This is a screen shot of NextGene v1.6 Viewer, showing Variant 1.   
The top panel shows the reference sequence (top line) and the consensus sequence for the sample (second line) the 
homozygous T>A call is seen at the end of stretch of 5 adenines.  The bottom panel shows the individual reads for the sample 
and the base with difference from the reference sequence is highlighted in light blue.  The vast majority of the bases are 
adenines, however a small proportion are showing a 1 base deletion. 
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In addition, this mutation detection analysis was used to determine the 
optimum mutation filter threshold for the assay (see Table 3.6).  Using a 
mutation filter threshold of 15%, and when combined with a minimum depth of 
coverage of 30, the confidence for detection of heterozygous calls has been 
estimated as 99.995% (De Leeneer et al., 2011).  This assumes both the wild 
type and mutant sequence are amplified equally, however when this is not the 
case variants may be missed by these thresholds (Rattenberry et al., 2013).  
For this tNGS assay, all known variants were detected and therefore the 
sensitivity was 100%.  It was noted that many of the same limitations of FS 
apply to this assay, for example the possibility of allele drop out due to variants 
in the primer binding sites, inability to detect large-scale deletions, duplications 
and rearrangements, and the absence of intronic and promoter regions. 
Table 3.6:  The proportion of reads containing the variant base for all known 
sequence variants identified in Run 1.  
The heterozygous calls ranged from 27.78-50% and shows that all calls would 
be detected by a mutation filter threshold of less than 25%. The data for the 
homozygous calls identifies an outlier at 82.98% as the average and median 
were 98.89% and 100% respectively. This reflects the identification of Variant 
1. 
 
 
 
Run 1 
Heterozygous 
variants 
Homozygous 
variants 
Total 
number 
67 30 
Average 47.51% 98.89% 
Median 47.83% 100.00% 
Minimum 27.78% 82.98% 
Maximum 50.00% 100.00% 
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3.3.3.2.7. False positives 
16 potential variants were identified in Runs 1 to 3 in regions of the genes in 
which FS had not previously been done. Sequencing artefacts had been 
excluded as being present in more than one sample.  The 16 variants were 
sequenced using FS and the results compared with the tNGS.  9 were not 
present in the FS results and were false positives (and of these only 6 had 
tNGS coverage of 30 reads or more) therefore giving a false positive rate of 
0.2% (6 false positive results in a total of 5857 ROIs analysed). 7 variants were 
confirmed as real and were either low frequency polymorphisms or VUS. 
3.3.3.3. Data analysis validation 
NextGene software was available in the laboratory therefore it was selected as 
the primary data analysis method for the tNGS assay.  Here the overall 
strategy is described as well as the considerations made to risks identified 
during the tNGS Optimisation stage. 
3.3.3.3.1. File conversion 
The .sff file produced by the GS Junior was converted to an .fna file using the 
NextGene File Conversion tool.  These files are the equivalent of .fastq and 
.fasta, respectively, and the conversion leads to a small number of poor quality 
reads being discarded. Various parameters of the conversion settings were 
compared and only small differences to the percentage of bases converted 
were observed.  The settings used for file conversion were median score 
threshold greater than 20, maximum number of uncalled bases 3 or fewer, 
called base number of each read of 25 or fewer, trim or reject read when 3 or 
Kirsten McKay Bounford   
107 
 
more bases had a score of 16 or less. Reads and or bases not meeting these 
criteria were discarded. 
3.3.3.3.2. Contamination checks 
In order to check whether contamination from previous runs, or contamination 
of the negative control, were present, the NextGene Barcode Sort tool was 
used to sort the .fna file using all possible MID sequences (see 2.1.12.2, Table 
2.2).  Any MID which had more than a few reads present was investigated to 
find the cause of contamination.  A small number of reads was often present in 
the negative control, however when these were mapped against the tNGS 
reference sequences, very few of them matched.  This meant that these reads 
would not interfere with the interpretation of the results and could be ignored. 
3.3.3.3.3. Barcode Sort, Alignment and Variant Calling 
The .fna file was used to create individual sample projects in which the reads 
for each MID were mapped against GenBank files for each gene.  This was 
done automatically using the NextGene Autorun tool.  The Alignment settings 
used were a minimum of 100 bases or 85% of bases in a read mapped, 
ambiguously mapped reads were removed, rigorous alignment and detection 
of large indels was selected and unmatched ends were hidden.  For Variant 
Calling the mutation filter settings were that variants with less than 15% of 
reads, less than 3 mutant reads and less than 15 total reads were not called.  
This threshold was chosen based on calculations from De Leeneer et. al. (De 
Leeneer et al., 2011). 
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3.3.3.3.4. Variant Comparison 
Variants were called by NextGene using the Variant Comparison tool.  To do 
this modified GenBank files for the six genes were created.  Firstly exons with 
known mutations outside of 5 bases from the intron exon boundaries were 
noted.  Then GenBank files for each gene were annotated with Regions of 
Interest (ROIs).  In general, this was set to + or – 5 bases from the intron exon 
boundaries, with the exception of those exons in which known mutations 
existed outside of this.  The ROI for those exons were extended accordingly.  
Then the Variant Comparison tool was used to create a .vcf file listing all the 
variants called within those regions of interest for all the samples on the run.  
This allowed information on all samples to be interpreted at the same time, 
even those in whom a particular variant did not reach the mutation filter cut off 
(15% of reads).  This strategy was useful for the interpretation of sequencing 
artefacts generated by the GS Junior (see 3.3.3.3.6). 
3.3.3.3.5. Variant comparison checking 
The Variant Comparison .vcf file for the run was manipulated using Microsoft 
Excel to annotate and compare the variants.  Firstly, a polymorphism list was 
generated using prior knowledge of the genes and this was used to annotate 
any variants that were on that list as polymorphisms.  Secondly, any variants 
that were present in only one sample, and not on the polymorphism list, were 
automatically highlighted for confirmation by FS.  Thirdly, other variants were 
very likely to be sequencing artefacts.  The percentage of mutant alleles, and 
the direction bias were carefully checked to identify outliers from the run as a 
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whole.  Those outliers were highlighted for confirmation by FS.  The .vcf file 
was checked by two independent scorers and the most cautious interpretation 
of each variant was used. 
3.3.3.3.6. False positives 
As mentioned in section 3.3.3.2.6, sequencing of homopolymer stretches of 
DNA are a known problem for 454 sequencing (Loman 2012) and the reads 
are prone to insertion and deletion errors.  This manifested as dozens of false 
positive variant calls in the validation runs using the mutation filter of 15%. 
Most of these were insertions or deletions of one base in homopolymer 
stretches of more than 4 or 5 bases; however artefact base substitutions and 
errors in other regions of DNA were also routinely seen.  One reason for this 
was that quality scores for variant bases were not taken into account by this 
analysis pipeline and instead all calls were interpreted manually using the 
variant comparison method described above.  This was in an attempt to 
minimise the possibility of missing a sequence variant in the same region as an 
artefact.  As described above the mutant allele percentage and direction bias 
for all samples on the run was evaluated and any outliers were treated like a 
potential real variant and investigated by FS.  Outliers were identified by being 
outside of two standard deviations from the mean mutation percentage.  During 
the assay validation, potential variants that were identified by these criteria 
gave normal results using FS (n=76).   
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3.3.3.3.7. Overlapping fragments 
As identified during the assay validation (3.3.3.2.6), sequence variants may be 
masked if they are present in the same region of DNA as a primer from an 
overlapping fragment.  Ideally primer sequences should be trimmed off, 
however this was not possible within the NextGene software therefore a 
manual check of such regions was instigated.  There were a total of 8 
fragments whose primers overlapped ROIs and these were; ABCB11 Exon 
14A reverse and 14B forward, Exon 20 reverse, Exon 21 forward, ABCB4 
Exon 21A reverse, Exon 21B reverse, Exon 28A reverse, Exon 28B reverse, 
ATP8B1 Exon 5 forward, Exon 8 reverse, Exon 21A reverse and Ex21B 
forward, NPC1 Exon 8A reverse and Exon 08B forward, Exon 16 reverse and 
SLC25A13 Exon 16 reverse and Exon 17 forward. 
3.3.3.3.8. Depth of coverage 
For the project described in Chapter 4, it was not practical for financial reasons 
to FS all of the fragments that did not meet the minimum of 30 reads.  However 
the depth of coverage was recorded for all of the ROIs and if one heterozygous 
sequence variant was identified in any gene, the gaps for that gene were filled 
by FS.  In general, coverage was good and apart from those ROIs removed 
from the assay during the validation very few failed to meet the minimum 
threshold.  A few patients amplified poorly overall and these were repeated 
using the tNGS assay. 
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3.4. Discussion 
3.4.1. Microarray sequencing 
MS is an attractive alternative to traditional FS for genetic testing in neonatal 
cholestasis (Liu et al., 2009).  The BRUM1 microarray used in this study has a 
much larger capacity than was utilised in this experiment, as it contains probes 
for 92 genes associated with inherited disorders (Bruce et al., 2010).  Analysis 
of the ability of this microarray to detect known gene mutations has shown a 
97% mutation detection rate for base substitutions (Bruce et al., 2010).  The 
major advantage of MS over FS is increased capacity, allowing sequencing of 
multiple genes in one experiment as quickly as one gene using FS.  The main 
bottleneck is the requirement to quantify and to pool individual PCR products 
before hybridisation.  This step is time-consuming and prone to error (due to 
pipetting volume variations and potential sample mix-ups).  Therefore, 
automation of processes to minimise such errors would be useful, if not 
essential, for adoption of this method into clinical laboratories.  Alternatively, 
use of long range PCR as the preparatory step for the MS protocol could 
reduce the number of reactions to be pooled, although this is more sensitive to 
fragmented DNA than standard PCR (Cheng et al., 1995).  Finally, 
microfluidics-based PCR systems, such as the 48.48 Access Array (Fluidigm 
Corporation, San Francisco, CA), might be combined with MS to avoid the 
quantification and pooling step altogether.  This system allows the 
simultaneous but separate amplification of up to 48 PCR products for up to 48 
samples, in nanolitre-sized reactions, using a semi-automated process.  The 
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end product of the process is a pool of PCR products for each sample, and it is 
commonly used for target enrichment for benchtop next-generation 
sequencers.  
Of the mutations recorded in the Human Gene Mutation Database in ATP8B1 
and ABCB11, 24% and 16% respectively were small insertions or deletions 
(indels), although their combined frequency in PFIC cases is unknown as most 
are private mutations.  The major disadvantage of MS is it’s insensitivity for the 
detection of indels (Bruce et al., 2010).  Whilst known indels can be detected 
with proper microarray design, novel indels will be missed.  Larger insertions 
and deletions involving whole exons, of the type routinely detected by MLPA 
(Schouten et al., 2002), are not detected by either MS or FS.  Another 
disadvantage, underscored by the results of this study, is that mis-called base 
substitutions (both false negative and false positive calls), are frequent and 
were found in approximately 10% of samples in this study.   
In summary, MS allows rapid and cost-effective genetic screening in neonatal 
cholestasis and yields results relevant for patient management.  Many clinical 
laboratories are experienced in aCGH and thus have access to equipment 
required for MS, suggesting that MS could be implemented for a relatively 
small monetary investment.  In principle, MS could be applied to many clinical 
scenarios involving heterogeneous conditions, especially if the mutations tend 
to be base substitutions.   
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3.4.2. Targeted next generation sequencing 
The custom-designed tNGS strategy used here, incorporating 48.48 Access 
Arrays, GS Junior sequencing and NextGene analysis software, is a useful and 
attractive alternative to FS for sequencing genes involved in cholestasis.  Our 
evaluation found a sensitivity of 100% and a specificity of over 99%.  The main 
advantage of tNGS over FS is the capacity and if this is used optimally, the 
volume of sequencing data generated is greatly increased for the time put in.  
A few disadvantages were identified, primarily the inaccurate sequencing of 
homopolymer tracts and the problems of overlapping primer sequences.  Both 
of these potentially could be reduced or eliminated using bioinformatics 
expertise as described in the results section.  The main advantage over MS is 
that the AA TEM has avoided the PCR bottleneck, and in addition, many 
samples may be sequenced at the same time vastly reducing both the total 
preparation time and the hands-on time required compared to FS.  As 
previously mentioned, some of the limitations of FS also apply to the tNGS 
assay. The tNGS assay described here was chosen as the best method for the 
sequencing of samples for the research project described in Chapter 4. 
3.4.3. Alternative strategies 
Since the development of this tNGS assay, Illumina sequencing has become 
established as the NGS method of choice for the vast majority of research and 
clinical applications for testing of human DNA. A Pubmed seach for 
publications using ‘Illumina sequencing’ as the search term, returned 83 results 
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in 2009 (when this project began) and 1,323 in 2015; compare this with ‘454 
sequencing’ which returned 123 publications in 2009 and 358 in 2015. 
Illumina now produce a benchtop sequencer, the MiSeq, which has several 
advantages over the GS Junior.  Firstly, the capacity of the MiSeq is much 
higher therefore the cost per base is reduced (see 1.4.6.2).  Secondly, the 
clonal PCR step of the process is done on the machine instead of on the bench 
and is fully automated (compared to at least a day of lab work for the GS 
Junior for the emPCR).  Thirdly, Illumina sequencing has generally higher 
quality scores and less difficulty sequencing homopolymer stretches (Loman et 
al., 2012).  These factors combined mean the MiSeq would be the machine of 
choice if this assay were being designed now. 
Assuming the MiSeq was selected as the sequencer, the next decision would 
be the TEM.  If the same six genes were to be sequenced then a small-scale 
TEM such as TSCA or Haloplex might have been the best option.  However, 
there are many more genes associated with cholestasis, and in fact, the choice 
of genes for the tNGS assay was limited by the TEM and sequencer 
combination that was originally chosen.  Instead, a much larger group of genes 
could be targeted and for this a hybridisation approach might have been 
selected, for example SureSelect.  Alternatively a whole exome or clinical 
exome approach might have been more suitable, as off-the-shelf products 
would have required less optimisation than custom-designed products.  If so, 
the genes of interest may be selected at the data analysis stage by applying a 
ROI filter to the variant call file (.vcf).  The disadvantages of targeting a larger 
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number of genes include that although more mutations might be detected, 
undoubtedly more VUS be more likely required for larger data analysis 
projects.  Also, computing capabilities for data processing and data storage 
would become a greater consideration.   
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Chapter 4 – 
GENETIC INVESTIGATION OF 
INFANTS WITH LIVER DISEASE 
4.1. Introduction 
4.1.1. Liver disease in infants 
Neonatal cholestasis occurs at a frequency of approximately 1 in 2,500 births 
(Dick and Mowat 1985).  This diagnosis is considered in neonates presenting 
with prolonged neonatal jaundice, pale stools or dark urine and urgent 
investigations to differentiate between unconjugated and conjugated 
bilirubinaemia are indicated which include a fractionated bilirubin level and also 
ultrasound scan of the liver and biliary tree (De Bruyne et al., 2011b).  
Measurement of bilirubin in blood allows detection of conjugated 
bilirubinaemia; commonly agreed as direct bilirubin of greater than 1mg/dL or 
greater than 20% of total bilirubin (De Bruyne et al., 2011b).  Cholestasis may 
lead to progressive pruritus, growth retardation, fat-soluble vitamin 
deficiencies, hepatomegaly, splenomegaly, and cirrhosis and liver failure if left 
untreated (Roberts, 2003).  Treatment for neonatal cholestasis varies 
dependent upon the underlying defect.  For example, early surgical 
intervention for biliary atresia with the Kasai procedure can successfully re-
establish bile flow in some cases (Altman et al., 1997).  Also, liver 
transplantation can be curative in PFIC type 2, however the extra-hepatic 
features of PFIC type 1 will remain or even worsen following a liver transplant 
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(Davit-Spraul et al., 2009).  Several of the metabolic genetic conditions 
mentioned in Chapter 1 can be diagnosed using biochemical measurements of 
metabolites in blood or urine, or by measuring enzyme activity.  Others, 
including NPC, PFIC and NICCD, are difficult to diagnose by methods other 
than genetic diagnosis (Patterson et al., 2012), (Davit-Spraul et al., 2009). 
4.1.2. Genetic testing 
Genetic testing for NPC, PFIC and NICCD requires sequencing to identify 
unknown mutations in the coding regions and splice sites of the six genes 
involved.  Typically this is done using fluorescent Sanger sequencing (FS) 
however genetic testing is not routine in this patient group and genetic 
diagnosis may take months or years.  As a result, the incidence of NPC, PFIC 
and NICCD in patients presenting with neonatal liver disease is not known. 
4.1.3. Background to chapter 
Infants presenting with liver disease were recruited from worldwide centres and 
sent to the West Midlands Regional Genetics Laboratory where they were 
tested for mutations in the six genes involved in PFIC, NPC and NICCD.  
Initially microarray sequencing (MS) was used however this was replaced early 
in the project by targeted next generation sequencing (tNGS).  The 
development of the tNGS assay has been described in Chapter 3.  This study 
was a collaborative project involving the University of Birmingham, Birmingham 
Children’s Hospital and Birmingham Women’s Hospital and was funded by 
Actelion Pharmaceuticals.  Professor Paul Gissen, Professor Deirdre Kelly and 
Dr Chris Hendrickzs were responsible for the design of the project. Zoe Gray 
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and Carla Lloyd were responsible for the collection of the clinical data.  A 
manuscript has been prepared for publication and is presented in Appendix II.   
4.1.4. Chapter 4 Objectives 
 To test infants with liver disease for mutations in the ATP8B1, ABCB11, 
ABCB4, NPC1, NPC2 and SLC25A13 genes. 
 To determine the incidence of PFIC, NPC and NICCD in infants with 
liver disease. 
 To evaluate where possible the contribution of variation in these genes 
to infantile liver disease. 
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4.2. Materials & Methods 
4.2.1. Patients 
Two hundred and twenty two patients were recruited from twelve centers 
worldwide; seventy four from Germany, seventy three from the UK, sixteen 
from Poland, thirteen from Turkey, twelve from India, eleven from Oman, six 
from Denmark, five from the Netherlands, five from Bulgaria, four from Greece, 
two from Canada and one from Hungary. 
The patients met the recruitment criteria which allowed inclusion for patients 
presenting under the age of two years with either cholestasis (measured by 
serum conjugated bilirubin levels greater than 20μmol/L or more than 20% of 
total bilirubin), acute liver failure (prothrombin time greater than twice the upper 
limit of normal for age), hepatomegaly or splenomegaly (observed on 
examination or by ultrasound scan). Patients were excluded if they did not 
meet the above criteria or if a family member had a diagnosis of a genetic 
condition known to cause neonatal cholestasis. 
Questionnaires were completed by the referring centres detailing clinical 
features and investigations carried out.  Follow-up questionnaires were 
requested from referring centres after a minimum of one year.  In some cases, 
no follow-up information was obtained from the referring centres, and this is 
recorded as ‘Not available’ in tables 4-6. 
Ethical approval was obtained for the study prior to commencement, and all 
patients recruited were done so on this basis with ethical approval obtained 
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from the individual referral centres.  This testing was carried out in parallel to 
the usual diagnostic procedures used at the individual referral centres.  The 
results were fed back to the referral centres in order to aid with diagnosis 
where possible. 
4.2.2. DNA extraction 
DNA was extracted from peripheral blood samples using a variety of DNA 
extraction methods by the individual referring centres and sent to the West 
Midlands Regional Genetics laboratory for further processing.  Once received 
the DNA samples were quantified using the Nanodrop Spectrophotometer (See 
2.2.2.1). 
4.2.3. Sequencing methods 
The original sequencing method chosen for this work was MS; validation of this 
method has been reported previously (Bruce et al., 2010) (McKay et al., 2013).  
In the early stages of the project, the tNGS method became available, and it 
was decided to change the sequencing method. The reasoning for the change 
was that tNGS was less labour intensive and more sensitive than MS. The 
design and optimisation of this assay is described in Chapter 4. The regions 
interrogated by the microarray were fully covered by the tNGS assay therefore 
it was possible to combine the data gathered using both methods.  Forty four 
patients were tested using the MS method and one hundred and eighty seven 
patients were tested using the tNGS method.   
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4.2.3.1. BioMix Red PCR 
PCR was used to amplify the coding exons of NPC1, NPC2, ATP8B1, 
ABCB11, ABCB4 and SLC25A13 including the intron-exon boundaries prior to 
MS (See 2.2.3.2).  
4.2.3.2. Microarray Sequencing 
MS and data analysis was performed as described previously (2.2.6.2 and 
2.2.8.2). 
4.2.3.3. Access Array PCR for tNGS 
PCR was to amplify the coding exons of NPC1, NPC2, ATP8B1, ABCB11, 
ABCB4 and SLC25A13 including the intron-exon boundaries prior to tNGS.  
This was done using the Access Array system and is described in the chapter 
3 and 2.2.3.4. 
4.2.3.4. Targeted next generation sequencing 
The tNGS assay was performed using the GS Junior system as described in 
Chapter 3 and 2.2.6.3.  
4.2.3.5. NGS data analysis 
Analysis of tNGS data was done using NextGENe™ software as described in 
the chapter 3.  
4.2.3.6. Fluorescent Sanger sequencing 
9 amplicons in the tNGS design failed to give adequate sequencing results 
(see Chapter 3).  These were removed and instead tested using FS.  In 
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addition, sequence variants identified by tNGS were confirmed using FS 
(2.2.6.1). 
4.2.3.7. FS data analysis 
Analysis of the Sanger sequencing data was done using Mutation Surveyor™ 
as described in 2.2.8.1. 
4.2.4. Mutation nomenclature 
GenBank reference files are listed in Chapter 2 (2.2.9). 
4.2.5. Variant interpretation 
Variant interpretation was done using the methods described in Chapter 2 
(2.2.10).  
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4.3. Results 
4.3.1. Presenting features of cohort 
Two hundred and twenty two patients were recruited to this study; two hundred 
and twelve of them had cholestasis, one hundred and thirty seven of them had 
hepatomegaly, ninety nine had splenomegaly and thirty nine had acute liver 
failure amongst their presenting features.  On the whole cholestasis was the 
most common feature and acute liver failure was the least common feature, 
however further grouping of the presenting features of the cohort is shown in 
Figure 4.1. 
Figure 4.1: The presenting features of the cohort at the time of recruitment.  
KEY; C=cholestasis, H=hepatomegaly, S=splenomegaly, ALF=acute liver 
failure. 
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4.3.2. Sequence variants and interpretation 
One hundred and one unique sequence variants were identified by this study. 
All sequence variants were classified into the following categories; pathogenic, 
possibly pathogenic, uncertain significance, possibly benign and benign using 
guidelines previously described (see 2.2.10). The complete results of the 
analysis of variants are listed in Tables 4.1 to 4.4.  Variants classed as benign 
will not be discussed further. 
Nineteen patients were diagnosed with autosomal recessive genetic conditions 
in this study, and in addition twenty patients were found to have single 
heterozygous mutations.  A further forty four patients were identified who had 
variants of uncertain clinical significance that did not explain their clinical 
presentation, and the remainder of the patients (n=139), no sequence variants 
other than known benign polymorphisms were identified. 
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Table 4.1: Nonsense and frameshift mutations identified in the cohort.  Since 
these are all predicted to result in nonsense-mediated decay they were all 
considered pathogenic. 
 
Gene DNA Protein Known/Novel Conclusion Patient 
ABCB11 c.1081C>T p.Gln361* Novel Pathogenic 180 
ABCB11 c.1416T>A p.Tyr472* 
(Knisely et 
al., 2006) 
Pathogenic 156 
ABCB11 c.1558A>T p.Arg520* 
(Strautnieks 
et al., 2008) 
Pathogenic 185 
ABCB11 c.3904G>T p.Glu1302*  
(Strautnieks 
et al., 2008) 
Pathogenic 11 
ABCB11 c.3933C>G p.Tyr1311* Novel Pathogenic 218 
ABCB11 c.731_732insA p.Ile245Thrfs*26  Novel Pathogenic 194 
ATP8B1 c.2788C>T p.Arg930* 
(Klomp et al., 
2004) 
Pathogenic 36 
NPC1 c.2010C>A p.Cys670* Novel Pathogenic 28 
 
Table 4.2: Non-coding changes identified in the study, i.e changes in intronic or 
untranslated regions of the gene.   
Table 4.3: Amino acid changes identified in the study.   
Table 4.4 Synonymous changes identified in the study, i.e no change to the 
protein sequence is predicted, however there is a possibility of altered mRNA 
splicing patterns. 
KEY: 
Frequency data includes HET= heterozygosity figure from dbSNP (NCBI) 
1KG=1000Genomes data listed as number of alleles observed,                 
ESP=Exome Sequencing Project data listed as number of alleles observed, 
AA=African American, EA= European American.   
Conservation includes nucleotide (NA) conservation and amino acid (AA) 
conservation as scored by Alamut software.  
Protein Predictions include AGVGD=Align GVGD, SIFT and PP=PolyPhen-2 
tools.  
Splicing predictions were done using SSF=Splice-site finder, 
MES=MaxEntScan, NNS=NNSplice, GS=Genesplicer and HSF=Human 
Splicing Finder.  Results were ‘no change’= no change when compared to wild 
type sequence, ‘donor/acceptor destroyed’= predicted loss of wild type splice 
site or ‘cryptic donor/acceptor’=predicted creation of a novel splice site.  
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Table 4.2 Non-coding changes. 
 
Gene DNA HGMD SNP reference Frequency 
Splicing 
prediction tools 
Conclusion Patient 
ABCB11 c.1084-2A>G Novel No   
SSF acceptor destroyed, 
cryptic acceptor  
MES acceptor destroyed, 
cryptic acceptor  
NNS acceptor destroyed, 
cryptic acceptor  
GS acceptor destroyed, 
cryptic acceptor  
HSF acceptor destroyed 
Pathogenic 211 
ABCB4 c.1230+1G>T Novel No   
SSF donor destroyed 
MES donor destroyed 
NNS donor destroyed 
GS donor destroyed  
HSF donor destroyed 
Pathogenic 200 
ATP8B1 c.1918+8C>T Novel No   
SSF no change 
MES no change 
NNS no change 
GS no change 
HSF no change 
Likely benign 169 
ATP8B1 c.555-3T>C Novel No   
SSF no change 
MES cryptic donor 
NNS no change 
GS no change 
HSF no change 
Likely benign 91 
NPC1 
c.2131-5_2131-
4delTT 
Novel rs201618643 
No frequency 
data 
SSF no change 
MES no change 
NNS no change 
GS no change 
HSF no change 
Likely benign 77 
NPC2 c.441+1G>A 
(Bauer et 
al., 2013) 
rs140130028 
dbSNP HET 0.002 
1KG 2/2184 alleles 
ESP AA 7/4406 
and EA 76/8600 
alleles 
SSF donor destroyed 
MES donor destroyed 
NNS donor destroyed 
GS donor destroyed  
HSF donor destroyed 
Uncertain 
significance 
219, 162, 84, 
128, 132, 37, 
182 
SLC25A13 c.-115G>T Novel No   
SSF no change 
MES no change 
NNS no change 
GS no change 
HSF cryptic donor 
Likely benign 189 
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Table 4.3 Amino acid changes. 
 
Gene DNA Protein 
Known or 
Novel 
SNP 
refere
nce 
Frequency 
Conservatio
n 
Amino 
Acid 
differe
nce 
Protein prediction 
tools 
Splicing prediction 
tools 
Conclusion 
Patien
t 
ABCB11 c.127G>A V43I No 
rs1834
06496 
dbSNP not 
recorded 
1KG 2/2196 alleles 
ESP 4/3246 AA and 
24/8214 EA alleles 
NA not 
AA weak 
Small 
AGVGD C0  
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF Cryptic donor 
Likely benign 
143, 
173 
ABCB11 c.779G>A G260D  Novel No   
NA weak 
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Deleterious  
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
194 
ABCB11 c.1097T>G V366G Novel No   
NA high 
AA 
moderate 
Moder
ate 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
148 
ABCB11 c.1396C>A Q466K 
(Strautnieks 
et al., 2008) 
rs2001
48505 
dbSNP not 
recorded 
1KG not seen 
ESP 9/3246 AA and 
0/8214 EA alleles 
NA high 
AA high 
Small 
AGVGD C45 
SIFT Deleterious 
PP Probably 
damaging 
SSF Cryptic acceptor 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
101 
ABCB11 c.1409G>A R470Q 
(Strautnieks 
et al., 2008) 
(Byrne et al., 
2009)  
No   
NA high 
AA high 
Small 
AGVGD C35 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Pathogenic 
159,  
ABCB11 c.1445A>G D482G 
(Strautnieks 
et al., 2008) 
 
rs7254
9402 
Not frequency data 
NA high 
AA high 
Moder
ate 
AGVGD C65 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES Cryptic donor 
NNS No changes 
GS No changes 
HSF Cryptic donor 
Pathogenic 
181, 
180, 
179 
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ABCB11 c.1621A>C I541L 
(Nobili et al., 
2006) (Byrne 
et al., 2009) 
 
No   
NA high 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Pathogenic 
193 
ABCB11 c.1676T>C M559T Novel No   
NA high 
AA high 
Moder
ate 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF Cryptic donor 
Possibly 
pathogenic 
218 
ABCB11 c.1829T>C I610T Novel No   
NA weak 
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
54 
ABCB11 c.2093G>A R698H 
(Anzivino et 
al., 2013) 
rs1386
42043 
dbSNP HET 0.1 
1KG 52/2196 
ESP 38/3246 AA 
and 29/8214 EA 
alleles 
NA high  
AA moderate 
Small 
AGVGD C0 
SIFT Deleterious 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
29 
ABCB11 c.2596T>G  S866A Novel No   
NA moderate 
AA high 
Moder
ate 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
139 
ABCB11 c.2678C>T A893V Novel No   
NA high 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
164 
ABCB11 c.2708T>G V903G  Novel No   
NA high 
AA high 
Moder
ate 
AGVGD C35 
SIFT Deleterious 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
14 
ABCB11 c.2834G>A S945N Novel 
rs2008
57579 
dbSNP not 
recorded 
1KG not seen 
ESP 1/8214 EA 
alleles, AA not seen 
NA weak  
AA moderate 
Small 
AGVGD C0  
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
118 
ABCB11 c.2918C>T T973I Novel No   
NA moderate 
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
92 
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ABCB11 c.3517A>G 
N1173
D 
Novel No   
NA high 
AA moderate 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
216 
ABCB11 c.3628A>C T1210F 
(Strautnieks 
et al., 2008) 
(Byrne et al., 
2009) 
(Gonzales et 
al., 2012) 
No   
NA high 
AA moderate 
Small 
AGVGD C0  
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Pathogenic 
216 
ABCB4 c.217C>G L73V 
(Pauli-
Magnus et 
al., 2004) 
(Colombo et 
al., 2011) 
(Anzivino et 
al., 2013)  
rs8187
788 
dbSNP HET 0.001 
1KG 1/2184 alleles 
ESP 11/8600 EA 
alleles, AA not seen 
NA weak 
AA high 
Small 
AGVGD C15 
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
93 
ABCB4 c.262A>G T88A Novel No   
NA weak 
AA moderate 
Small 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
147 
ABCB4 c.523A>G T175A 
10 
(Rosmorduc 
et al., 2001) 
, 11 
(Wendum et 
al., 2012) 
rs5823
8559 
dbSNP HET 0.012 
1KG 13/2184 
alleles 
ESP 103/8600 EA 
and 7/4406 AA 
alleles 
NA high 
AA high 
Small 
AGVGD C55 
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
20 
ABCB4 c.524C>T T175M Novel No   
NA moderate 
AA high 
Moder
ate 
AGVGD C65 
SIFT Deleterious 
PP Probably 
damaging 
SSF Cryptic acceptor 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
213 
ABCB4 c.598G>T A200S Novel No   
NA weak 
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS Cryptic acceptor 
HSF No changes 
Likely benign 
30 
ABCB4 c.1529A>G N510S 
(Davit-Spraul 
et al., 2010) 
(Anzivino et 
al., 2013)  
 
rs3753
15619 
dbSNP not 
recorded 
1KG not seen 
ESP 1/8600 EA 
alleles, AA not seen 
NA weak 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Possibly 
damaging 
SSF Cryptic donor 
MES No changes 
NNS No changes 
GS No changes 
HSF Cryptic acceptor 
Possibly 
pathogenic 
18 
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ABCB4 c.1584G>C E528D 
(Rosmorduc 
et al., 2003) 
rs8187
797 
dbSNP HET 0.019 
1KG 21/2184 
alleles 
ESP 138/4406 AA 
alleles, EA not seen 
NA not 
AA moderate 
Small 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
23 
ABCB4 c.1597C>A L533M Novel No   
NA moderate 
AA high 
Small 
AGVGD C0 
SIFT Tolerated 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
19 
ABCB4 c.1624G>C A542P  Novel No   
NA high 
AA high 
Small 
AGVGD C25  
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
2 
ABCB4 c.1652C>T P551L Novel No   
NA high 
AA high 
Moder
ate 
AGVGD C65 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
148 
ABCB4 c.1769G>A R590Q 
(Degiorgio 
et al., 2007) 
rs4557
5636 
dbSNP HET 0.15 
1KG 16/2184 
alleles 
ESP 74/8600 EA 
and 28/4406 AA 
alleles 
NA high 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
33, 4 
ABCB4 
c.1858_186
0delAAG 
K620de
l 
Novel No   AA moderate     
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
203 
ABCB4 c.1954A>G R652G 
(Liu et al., 
2009) (Davit-
Spraul et al., 
2010)  
 
rs2230
028 
dbSNP HET 0.243 
1KG 
ESP 679/8600 EA 
and 1513 AA alleles 
NA not 
AA weak 
Moder
ate 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
28, 
23, 
20, 
34 
ABCB4 c.2324C>T T775M 
(Degiorgio et 
al., 2007)  
rs1480
52192 
dbSNP HET 0.001 
1KG not seen 
ESP 7/8600 EA and 
NA weak 
AA high 
Moder
ate 
AGVGD C0 
SIFT Deleterious 
PP Probably 
SSF No changes 
MES No changes 
NNS No changes 
Uncertain 
significance 
135 
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1/4406 AA alleles damaging GS No changes 
HSF No changes 
ABCB4 c.2363G>A R788Q 
(Rosmorduc 
et al., 2003) 
rs8187
801 
dbSNP HET 0.045 
1KG 50/2184 
alleles 
ESP 4/8600 EA and 
330/4406 AFR 
alleles 
NA moderate 
AA high 
Small 
AGVGD C35  
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
202 
ABCB4 c.2800G>A A934T 
(Rosmorduc 
et al., 2003) 
 
rs6173
0509 
dbSNP HET 0.006 
1KG 7/2184 alleles 
ESP 54/4406 AFR 
alleles, EA not seen 
NA high 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
163 
ABCB4 c.2809T>C T937H Novel No   
NA moderate 
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
11 
ABCB4 c.3317A>G 
E1106
G 
Novel 
rs1390
42803 
dbSNP not 
recorded 
1KG not seen 
ESP 2/4406 AA 
alleles, EA not seen 
NA moderate 
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Deleterious 
PP Possibly 
damaging 
SSF Cryptic acceptor 
MES Cryptic acceptor 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
185 
ABCB4 c.3403G>A 
E1135
K 
Novel No   
NA high 
AA high Small 
AGVGD C55 
SIFT Deleterious 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
195 
ATP8B1 c.134A>C N45T 
(Painter et 
al., 2005) 
rs1465
99962 
dbSNP HET 0.005 
1KG 5/2184 alleles 
ESP 37/8600 EA 
and 4/4406 AA 
alleles 
NA weak 
AA moderate 
Small 
AGVGD C0 
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
51 
ATP8B1 c.208G>A D70N 
(Klomp et al., 
2004)  
(Mullenbach
, 2005) 
(Folmer et 
al., 2009) 
rs3471
9006 
dbSNP HET 0.007 
1KG 8/2184 alleles 
ESP 26/8600 EA 
and 5/4406 AA 
alleles 
NA moderate 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
187, 
83, 6 
ATP8B1 c.287C>G A96G Novel No   
NA moderate  
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
109 
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ATP8B1 c.607A>G K203E 
(Painter et 
al., 2005) 
rs5635
5310 
dbSNP 2/2184 
alleles 
1KG 16/8600 EA 
and 3/4406 AA 
alleles 
ESP 
NA moderate 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
83 
ATP8B1 c.1177A>G I393V Novel 
rs3431
5917 
dbSNP HET 0.012 
1KG 13/2184 
alleles 
ESP 64/8600 EA 
and 6/4406 AA 
alleles 
NA high 
AA high 
Small 
AGVGD C0 
SIFT Tolerated 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF Cryptic donor 
Likely benign 
14 
ATP8B1 c.1244A>G Q415R Novel No   
NA high 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
199 
ATP8B1 c.1286A>C E429A 
(Klomp et 
al., 2004) 
rs3401
8205 
dbSNP HET 0.014 
1KG 15/2184 
alleles 
ESP 37/8600 EA 
and 4/4406 AA 
alleles 
NA weak 
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
160 
ATP8B1 c.1367C>T T456M 
(Klomp et 
al., 2004) 
rs1219
09104 
Not frequency data 
NA high 
AA high 
Moder
ate 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
183 
ATP8B1 c.2083G>A E695K Novel No   
NA high 
AA high 
Small 
AGVGD C55 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
183 
ATP8B1 c.2425A>C I809L Novel No   
NA moderate 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
23 
ATP8B1 c.2498G>A R833Q Novel No   
NA weak 
AA moderate 
Small 
AGVGD C0 
SIFT Tolerated 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
213 
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ATP8B1 c.3043T>C F1015L Novel No   
NA high 
AA high 
Small 
AGVGD C15 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
139 
ATP8B1 c.3633C>A F1211L Novel No   
NA moderate 
AA high 
Small 
AGVGD C15 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
30 
ATP8B1 c.3656A>G 
D1219
G 
Novel No   
NA moderate 
AA high 
Moder
ate 
AGVGD C65 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
33 
NPC1 c.467T>C M156T Novel 
rs1476
15070 
dbSNP not 
recorded 
1KG not seen 
ESP 1/8600 EA 
alleles, AA not seen 
NA high 
AA high 
Moder
ate 
AGVGD C25 
SIFT Deleterious 
PP benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
116 
NPC1 c.873G>T W291C Novel 
rs1381
51007 
dbSNP HET 0.002 
1KG 2/2184 alleles 
ESP 1/8600 EA and 
6/4406 AA alleles 
NA high 
AA high 
Large 
AGVGD C15 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
153 
NPC1 c.885A>C K295N Novel No   
NA weak  
AA moderate 
Moder
ate 
AGVGD C0 
SIFT Deleterious 
PP Benign 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
26 
NPC1 c.2000C>T S667L 
(Tamura et 
al., 2006) 
No   
NA high 
AA high 
Large 
AGVGD C65 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS Cryptic acceptor 
HSF No changes 
Pathogenic 
43 
NPC1 c.3107C>T 
T1036
M 
(Carstea, 
1997) 
rs2894
2104 
Not frequency data 
NA high 
AA moderate 
Moder
ate 
AGVGD C15 
SIFT Deleterious 
PP Probably 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Pathogenic 
115 
NPC1 c.3182T>C I1061T 
(Yamamoto 
et al., 1999) 
(Pipalia et al., 
2011) 
(Gelsthorpe 
rs8035
8259 
dbSNP not 
recorded 
1KG not seen 
ESP 4/8600 EA and 
1/4406 AA alleles 
NA high 
AA high 
Moder
ate 
AGVGD C25 
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Pathogenic 
43 
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et al., 2008) 
NPC1 c.3362T>G L1121R Novel No   
NA high 
AA moderate 
Moder
ate 
AGVGD C35 
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS Cryptic donor 
HSF No changes 
Possibly 
pathogenic 
157 
NPC1 c.3614C>T T1205I Novel No   
NA high 
AA high 
Small 
AGVGD C65 
SIFT Deleterious 
PP Probably 
damaging 
SSF Cryptic acceptor 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
54 
NPC2 c.212A>G K71R Novel 
rs1420
75589 
dbSNP HET 0.001 
1KG 1/2184 alleles 
ESP 2/8600 EA 
alleles, AA not seen 
NA moderate 
AA moderate 
Small 
AGVGD C0 
SIFT Tolerated 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Uncertain 
significance 
172 
SLC25A13 c.639T>G H213Q Novel No   
NA weak 
AA high 
Small 
AGVGD C0 
SIFT Deleterious 
PP Benign 
SSF Cryptic donor 
MES No changes 
NNS No changes 
GS No changes 
HSF Cryptic acceptor 
Uncertain 
significance 
21 
SLC25A13 c.1903G>T D635Y Novel No   
NA moderate 
AA high 
Large 
AGVGD C15 
SIFT Deleterious 
PP Possibly 
damaging 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Possibly 
pathogenic 
147 
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Table 4.4 Synonymous changes 
Gene DNA Protein 
Known 
or Novel 
SNP 
reference 
Frequency 
summary 
Splicing 
prediction tools 
Conclusion Patient 
ABCB11 c.1281C>T p.= Novel rs11568360 
dbSNP HET 0.02 
1KG 2/2196 alleles 
ESP 1/3246 AA and 0/8214 
EA alleles 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
111 
ABCB11 c.1530C>A p.=  Novel 
rs37470110
9  
dbSNP not recorded 
1KG not seen  
ESP 1/8330 AA and 2/3924 
EA alleles 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
135 
ABCB11 c.3589C>T p.=  Novel No   
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
210 
ABCB11 c.3846C>T p.=  Novel 
rs36953886
3  
dbSNP not recorded 
1KG not seen 
ESP 2/4240 EA alleles, AA 
not seen 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
210 
ABCB4 c.1143A>G p.= Novel 
rs14267196
9  
dbSNP not recorded 
1KG not seen 
ESP 1/8600 EA alleles, AA 
not seen 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
166 
ABCB4 c.3037A>C p.=  Novel rs2230029 
dbSNP HET 0.004 
1KG not seen 
ESP not seen 
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
214, 69 
ABCB4 c.696C>T p.=  Novel rs8187791 
dbSNP HET 0.004 
1KG 4/2184 alleles 
ESP 4/8600 EA and 1/4406 
AA alleles 
SSF cryptic acceptor 
MES No changes 
NNS cryptic acceptor 
GS No changes 
HSF No changes 
Uncertain 
significance 
155 
ATP8B1 c.2937A>C p.= Novel No   
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
148 
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ATP8B1 c.852A>C p.=  Novel No   
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
128 
NPC1 c.3519A>G p.=  Novel No   
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF cryptic acceptor 
Likely benign 
105 
NPC1 c.3756G>A p.=  Novel No   
SSF No changes 
MES No changes 
NNS No changes 
GS No changes 
HSF No changes 
Likely benign 
75 
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A summary of the results is shown by Figure 4.2.  Genetic diagnoses of the 
autosomal recessive conditions were made by identification of two changes in 
the same gene which were determined to be ‘Pathogenic’ or ‘Possibly 
pathogenic’; and this was identified in 8.5% (n=19) of the cohort (Table 4.5).  
Thirteen patients carried homozygous variants, and 6 of these were known to 
have consanguineous parents.  Patient 179 was known to have non-
consanguineous parents but is homozygous for a relatively frequent missense 
mutation in ABCB11. Cholestasis was a presenting feature of all of the PFIC 1 
and 2 patients as would be expected.  Cholestasis was more frequent in the 
patients with diagnoses than in the whole cohort, presumably because of the 
frequency of PFIC cases. As a result, patients with cholestasis were more likely 
to have a genetic diagnosis made than patients without cholestasis. 
Single heterozygous variants, classified as pathogenic or possibly pathogenic, 
were identified in 9% of the patients (n=20, see Table 4.6). 
 
 
9% 
9% 
18% 
64% 
Two mutations (homozygous or
compound heterozygous)
One mutation (heterozygous)
VUS only
No variants identified
Figure 4.2: Summary of genetic findings in patients (n=222) 
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No pathogenic variants or variants classified as possibly pathogenic were 
identified in one hundred and eighty three of the two hundred and twenty two 
patients tested, however in forty one of these (18%), variants were identified 
which were classified as of unknown significance (VUS) or as possibly benign 
(see Table 4.7). 
Thirteen sequence variants were classified as VUS because there was 
evidence for and against pathogenicity.  None of these variants were identified 
in a patient who also had a variant classed as ‘pathogenic’ or ‘possibly 
pathogenic’ in the same gene (see Table 4.7). For this reason it has not been 
possible to confirm that any of these VUS are causative of autosomal 
recessive disease.   
4.3.3. Clinical and genetic features of patients with ATP8B1 
mutations and variants 
Three patients were diagnosed with PFIC-1 (Table 4.5). All three presented 
with cholestasis, and two of the three also presented with hepatomegaly. One 
patient had a PEBD aged seven months, one had a liver transplant, and 
information was not available for the third.  
Five patients were identified with single heterozygous mutations in ATP8B1 
(Table 4.6). All five presented with cholestasis, one of whom also had 
hepatomegaly, and one of whom had hepatosplenomegaly and acute liver 
failure. Symptoms of progressive liver disease resulted in liver transplantation 
in three patients, although BA was cited as an alternative diagnosis in two of 
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these cases. The symptoms of the remaining two cases were reported to have 
resolved. 
Eight patients were identified with VUS in the ATP8B1 gene (Table 4.7). Seven 
of these had cholestasis, six had hepatomegaly, five had splenomegaly, and 
three had acute liver failure. Two of the eight patients also had symptoms of 
progressive liver disease which resulted in liver transplants, and both had 
alternative diagnoses of BA and VACTERL association. Another two patients 
also had alternative diagnoses of biliary atresia, but their condition had 
stabilised following Kasai portoenterostomy. No follow-up information was 
available for the remaining four patients with VUS in the ATP8B1 gene. 
4.3.4. Clinical and genetic features of patients with ABCB11 
mutations and variants 
Eleven patients were diagnosed with PFIC-2 (Table 4.5), and all presented 
with cholestasis. Additionally nine patients had hepatomegaly, seven had 
splenomegaly, and four had acute liver failure. Three patients underwent 
PEBD procedures, among which cholestasis persisted in two cases. Three 
patients underwent liver transplants, and all were asymptomatic at follow up. 
There were no follow-up data available for the remaining five patients.  
Four patients were identified with single heterozygous mutations in ABCB11, 
and one of these also had a possibly pathogenic change in ABCB4 (Table 4.6). 
Symptoms resolved without intervention in two of these cases, one patient 
improved after a PEBD procedure, and no information was available for the 
fourth patient. 
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Nine patients were identified with only VUS in the ABCB11 gene (Table 4.7); 
eight of which presented with cholestasis, seven with splenomegaly, and five 
with hepatomegaly. None of these patients had acute liver failure. At follow up; 
one patient was reported to have had progressive liver disease and an 
alternative diagnosis of AGS. Two patients were found to have BA and were 
stable following Kasai portoenterostomy. One patient had an alternative 
diagnosis of Abernathy malformation and was stable. Two were asymptomatic, 
with no further information available. 
4.3.5. Clinical and genetic features of patients with ABCB4 
mutations and variants 
Four patients were diagnosed with PFIC-3 (Table 4.5). All four presented with 
hepatomegaly, three presented with cholestasis, two had acute liver failure, 
and one had splenomegaly. One patient with cholestasis, hepatomegaly and 
acute liver failure had a liver transplant and was asymptomatic at follow up. No 
follow-up information was available for the other three cases.  
Single heterozygous ABCB4 mutations were identified in three patients 
(excluding the previously mentioned patient 100 who had mutations in ABCB11 
and ABCB4 (Table 4.6). All three presented with cholestasis: two had 
splenomegaly, one had hepatomegaly, and one had acute liver failure. Follow-
up information was available for two of these three cases. One had BA 
resulting in a liver transplant, and one died aged fifteen months due to multi-
organ failure. 
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Thirteen patients were identified with only VUS in the ABCB4 gene (Table 4.7), 
all of whom presented with cholestasis. Nine also had hepatomegaly, eight had 
splenomegaly, and three had acute liver failure. Six of the patients were 
subsequently diagnosed with biliary atresia, three of whom had a liver 
transplant and three of whom underwent Kasai portoenterostomy. Another 
patient had symptoms of progressive liver disease and was suspected of 
having a long-chain fatty acid oxidation defect. One patient was reported to be 
asymptomatic at follow up, and no follow-up information was available for the 
remaining four patients. 
4.3.6. Clinical and genetic features of patients with NPC1 
mutations and variants 
One patient was diagnosed with NPC1 (Table 4.5). This patient presented with 
cholestasis and splenomegaly but no further information was available at 
follow-up. A further seven patients were identified with a single heterozygous 
mutation in the NPC1 gene (Table 4.6). All seven had cholestasis: five had 
hepatomegaly, two had splenomegaly, and one had acute liver failure at 
presentation. In four patients, visceral symptoms resolved with no intervention. 
One patient with progressive liver disease received an alternative diagnosis of 
BA and required a liver transplant. However, a further two patients had 
progressive liver disease and no alternative diagnosis.  
Four patients were identified with VUS in the NPC1 gene (Table 4.7), three of 
whom presented with cholestasis (two with splenomegaly; and one with acute 
liver failure). Three patients had symptoms of progressive liver disease that 
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resulted in liver transplantation. Alternative diagnoses of neonatal 
hemochromatosis, transient myelodysplastic syndrome associated with 
Trisomy 21 syndrome, and AGS were reported in three patients. 
4.3.7. Clinical and genetic features of patients with NPC2 
mutations and variants 
No patients were diagnosed with Niemann Pick disease type C2, and no 
patients were found with single heterozygous mutations in the NPC2 gene. 
VUS in the NPC2 gene were identified in eight patients (Table 4.7). Patient 172 
presented with cholestasis, hepatomegaly and splenomegaly, and had a final 
diagnosis of extrahepatic biliary atresia (BA).  Seven of the eight patients were 
found to be heterozygous for the same NPC2 variant; c.441+1G>A (see Figure 
4.3).  All of these presented with cholestasis, six patients had hepatomegaly, 
two had splenomegaly, and one had acute liver failure. One patient had 
progressive liver disease and was subsequently diagnosed with acute 
lymphoblastic leukaemia. Three more patients had features of progressive liver 
disease but no alternative diagnosis was found. No follow-up information was 
available for the remaining three patients.  This variant was the most frequent 
finding in this cohort, occurring in 1.5% of patients. 
4.3.8. Clinical and genetic features of patients with SLC25A13 
mutations and variants 
No patients were diagnosed with NICCD, but one patient with a single 
heterozygous mutation in SLC25A13 was identified (Table 4.6). This patient 
had cholestasis and hepatosplenomegaly, and these symptoms resolved 
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without intervention. A further two patients had VUS in the SLC25A13 gene 
(Table 4.7). Both presented with cholestasis and were asymptomatic at follow 
up. 
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Table 4.5: Genetic findings, presenting features and outcomes in patients diagnosed with autosomal recessive conditions. 
12 had PFIC2, 5 had PFIC3, 3 had PFIC1 and 1 had NPC.  Parental samples were not tested therefore it has been 
assumed that patients with two different mutations were compound heterozygotes.   
KEY: C=cholestasis, H=hepatomegaly, S=splenomegaly, ALF=acute liver failure, LT=liver transplant, PEBD=partial 
extrahepatic biliary diversion. 
Patient Mutation 1 Mutation 2 
Diagnosi
s 
Presenting 
features 
Features at follow-up 
43 NPC1 c.2000C>T  p.(S667L) NPC1 c.3182T>C  p.(I1061T) NPC C, H Not available 
199 ATP8B1 c.1244A>G p.(Q415R) ATP8B1 c.1244A>G p.(Q415R) PFIC 1 C, H Not available 
183 ATP8B1 c.1367C>T p.(T456M) ATP8B1 c.2083G>A p.(E695K) PFIC 1 C, H PEBD at 7m, C gradually resolved 
36 ATP8B1 c.2788C>T p.(R930*) ATP8B1 c.2788C>T p.(R930*) PFIC 1 C LT. Current symptoms unknown 
194 
ABCB11 c.731_732insA 
p.(I245Tfs*26)  
ABCB11 c.779G>A p.(G260D)  PFIC 2 C, H 
PEBD at 14m  
Pruritis resolved C persists 
180 ABCB11 c.1081C>T p.(Q361*) ABCB11 c.1445A>G  p.(D482G) PFIC 2 C, S PEBD at 14m. C persists 
211 ABCB11 c.1084-2A>G ABCB11 c.1084-2A>G PFIC 2 C, S, H, ALF Not available 
159 ABCB11 c.1409G>A p.(R470Q) ABCB11 c.1409G>A p.(R470Q) PFIC 2 C, H LT. Asymptomatic post-transplant 
205 ABCB11 c.1409G>A p.(Q470R) ABCB11 c.1409G>A p.(Q470R) PFIC 2 C, S, H Not available 
156 ABCB11 c.1416T>A p.(Y472*) ABCB11 c.1416T>A p.(Y472*) PFIC 2 C, H, ALF Not available 
179 ABCB11 c.1445A>G p.(D482G) ABCB11 c.1445A>G p.(D482G) PFIC 2 C, S, H PEBD at 9m. C resolved 
218 ABCB11 c.1676T>C p.(M559T) ABCB11 c.3933C>G p.(Y1311*) PFIC 2 C, S, H, ALF LT. Asymptomatic post-transplant 
14 ABCB11 c.2708T>G p.(V903G)  ABCB11 c.2708T>G p.(V903G)  PFIC 2 C, S, H, ALF Not available 
216 ABCB11 c.3517A>G p.(N1173D) ABCB11 c.3628A>C p.(T1210F) PFIC 2 C LT. Asymptomatic post-transplant 
11 ABCB11 c.3904G>T p.(E1302*)  ABCB11  c.3904G>T p.(E1302*)  PFIC 2 C, S, H Not available 
200 ABCB4 c.1230+1G>T ABCB4 c.1230+1G>T PFIC 3 C, S, H, ALF Not available 
2 ABCB4 c.1624G>C p.(A542P)  ABCB4 c.1624G>C p.(A542P)  PFIC 3 C, H Not available 
148 ABCB4 c.1652C>T p.(P551L) ABCB4 c.1652C>T p.(P551L) PFIC 3 C, H, ALF LT. Asymptomatic post-transplant 
203 
ABCB4 c.1858_1860delAAG 
p.(K620del) 
ABCB4 c.1858_1860delAAG 
p.(K620del) 
PFIC 3 H Not available 
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Table 4.6: Genetic findings, presenting features and outcomes in patients with only single heterozygous mutation. 6 had 
NPC1 mutations, 3 had ATP8B1 mutations, 3 had of ABCB11 mutations, 2 had ABCB4 mutations and one had an 
ABCB11 mutation plus an ABCB4 mutation.   
KEY: C=cholestasis, H=hepatomegaly, S=splenomegaly, ALF=acute liver failure, LT=liver transplant, PEBD=partial 
extrahepatic biliary diversion, PN=parenteral nutrition, Dx=diagnosis, BA=biliary atresia. 
Gene Mutation 
Patien
t 
Presenting 
features 
Final diagnosis and status at follow-up 
NPC1  c.467T>C p.(M156T) 116 C, H, S 
Symptoms resolved. No intervention 
Alternative diagnosis: multisystem juvenile 
xanthogranuloma 
NPC1 c.873G>T p.(W291C) 153 C Symptoms resolved. No intervention 
NPC1  c.2010C>A p.(C670*) 28 C, H 
Progressive liver disease 
Alternative diagnosis: BA  
LT (22m). Asymptomatic post-transplant 
NPC1  c.2010C>A p.(C670*) 22 C, S 
Symptoms resolved. No intervention 
Alternative diagnosis: Hirschsprung's disease 
necessitating PN. 
NPC1  
c.3107C>T 
p.(T1036M) 
115 C, H Symptoms resolved. No intervention 
NPC1  c.3614C>T p.(T1205I) 54 C, H Progressive liver disease with portal hypertension 
NPC1  c.3614C>T p.(T1205I) 157 C, H, ALF 
Progressive liver disease 
LT. Asymptomatic post-transplant 
ATP8B1 c.287C>G p.(A96G) 109 C, H Symptoms resolved. 
ATP8B1 c.2425A>C p.(I809L) 23 C 
Progressive liver disease 
Alternative diagnosis: BA 
LT (15m). Asymptomatic post-transplant 
ATP8B1  
c.3043T>C 
p.(F1015L) 
139 
C, H, S, 
ALF 
Progressive Liver disease 
Alternative diagnosis: BA 
LT(10m). Asymptomatic post-transplant 
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ATP8B1  
c.3633C>A 
p.(F1211L) 
30 C Symptoms resolved. No intervention 
ATP8B1  
c.3656A>G 
p.(D1219G) 
33 C 
Progressive liver disease 
LT(30m). Asymptomatic post-transplant 
ABCB11  c.1445A>G p.(D482G) 179 C, ALF PEBD at 5m, symptoms resolved. 
ABCB11 
ABCB4  
c.1558A>T p.(R520*) 
c.3317A>G 
p.(E1106G) 
185 C, H, S 
Symptoms resolved. No intervention 
ABCB11  c.1621A>C p.(I541L) 193 C Symptoms resolved. No intervention 
ABCB11  c.2678C>T p.(A893V) 164 C, H, S Not available 
ABCB4  c.524C>T p.(T175M) 213 C, H Not available 
ABCB4  c.1529A>G p.(N510S) 18 C, S 
Progressive liver disease 
Alternative diagnosis: BA 
LT (8m). Asymptomatic post-transplant 
ABCB4 
c.3403G>A 
p.(E1135K) 
195 C, S, ALF 
Progressive liver disease (multi-organ failure) 
Died age 15m 
SLC25A
13 
c.1903G>T p.(D635Y) 134 C, H, S Symptoms resolved. No intervention 
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Table 4.7 – Genetic findings, presenting features and outcomes in patients with only VUS or likely benign variants. 
KEY: C=cholestasis, H=hepatomegaly, S=splenomegaly, ALF=acute liver failure, EHBA=extrahepatic biliary atresia, 
LT=liver transplant, PEBD=partial extrahepatic biliary diversion, PN=parenteral nutrition, ICP=intrahepatic cholestasis of 
pregnancy 
Gene Sequence change Patient  
Presenting 
features 
Final diagnosis and status at follow-up 
NPC1 c.885A>C p.(K295N) 26 ALF 
Progressive liver disease 
Alternative diagnosis: Neonatal hemochromatosis 
LT (1m). Asymptomatic post-transplant 
NPC1 c.2131-5_2131-4delTT 77 C, H 
Progressive liver disease 
Alternative diagnosis: Trisomy 21; transient myelodysplastic syndrome  
LT (3m). Asymptomatic post-transplant 
NPC1 c.3519A>G p.(=) 105 C Suspected Alagille syndrome (phenotypic features); lost to follow-up. 
NPC1 c.3756G>A p.(=) 75 C, H 
Progressive Liver disease 
Two LTs; living related LT at 14m and cadaveric LT 4 days later.  
Asymptomatic post-transplant 
NPC2 c.212A>G p.(K71R) 172 C, H, S 
Progressive liver disease with portal hypertension 
Alternative diagnosis: BA. Stable post-Kasai 
NPC2 c.441+1G>A 
37 C, H Progressive liver disease 
219 C, H Progressive liver disease 
155 C, H, S 
Progressive liver disease  
Alternative diagnosis: acute lymphoblastic leukaemia 
182 C, H, S, ALF 
Progressive liver disease 
LT (13m). Asymptomatic post-transplant 
84 C, H Not available 
128 C, H Not available 
132 C, ALF Not available 
ATP8B1 c.134A>C p.(N45T) 51 C, S 
Stable liver disease 
Alternative diagnosis: BA and Cat Eye syndrome. Stable post-Kasai 
ATP8B1 c.208G>A p.(D70N) 
187 H, S, ALF 
Progressive liver disease 
Alternative diagnosis:  VACTERL association; required PN support. 
LT. Asymptomatic post-transplant 
83 C, S, ALF Not available 
6 C, H, ALF Not available 
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ATP8B1 c.555-3T>C 91 C, H, S 
Stable liver disease 
Alternative diagnosis:  BA. Stable post-Kasai 
ATP8B1 c.852A>C p.(=) 128 C, H Not available 
ATP8B1 
c.1918+8C>T 
(Homozygous) 
169 C, H, S 
Progressive liver disease 
Alternative diagnosis:  BA 
LT (10m) 
Asymptomatic post-transplant 
ATP8B1 c.1286A>C p.(E429A) 160 C, H Not available 
ABCB11 c.127G>A p.(V43I) 
173 C, S Asymptomatic  
143 C, H, S 
Stable liver disease 
Alternative diagnosis:  BA 
Stable post-Kasai 
ABCB11 c.1281C>T p.(=) 111 C, S 
Stable liver disease 
Alternative diagnosis:  Abernethy malformation 
ABCB11 c.1396C>A p.(Q466K) 101 C, S Asymptomatic 
ABCB11 c.1530C>A p.(=) 135 C, H, S 
Stable liver disease 
Alternative diagnosis: BA.  
Stable post-Kasai 
ABCB11 c.2093G>A p.(R698H) 29 S Not available 
ABCB11 c.2834G>A p.(S945N) 118 C, H 
Stable liver disease 
Alternative diagnosis: BA 
Stable post-Kasai 
ABCB11 c.2918C>T p.(T973I) 92 C, H, S Asymptomatic 
ABCB11 c.3589C>T p.(=) 210 C, H Not available 
ABCB11 c.3846C>T p.(=) 210 C, H Not available 
ABCB4 c.217C>G (L73V) 93 C 
Stable liver disease 
Alternative diagnosis:  BA Type 3 
Stable post-Kasai 
ABCB4 c.523A>G p.(T175A) 20 C, H, S 
Progressive liver disease 
Alternative diagnosis:  BA 
LT (7m). Asymptomatic post-transplant 
ABCB4 c.696C>T p.(=) 155 C, H, S Not available 
ABCB4 c.1143A>G p.(=) 166 C, ALF 
Progressive liver disease with recurrent episodes of ALF 
Alternative diagnosis: Suspected long chain fatty acid oxidation defect 
ABCB4 c.1597C>A p.(L533M) 19 C, H Asymptomatic 
ABCB4  c.1769G>A p.(R509Q) 4 C, H, ALF Not available 
ABCB4 c.1954A>G p.(R652G) 20 C, H, S Progressive liver disease 
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Alternative diagnosis: BA 
LT (7m). Asymptomatic post-transplant 
34 C, H, S 
Progressive liver disease 
Alternative diagnosis:  BA 
LT (8m). Asymptomatic post-transplant 
ABCB4 c.2324C>T p.(T775M) 135 C, H, S 
Stable liver disease 
Alternative diagnosis:  BA 
Stable post-Kasai 
ABCB4 c.2363G>A p.(R788Q) 202 C, H, S 
Stable liver disease 
Alternative diagnosis:  BA 
Stable post-Kasai 
ABCB4 c.2800G>A p.(A934T) 163 C, H, S, ALF Not available 
ABCB4 c.3037A>C p.(=) 
214 C, S No diagnosis. 
69 C, H, S Asymptomatic 
SLC25A13 c.-115G>T 189 C Asymptomatic 
SLC25A13 c.639T>G p.(H213Q) 21 C Asymptomatic 
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4.4. Discussion 
4.4.1. Incidence of autosomal recessive genetic disorders 
A diagnosis of PFIC was made in 8.5% of patients (n=19) and was the most 
prevalent genetic condition reported in this cohort, with type 2 being the most 
frequent.  PFIC2 is a severe and progressive condition associated with a significant 
risk of hepatocellular carcinoma at a young age, therefore accurate and early 
diagnosis of these patients allows appropriate planning for liver transplantation to 
begin.  Identification of only one case of NPC was lower than might have been 
predicted (Yerushalmi et al., 2002) however it is still a rare cause of infantile liver 
disease in this cohort.  No patients were diagnosed with NPC resulting from NPC2 
mutations or citrin deficiency.  This is not unexpected as both are very rare 
conditions.  Twenty four unique variants were identified in this study that have not 
previously been reported and are highly likely to be disease-causing. 
4.4.2. Significance of heterozygous mutations 
The combined incidence of the three autosomal recessive conditions is unknown but 
likely to be in the region of 1 in 100,000.  Using the Hardy-Weinberg equilibrium, the 
expected incidence of mutation carriers in the general population is predicted to be 
around 1 in 160.  Therefore there is an apparent increase in mutation carriers in this 
cohort (n=20 in 222, or 1 in 11). 
There are a number of proposed reasons for this finding of increased incidence of 
heterozygous gene mutations.  Firstly, the possibility that a second mutation in these 
patients has been missed and they are in fact affected by an autosomal recessive 
condition was considered.  The NGS strategy employed has a sensitivity of over 
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99%, however promoter regions and intronic regions were not sequenced.  In 
addition, large scale deletions, duplications and rearrangements, would not be 
detected by sequencing.  However, the vast majority of mutations reported in the 
Human Gene Mutation Database for these genes would have been detected by the 
NGS screen therefore this risk might contribute to but not fully explain the increased 
rate of mutation carriers in the cohort.  For example, patient 179 presented with 
cholestasis and acute liver failure and the previously reported missense mutation 
c.1445A>G p.(D482G) was identified in the ABCB11 gene (Strautnieks et al., 2008).  
This genotype does not explain this patient’s symptoms and therefore a second 
pathogenic mutation in ABCB11 cannot be ruled out.  In comparison, patient 193 
presented with cholestasis which resolved by fifteen months.  The previously 
reported missense mutation c.1621A>C p.(I541L) was identified, however a second 
pathogenic mutation in this patient would cause more severe progressive symptoms 
than was described in this patient. 
Secondly, the mutations listed in Table 4.7 were classified as either pathogenic or 
possibly pathogenic (see 2.2.10), and it is possible that some of those listed as 
possibly pathogenic may in fact be rare benign variation.  The features of liver 
disease in these patients may be caused by mutations in other genes or other 
factors such as infection or sensitivity to parenteral nutrition. Again this possibility 
may contribute to the apparent increased rate of mutation carriers in this cohort, but 
does not fully explain it as seven of the mutations in Table 4.7 did have significant 
evidence for pathogenicity in the literature or were truncating mutations.  
Thirdly, it is possible that single heterozygous mutations in these genes results in an 
increased risk of liver disease in infancy.  The three genes associated with PFIC are 
also associated with less severe phenotypes.  BRIC is traditionally reported to be 
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autosomal recessive and associated with missense mutations which have some 
residual protein function (Davit-Spraul et al., 2009).  There is evidence that some 
BRIC patients carry single heterozygous severe mutations (Kubitz et al., 2006).  ICP 
and LPAC are associated with single heterozygous mutations in the same genes 
(Davit-Spraul et al., 2009).  Both BRIC and ICP are known to result in periods of 
cholestasis in response to some known and some unknown factors, for example 
pregnancy, oral contraceptives or other drugs.  Evidence suggests that patients with 
mutations in the PFIC genes have a lower threshold of tolerance to these factors 
than individuals without mutations.  Patients with heterozygous mutations produce 
enough wild type protein under normal conditions, however when the system is 
stressed internally or by environmental factors there is a susceptibility to cholestasis.  
A few individuals with heterozygous mutations in the PFIC genes and transient 
neonatal cholestasis have been reported, however this study provides more 
evidence that there is a genetic susceptibility to infantile cholestasis similar to ICP.  
Long term follow up of individuals with single mutations, and retrospective analysis of 
neonatal phenotypes in BRIC and ICP patients, is required to determine penetrance 
and prognosis in these patients.   
Of the seven patients identified with mutations in NPC1 (Table 4.6), three had 
another explanation for their symptoms (patients 116, 28 and 22).  Two patients had 
severe disease (patients 54 and 157) and two patients had symptoms which 
resolved (patients 153 and 115).  Patient 115 carried a known NPC mutation; 
therefore this patient would be a good candidate for more in-depth analysis of NPC1 
gene expression and protein levels.  This type of work was outside the scope of this 
study.  Single mutations in NPC1 have not previously been reported to be associated 
with infantile liver disease, however a comparable study of the NPC1 and NPC2 
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genes in adults with neurological features identified several patients with single 
mutations (Bauer et al., 2013).  The authors speculated about the possibility of a 
late-onset reduced penetrance form of NPC.  It would certainly be interesting to 
investigate a cohort of NPC1 mutations carriers to determine whether there is an 
increased risk of infantile liver disease or adult-onset neurological or psychological 
problems.   
One patient with a novel heterozygous missense in SLC25A13 was identified 
(patient 147). Citrin deficiency would be predicted to resolve in infancy and therefore 
the significance of this finding is not yet clear. 
Four of the patients in this group were subsequently diagnosed with biliary atresia 
(Table 4.7) and all had liver transplants by the age of two years.  Two of the patients 
were reported to be in intensive care and receiving parenteral nutrition (patients 30 
and 22) and both were alive and well at follow-up.  The possibility of variants in these 
genes contributing to the risk of biliary atresia and sensitivity to total parenteral 
nutrition will be discussed later. 
4.4.3. Polygenic and epistatic effects 
None of the patients tested were found to carry ‘pathogenic’ mutations in more than 
one of the genes tested, however two patients (patient 148 and 185) were identified 
with novel sequence variants that were classified as ‘possibly pathogenic’ in more 
than one gene.  Patient 148 was found to be homozygous for the missense variant 
c.1652C>T p.(P551L) in ABCB4 and heterozygous for the missense variant 
c.1097T>G p. (V366G) in ABCB11. The former was classified as ‘possibly 
pathogenic’ was based upon all three in silico protein tools predicting a deleterious 
effect, the latter variant because two of the three tools predicted pathogenicity.  
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Since it has not been confirmed that either of these variants are definitely 
pathogenic, no conclusions about the effects of mutations in these two genes can be 
drawn.  Patient 185 was shown to be heterozygous for the nonsense mutation 
c.1558A>T p.(R520*) in ABCB11 and heterozygous for the missense variant 
c.3317A>G p.(E1106G) in ABCB4. The missense variant had not previously been 
reported to be associated with disease; however it had been detected at a low level 
in the 1000 Genomes project.  The nucleotide and codon are moderately conserved 
and two of the three in silico protein tools predicted it was deleterious to the protein.  
In addition, two of the 5 in silico splicing tools suggested it created a cryptic acceptor 
site.  However, without conclusive evidence to support the missense variant as 
pathogenic, the significance of this finding is unclear. In conclusion, no evidence of 
polygenic inheritance or epistatic effects was determined by this study. 
4.4.4. Variants of uncertain significance (VUS) 
A significant proportion of patients without mutations were identified with variants 
classified as VUS or possibly benign (19%, n=41).  This included seven patients who 
were found to be heterozygous for the NPC2 variant c.441+1G>A, none of which 
had another NPC1 or NPC2 variant.  Most sequence variants at position +1 would be 
predicted to disrupt the conserved splice donor site, lead to aberrant mRNA splicing 
and in accordance, all five in silico splicing tools predicted splice site disruption for 
this variant. However, the downstream effect would be determined by whether or not 
an alternative splice site is used and whether the resulting transcript maintained the 
reading frame. Since exon 4 is the penultimate exon of NPC2, any in-frame 
transcripts produced may evade nonsense-mediated decay and result in protein 
production albeit with an altered C-terminus (see Figure 4.3a). In addition, exon 5 of 
NPC2 codes for only four amino acids therefore the protein might tolerate such small 
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changes in amino acid sequence (see Figure 4.3b).  Furthermore, this variant has 
been identified in apparently normal individuals and although the frequency in this 
cohort is higher than reported in population studies, it is not statistically significant 
(see Table 4.8).  This evidence suggests therefore, that c.441+1G>A is not a loss of 
function NPC2 allele; however mRNA or protein studies would be required to confirm 
this.  In relation to the VUS and likely benign variants listed in Table 5.8, this study 
has not provided any evidence to support these variants as pathogenic and 
associated with autosomal recessive disease, however the possibility of reduced 
penetrance or modifier allele status cannot be excluded.   
Figure 4.3a: NPC2 gene structure 
 
 
Figure 4.3b: NPC2 gene sequence 
Exons= blue upper case in black box. Intron = black lower case.  Sequence variant 
c.441+1G>A highlighted in orange. Amino acid sequence encoded by exon 5 shown 
in green bold. 
 
ATAAAACTGGTGGTGGAGTGGCAACTTCAGGATGACAAAAACCAAAGTCTCTTCTGCTGGGAAATCCCAGTACA
GATCgtaagtctatctgggggtgagagggcatgggtggagggaagaaagtggaggagaaatcagactgaaacta
aatcagtgccataagataaaaggaatttcaagactgctgttttatgcctctcaacctctaaaagcatctgagac
cctatttcctgagagctcagaactgttgcctttgtaatatcctttgttaaaaaaaaaaaaggttgaaggaaaga
agagagagtgagactgtagagattgatttaactgtcttcattggtttttttctgtcggagtaaggaaggtccag
ccagacaggacctgaaggaggttgcttaggaatgtctgataacttgccctagggttattgccctgacagtggag
gaaaggttccaaaccacttccactgagctgggacattacatccacagGTTTCTCATCTCTAA 
        ValSerHisLeu*   
 
 
 
 
 
c.441+1G>A 
Ex1 Ex3 Ex4 Ex5 Ex2 
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Table 4.8: Frequency data for NPC2 c.441+1G>A 
Frequency data and associated p-values (using the Chi-Square statistical test) of 
NPC2 c.441+1G>A in various populations including this cohort, the study which first 
reported the variant (Bauer et al 2013), the 1000Genomes Project Phase 1, the 
NCBI-GO Exome Sequencing project (ESP) and ClinSeq project. p<0.05 was 
considered significant and p>0.05 was not considered significant.  In summary, the 
frequency in this cohort is not significant when compared against the European 
American ESP population.  In addition, the variant was identified in patients with 
possible adult onset NPC in the Bauer paper, although at a lower frequency.  
Although ethnicity was not recorded in this study, the country of origin for the 
majority of patients was within Europe therefore it is likely that the increased 
frequency reflects the ethnicity of the patients rather than an association with liver 
disease in infancy. 
Cohort 
This 
cohort 
Bauer 
et al 
2013 
1000 
Genomes 
Project 
ESP -
African 
Americans 
ESP -
European 
American 
ClinSeq 
Total number of 
individuals 
222 170 1092 2203 4300 659 
Number of 
heterozygotes 
7 3 2 7 76 6 
% 3.15 1.76 0.18 0.32 1.77 0.91 
p-value  0.39 0 0 0.13 0.02 
 
4.4.5. Patients with no genetic findings 
In 62% of patients no genetic findings were identified (n=139) and in 20% of patients 
only VUS were identified which do not sufficiently explain the clinical presentation 
(n=44).  These patients may have mutations in parts of the genes not tested by this 
study, or in other genes related to hepatic disease (known or unknown), or may have 
a non-genetic explanation for their clinical presentation.  The contribution of genetic 
disorders to cholestasis in infancy is not precisely known however biliary atresia is 
thought to account for around a third of cases, and infectious causes or toxic causes 
may account for another third.  A genetic contribution has been identified in 18% of 
patients in this study, which is a significant proportion of the possible genetic 
diagnoses. 
Kirsten McKay Bounford   
157 
 
4.4.6. Contribution of mutations in patients with other liver 
conditions 
Alagille syndrome (AGS) and alpha-1 anti-trypsin deficiency (AATD) are genetic 
conditions associated with variable expressivity of liver phenotypes in individuals 
with the same genotype; both between and within families.  The possible contribution 
of mutations in the six genes studied to the variable expressivity seen in AGS and 
AATD was evaluated.  Four patients were reported to have possible AGS and none 
had any clearly pathogenic mutations.  One had a synonymous change in NPC1 
(patient 105) and one had a missense in ABCB11 which is not predicted to be 
damaging to the protein (patient 118, see Table 4.7).  Six patients were reported to 
have AATD and one of those also had a diagnosis of PFIC type 1 (patient 36).  No 
other variants were detected in these patients.  The numbers of AGS and AATD 
cases were too few to draw any meaningful conclusions about the contribution of 
variants in the six genes to liver disease in these conditions. 
Isolated biliary atresia (BA) is described as a progressive obliterative cholangiopathy 
and is likely to be multifactorial in nature. Variation in the incidence of BA between 
populations suggest there are susceptibility factors involved however no 
environmental or genetic link to BA has yet been established.  There were forty eight 
patients in this cohort with biliary atresia (BA) and twelve of these had genetic 
changes in the genes studied.  Two patients were identified who carried single 
‘possibly pathogenic’ mutations in ATP8B1 (patients 23 and 139).  Another ten 
patients carried single VUS or likely benign variants spread across the six genes.  
Seven patients were reported to have been receiving parenteral nutrition (PN).  One 
of these patients was found to carry a single pathogenic mutation in NPC1 (patient 
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22), and two patients carried single possibly pathogenic mutations in ATP8B1 
(patients 30 and 33). 
4.4.7. Recommendations 
Diagnosis of genetic conditions that cause liver disease in infants is important for 
appropriate management of patients therefore genetic testing (especially for PFIC) 
should be routinely considered as part of the patient pathway.  Next generation 
sequencing allows multiple genes to be tested simultaneously and helps to reduce 
genetic testing costs and time to diagnosis.  Incorporation of further genes into one 
test would increase the proportion of diagnoses achievable; including the genes for 
AGS and AATD.   
Genetic testing does not replace other diagnostic methods in most cases and 
instead should be considered as a complimentary strategy.  Correlation of clinical 
features, biochemical test results and genetic results may be useful, especially for 
interpretation of ambiguous genetic findings. 
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Chapter 5 - GENOTYPE-PHENOTYPE 
CORRELATIONS IN PFIC GENES 
5.1. Introduction 
5.1.1. Genetic characterisation of PFIC and BRIC 
In 1998, Strautnieks et. al. reported that PFIC 2 was caused by mutations in the 
ABCB11 gene, which encodes the bile salt export protein (Strautnieks et al., 1998).  
Around the same time, Bull et. al. reported that mutations in ATP8B1 cause PFIC1 
and BRIC1 (Bull et al., 1998). That year de Vree and colleagues also reported the 
first human cases of MDR3 deficiency caused by mutations in ABCB4 and resulting 
in PFIC3 (De Vree et al., 1998).  The genetic cause of BRIC was subsequently 
expanded to include ABCB11 (van Mil et al., 2004b).  It is generally accepted that 
PFIC and BRIC are autosomal recessive conditions and are caused by mutations on 
both alleles of the gene.  The difference between them being more severe mutations 
cause PFIC and milder mutations cause BRIC (Bull et al., 1998), (van Mil et al., 
2004b). 
In 2003, Mullenbach et al reported a link between ABCB4 mutations and intrahepatic 
cholestasis of pregnancy (ICP) and then in 2005 the same group reported screening 
of the ATP8B1 gene in British cases of ICP cases (Mullenbach et al., 2003), 
(Mullenbach, 2005).  In 2009, Dixon et al reported that ABCB11 mutations were also 
linked to ICP (Dixon et al., 2009).  In addition, ABCB4 mutations have also been 
linked to transient neonatal cholestasis, adult biliary cirrhosis and LPAC syndrome in 
small numbers of patients (Jacquemin et al., 2001).  The mutation distribution in 
these genes for the UK population has not been widely reported. 
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5.1.2. Investigations in subjects suspected of PFIC and related 
diseases 
Mutation detection in subjects suspected of PFIC, and related diseases, was carried 
out by testing patients referred to the West Midlands Regional Genetics Service 
between January 2010 and May 2014.  Subjects were tested using FS, or tNGS after 
the assay had been developed in January 2013.  Both methods allowed interrogation 
of the coding regions of the genes plus the intron-exon boundaries allowing the 
findings to be collated.  Sequence variant interpretation was performed on all 
variants identified except those considered benign polymorphisms.  Questionnaires 
were completed, where possible, by the referring clinicians for patients in whom 
sequence variants were identified in order to correlate phenotypes with genetic 
findings.   
5.1.3. Chapter 5 Objectives 
 To broaden the knowledge of the mutation spectrum of the ATP8B1, ABCB11 
and ABCB4 genes. 
 To establish the mutation spectrum of these genes with respect to the UK 
population. 
 To evaluate genotype-phenotype correlations in the PFIC genes.  
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5.2. Methods 
5.2.1. Patient material 
Patients suspected of PFIC or related diseases were referred for diagnostic testing; 
mainly by consultant hepatologists or paediatricians.  Consent was taken by the 
referring clinicians, and this included the anonymous reporting of sequence variants.  
Samples received were mainly venous blood samples in EDTA or occasionally 
Lithium Heparin.  Some DNA samples were received from outside of the West 
Midlands region or from other countries.  All results were reported back to the 
patients via the referring clinicians. 
5.2.2. DNA extraction  
DNA was extracted from blood samples using Gentra Autopure method between 
January 2010 and February 2013.  After that, the lab method switched to the Qiagen 
Qiasymphony method.  Occasionally the phenol chloroform method was used for 
samples which appeared to be in poor condition, for example if they had a long 
transit time.  Samples of very small volumes or from very young babies were 
extracted using a manual version of the Autopure method.  Quantification of DNA 
samples was done using the Nanodrop Spectrophotometer.  All methods are 
described in 2.2.1.   
5.2.3. PCR primer design 
PCR primers were designed for all coding exons of the ATP8B1, ABCB11 and 
ABCB4 genes.  This was done using the online tools Exon-Primer (UCSC), Primer3 
and Primer-Blast (NCBI) using 60oC as the optimal annealing temperature and at 
least 30 bases of flanking intron each side.  All primer pairs were checked using the 
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NGRL SNPCheck tool to avoid polymorphisms of more than 1% in any population 
(2.1.14).  PCR primer sequences are listed in 2.1.12.1 (Table 2.1). 
5.2.4. Analysis methods 
All analysis methods are described in Chapter 2.  Please see sections 2.2.3.1 for 
PCR, 2.2.6.1 for FS and 2.2.8.1 for sequencing analysis.  FS was used to confirm 
sequence variants identified using tNGS and to test those exons not covered by the 
tNGS assay; these were ATP8B1 exon 18, ABCB11 exons 3, 6, 22 and 28.  Please 
see sections 2.2.3.4, 2.2.6.3 and 2.2.8.4 for the methods relating to the tNGS assay. 
These processes were optimised and validated as discussed in Chapter 3.  The 
methods for MLPA are described in section 2.2.7 and GeneMarker analysis in 
section 2.2.8.2. 
5.2.5. Bespoke assay to detect deletion in ATP8B1 
PCR primers were designed for Long  PCR in introns 11 and 14 of ATP8B1 using 
Primer3.  Long PCR amplification, gel electrophoresis, sequencing and analysis was 
performed using the methods described Chapter 2 (2.2.3.3).  
5.2.6. Variant interpretation 
All sequence variants were investigated for potential pathogenicity using the variant 
interpretation pipeline described in Chapter 2 (2.2.10).   
5.2.7. Phenotype questionnaires 
Phenotype questionnaires were sent to referring clinicians for all subjects in whom 
sequence variants were identified in order to gather clinical information.  The 
template is shown in Appendix III. 
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5.3. Results 
5.3.1. Sequence variants detected 
One hundred and fifty nine patients with clinical suspicion of an inherited cholestasis 
disease were tested for mutations in at least one of the ATP8B1, ABCB11 and 
ABCB4 genes between 2009 and 2014.  At the time of referral, forty five patients 
were under three years of age, twenty four were between three and twelve years, 
thirty one were between thirteen and twenty one years and fifty nine were aged 
twenty two years or over (see Figure 5.1).  The majority were referred from centres 
in the UK, however five were from Ireland, two were from Australia, and single 
samples were received from Germany, Hong Kong and Jordan.  Eighty five of these 
were tested using the FS method and seventy four using the tNGS method, with FS 
used to confirm any variants found and to complete any missing exons due to low 
coverage on the tNGS assay.  
Sequence variants were identified in this cohort and classified according to the 
method described in Chapter 2 (2.2.10).  ‘Pathogenic’ and ‘possibly pathogenic’ 
mutations were detected in twenty eight patients (17%) and VUS only were detected 
in another eighteen patients (11%) meaning a genetic finding was observed in a total 
of 29% of patients tested.  The proportion of patients with genetic variants varied 
with age (Figure 5.2).  This ranged from 16% in those between three and twelve 
years of age, to 35% in the thirteen to twenty one year olds.  Figure 5.3 shows the 
proportion of such mutations identified per gene screen performed for ATP8B1, 
ABCB11 and ABCB4; this was 10%, 16 and 13%, respectively.   
In ATP8B1, twelve sequence variants were identified, eighteen were observed in 
ABCB11 and sixteen in ABCB4 (Tables 5.1A-C). The tables include nonsense, 
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frameshift and splice site (+/- 1 or 2 bases from exon) mutations detected in this 
cohort, and also missense mutations that had previously been reported in the 
literature in association with cholestatic conditions.  In addition, these tables include 
sequence variants that were novel and the clinical significance was unclear.  In 
summary, eight nonsense, three frameshift, twenty nine missense, four splice site 
and two deletions were identified.  The tables show the key information gathered in 
order to classify the sequence variants.  Twenty one of these were classified as 
‘pathogenic’, five as ‘possibly pathogenic’ and twenty as of ‘uncertain significance’.   
Twenty seven variants were described that had not previously been reported in the 
literature.  Seven novel sequence variants in ATP8B1 were detected including one 
nonsense (R271*), one large deletion, two which affect splicing (c.1630+2T>G and 
c.2707+3T>C), and three missense variants that are of uncertain clinical significance 
(see Table 5.1C).  Eight novel sequence variants in ABCB11 were also identified; 
three nonsense mutations (W314*, Q1053*, R1235*) and an in-frame deletion of six 
amino acids (F383_A389del) as well as four missense variants of uncertain clinical 
significance.  Lastly, twelve novel sequence variants were detected in the ABCB4 
gene.  In summary, these were three frameshifts (V336Ffs*5, G362Efs*5 and 
I980Sfs*19), one nonsense mutation (Q734*), one conserved splice site mutation 
(c.2211+1G>C) and seven missense variants of uncertain clinical significance.   
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Figure 5.1: PFIC patients by age at time of referral. 
 
Figure 5.2: Variant detection rate by age group. 
 
Figure 5.3: Proportion of tests in which genetic variants were found.
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Table 5.1 The sequence variants identified in the cohort, grouped by gene (A=ATP8B1, B=ABCB11 and C=ABCB4). 
KEY: DNA change; standard genetic code using single amino acid code and HGVS nomenclature.  Type; MS=missense, 
FS=frameshift, NS=nonsense, SS=splice site, Int=intronic, Del=deletion. Population frequency; 1KG=1000 Genomes project using 
their three letter code for populations, ESP=exome sequencing project. NA cons=Nucleic acid conservation, AA cons=Amino acid 
conservation, AA diff=amino acid difference. The terms used were those generated using Alamut software.  Protein prediction; 
AGVGD=Align GVGD, S=SIFT, MT=Mutation Taster, PP=PolyPhen2.  Splicing prediction; SSF=Splice site finder, 
MES=MaxEntScan, NNS=NNSplice, GS=GeneSplicer, HSF=Human Splice Finder. 
5.1A ATP8B1 sequence changes  
# Gene DNA change Type Reference 
Population 
frequency 
NA cons 
AA cons 
AA diff 
Protein prediction Splicing prediction Conclusion 
P07 ATP8B1 c.8C>A p.(T3K) MS N 
rs202024093 
1KG 1 allele 
Weak  
Moderate  
Moderate 
AGVGD C0  
S Deleterious  
MT 
Polymorphism  
PP Benign 
SSF N  
MES N  
NNS N 
GS N  
HSF Donor created 
Uncertain 
significance 
P42 ATP8B1 
c.134A>C 
p.(N45T) 
MS 
(Painter et 
al., 2005) 
rs146599962 
1KG <1% ALL, 
1% AMR 8 
alleles, ESP 
41/13016 
alleles 
Weak  
Moderate  
Small 
AGVGD C0  
S Deleterious  
MT Disease-
causing 
PP Possibly 
damaging 
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
P43 ATP8B1 
c.208G>A 
p.(D70N) 
MS 
(Klomp et al., 
2004), 
(Mullenbach, 
2005), 
(Folmer et 
al., 2009), 
(Strautnieks 
et al., 2008) 
rs34719006 
0.7%, 1KG 
<1% ALL,  1% 
GBR, 9 alleles, 
ESP 31/13016 
alleles 
Moderate 
High  
Small 
AGVGD C0  
S Deleterious  
MT Disease-
causing  
PP Probably 
damaging 
SSF N  
MES N  
NNS N 
GS N  
HSF N 
Uncertain 
significance 
P18 ATP8B1 
c.601C>A 
p.(R201S) 
MS N N 
Moderate  
High  
Moderate 
AGVGD C65  
S Deleterious  
MT Disease-
causing  
PP Probably 
SSF N 
MES N  
NNS N 
GS N  
HSF Acceptor created 
Uncertain 
significance 
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damaging 
P44 ATP8B1 
c.811A/C>T 
p.(R271*) 
NS N N n/a n/a n/a Pathogenic 
P18 ATP8B1 c.1630+2T>G SS N N 
High   
n/a 
n/a 
 
SSF Donor destroyed 
MES Donor destroyed  
NNS Donor destroyed 
GS Donor destroyed  
HSF Donor destroyed 
Pathogenic 
P09 ATP8B1  
c.1286A>C 
p.(E429A) 
MS 
(Klomp et al., 
2004) 
rs34018205 
1.4%, 1KG 1% 
of ALL, 6% of 
LWK, 16 
alleles, ESP 
25/13016 
Weak  
Moderate  
Moderate 
AGVGD C0  
S Tolerated  
MT Disease-
causing  
PP Benign 
SSF N  
MES N  
NNS N 
GS N  
HSF N 
Uncertain 
significance 
P45 
P46 
ATP8B1  
c.2498G>A 
p.(R833Q) 
MS N N 
Weak  
Moderate  
Small 
AGVGD C0  
S Tolerated  
MT Disease-
causing  
PP  Benign 
SSF N  
MES N  
NNS N 
GS N  
HSF Acceptor created 
Uncertain 
significance 
P19 ATP8B1 c.2707+3G>C SS N N 
Moderate 
n/a 
n.a 
 
SSF N  
MES  
Donor reduced  
NNS Donor destroyed 
GS Donor reduced  
HSF N 
Possibly 
pathogenic 
P20 ATP8B1 
c.2941G>A 
p.(E981K) 
MS 
(Numakura 
et al., 2011), 
(Stone et al., 
2012) 
N 
High  
High  
Small 
AGVGD C55  
S Deleterious  
MT Disease-
causing  
PP Probably 
damaging 
SSF N  
MES N  
NNS N 
GS N  
HSF N 
Pathogenic 
P10 ATP8B1 
c.3040C>T 
p.(R1014*) 
NS 
(Klomp et al., 
2004) 
N n/a n/a n/a Pathogenic 
P08 ATP8B1 Del Ex12-14 Del N N n/a n/a n/a Pathogenic 
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5.1B ABCB11 sequence changes  
# Gene DNA change Type Reference 
Population 
frequency 
NA cons 
AA cons 
AA diff 
Protein prediction Splicing prediction Conclusion 
P04 ABCB11 c.149T>C p.(L50S) MS 
(Strautnieks 
et al., 2008), 
(Byrne et al., 
2009) 
N  
Moderate 
Moderate 
Large 
AGVGD C0  
S Deleterious  
MT Disease-
causing  
PP Probably 
damaging 
SSF N  
MES N  
NNS N  
GS N 
HSF N 
Pathogenic 
P11 ABCB11 c.149T>G p.(L50W) MS N N  
Moderate 
Moderate 
Small 
AGVGD C0  
S Deleterious MT 
Disease-causing  
PP Probably 
damaging 
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
P01 ABCB11 c.673A>C p.(T225P) MS 
(Strautnieks 
et al., 
1998)(Jirsa, 
2011) 
N  
Weak  
High  
Small 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Possibly 
pathogenic 
(personal 
communication) 
P04, 
P02, 
P21 
ABCB11 c.890A>G p.(E297G) MS 
(Strautnieks 
et al., 1998), 
(Wang et al., 
2002) 
rs11568372 
PharmaGKB, 
1/145 alleles 
High 
High 
Moderate 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Pathogenic 
P03 ABCB11 c.908+1G>A  SS 
(Strautnieks 
et al., 2008), 
(Tibesar et al., 
2014) 
rs147649016 
1KG 2 alleles 
TSI 
High 
n/a  
n/a 
n/a 
SSF Donor destroyed  
MES Donor destroyed  
NNS Donor destroyed  
GS Donor destroyed  
HSF Donor destroyed 
Pathogenic 
P22 ABCB11 c.942G>A p.(W314*) NS N N  n/a n/a n/a Pathogenic 
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P23, 
P24 
ABCB11 
c.1146_1166del21 
p.(F383_A389del) Del 
N 
N n/a n/a n/a 
Possibly 
pathogenic 
P24 ABCB11 
c.1409G>A 
p.(R470Q) 
MS 
(Strautnieks 
et al., 2008), 
(Byrne et al., 
2009) 
N  
High  
High  
Small 
AGVGD C35  
S Deleterious  
MT Disease-
causing  
PP probably 
damaging  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Pathogenic 
P01
  
ABCB11 
c.1724G>A 
p.(R575Q) 
 
MS 
N 
rs200667815 
No freq data 
High High 
Small 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP probably 
damaging  
SSF N MES N NNS N 
GS N HSF N 
Uncertain 
significance 
P12 ABCB11 c.1739T>C p.(L580P) MS 
N N  
High High  
Moderate 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP probably 
damaging  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
P26, 
P27, 
P13 
ABCB11 
c.2093G>A 
p.(R698H) 
MS 
(Anzivino et 
al., 2013),  (El 
Sherrif et al., 
2013) 
rs138642043 
1%, 1KG <1% 
of ALL 1% of 
AFR and 
GBR, 14 
alleles, ESP 
67/13016 
High 
Moderate 
Small 
AGVGD C0  
S Deleterious  
MT Disease-
causing  
PP Benign 
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
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P06 ABCB11 
c.3148C>T 
p.(R1050C) 
MS 
(van Mil et al., 
2004b), (Lam 
et al., 2007), 
(Byrne et al., 
2009) 
rs72549398 
No freq data 
High  
High  
Large 
AGVGD C15  
S Deleterious  
MT Disease-
causing  
PP Probably 
damaging 
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Pathogenic 
P28 ABCB11 
c.3157C>T 
p.(Q1053*) 
NS N N  n/a n/a n/a Pathogenic 
P29 ABCB11 
c.3382C>T 
p.(R1128C) 
MS 
(Strautnieks 
et al., 2008), 
(Byrne et al., 
2009) 
N  
Weak  
High  
Large 
AGVGD C25  
S Deleterious  
MT Disease-
causing  
PP Probably 
damaging 
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Pathogenic 
P14 ABCB11 
c.3634G>T 
p.(V1212F) 
MS 
(Evason et al., 
2011) 
N  
High  
Moderate  
Small 
AGVGD C0  
S Deleterious  
MT Disease-
causing  
PP Probably 
damaging 
SSF N MES N NNS N 
GS N HSF N 
Possibly 
pathogenic 
P15, 
P02 
ABCB11 
c.3669G>C 
p.(E1223D) 
MS 
(Byrne et al., 
2009) 
rs199649780 
ESP 5/13016 
alleles, AFR 
Weak  
Weak  
Small 
AGVGD C0  
S Tolerated  
MT Disease-
causing  
PP Possibly 
damaging 
SSF N MES N NNS N 
GS N HSF N 
Uncertain 
significance 
P03 ABCB11 
c.3703C>T 
p.(R1235*) 
NS N N  n/a n/a n/a Pathogenic 
P11 ABCB11 
c.3962G>A 
p.(S1321N) 
MS N 
rs201693189 
0.4%, 1KG 
<1% 2 alleles, 
ClinSeq 1 
allele 
High 
Moderate  
Small 
AGVGD C0 S 
Tolerated MT 
Disease-causing 
PP Probably 
damaging 
SSF N MES N NNS N 
GS N HSF N 
Uncertain 
significance 
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5.1C ABCB4 sequence changes  
# Gene DNA change Type Literature 
Population 
frequency 
NA/AA/AA 
diff 
Protein prediction Splicing prediction Classification 
P16 ABCB4 c.215C>G p.(P72R) MS N N  
High  
High 
Moderate 
AGVGD C65 S 
Deleterious MT 
Disease-causing 
PP probably 
damaging  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
P30 ABCB4 c.551T>C p.(I184T) MS N N  
High  
High 
Moderate 
AGVGD C65 S 
Deleterious MT 
Disease-causing 
PP probably 
damaging  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
P31 ABCB4 
c.1006_1009delGTTT 
p.(V336Ffs*5) 
FS N N  n/a n/a n/a Pathogenic 
P32 ABCB4 
c.1085delG 
p.(G362Efs*5) 
FS N N  n/a n/a n/a Pathogenic 
P33 ABCB4 c.1505T>C p.(I502T) MS N N  
Weak  
High 
Moderate 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP possibly 
damaging  
SSF N 
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
P34 ABCB4 c.1529A>G p.(N510S) MS 
(Anzivino et 
al., 2013), 
(Poupon et al., 
2013) 
N  
Weak  
High  
Small 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP possibly 
damaging  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Possibly 
pathogenic 
P35 ABCB4 c.1546A>G p.(M516V) MS N N  
Weak  
High  
Small 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP benign 
SSF N  
MES N  
NNS N  
GS N  
HSF Donor creation 
Uncertain 
significance 
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P38 ABCB4 c.1769G>A p.(R590Q) MS 
(Degiorgio et 
al., 2007), 
(Colombo et 
al., 2011), 
(Zimmer et al., 
2012), 
(Poupon et al., 
2013) 
rs45575636 
DB 0.9%, 
1KG <1% of 
ALL, 4% 
LWK, 1% 
GBR, 22 
alleles, ESP 
37/4406 
alleles 
High 
High  
Small 
AGVGD C0 S 
Deleterious MT 
Disease-causing 
PP probably 
damaging  
SSF N  
MES N  
NNS N 
GS N  
HSF N 
Uncertain 
significance 
P36 ABCB4 c.1783C>T p.(R595*) NS 
(Davit-Spraul 
et al., 2010) 
N  
Weak  
High  
n/a 
n/a n/a Pathogenic 
P37 ABCB4 c.1801G>A p.(A601S) MS N N 
High  
High  
Small 
AGVGD C0  
S Deleterious  
MT Disease-
causing  
PP possibly 
damaging 
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
P16 ABCB4 c.1801G>T p.(A601T) MS N N 
High  
High  
Moderate 
AGVGD C0  
S Deleterious  
MT Disease-
causing  
PP possibly 
damaging 
SSF N  
MES N  
NNS N GS  
N  
HSF N 
Uncertain 
significance 
P17 ABCB4 c.2200G>T p.(Q734*) NS N N  
Moderate 
Moderate  
n/a 
n/a n/a Pathogenic 
P38 ABCB4 c.2211+1G>C SS N N  n/a n/a 
SSF Donor destroyed 
MES Donor destroyed 
NNS Donor destroyed 
GS Donor destroyed 
HSF Donor destroyed 
Pathogenic 
P39 ABCB4 c.2869C>T p.(R957*) NS 
(De Vree et 
al., 1998) 
rs121918440 
No freq data 
Weak 
Moderate 
n/a  
n/a n/a Pathogenic 
P40 ABCB4 
c.2939_2940delTT 
p.(I980Sfs*19) 
FS N N  n/a   n/a n/a Pathogenic 
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P41 ABCB4 c.3011C>A p.(A1004E) MS N N  
High  
High 
Moderate 
AGVGD C65 S 
Deleterious MT 
Disease-causing 
PP probably 
damaging  
SSF N  
MES N  
NNS N  
GS N  
HSF N 
Uncertain 
significance 
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5.3.2. Multiplex-ligation dependent probe amplification 
MDR3 deficiency may be caused by biallelic ABCB4 mutations, and single 
heterozygous mutations in ABCB4 were identified in several patients (see Table 
5.2C).  Therefore, there was a possibility that a second mutation in ABCB4 was 
present in some patients that was not being detected by the sequencing methods 
employed.  In order to reduce the potential proportion of mutations being undetected, 
patients were tested using MLPA (MRC-Holland).  This technique is able to detect 
homozygous and heterozygous deletions and duplications of whole exons or regions 
of the gene (Schouten et al., 2002).  No additional mutations of this type were 
identified in ABCB4 in this cohort.  No MLPA kits are currently available for ATP8B1 
or ABCB11. 
5.3.3. ATP8B1 deletion case 
Three consecutive PCR fragments (exons 12, 13 and 14) of ATP8B1 failed to 
amplify in patient P08, therefore the possibility of a large homozygous deletion was 
investigated.  Long range PCR primers were designed in introns 11 and 14 to 
amplify the region and gel electrophoresis of the PCR products showed a band shift 
in the patient’s sample, consistent with a deletion of at least 5 kilobases (see Figure 
5.4a).  Sequencing of the PCR products showed the breakpoints of the deletion and 
allowed the deletion to be sized at 5948 base pairs and characterised as c.1221-
490_1630+986del (see Figure 5.4b and 5.4c).  Deletion of exons 12-14 is predicted 
to result in the introduction of a premature stop codon p.(S544Rfs*13) and is 
therefore predicted to be pathogenic.   
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Figure 5.4. Characterisation of ATP8B1 mutation in patient P08. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a)  Gel picture showing truncated PCR product 
consistent with a large homozygous deletion. 
b) and c) Sequencing trace in Mutation Surveyor 
using reference sequence NG_007148 for 
ATP8B1. b) shows the complete sequencing 
trace mapped against intron 11 and the variation 
from the reference sequence is clearly seen. c) is 
the sequence within the purple box and shows 
the breakpoints of the deletion, illustrated by the 
green and blue boxes.   
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5.3.4. Mutation spectrum in UK population 
Of the forty six patients with sequence variants identified, forty two of them were 
from within the UK.  Consequently, forty two of the forty six sequence variants 
identified were present in patients from the UK; including twenty two novel variants 
(see Tables 5.1 A-C). 
5.3.6. Categorisation of patients 
The clinical features of the patients in whom pathogenic, possibly pathogenic and 
unclassified variants were detected are summarised in Tables 5.2A-C.  The patients 
are categorised in sections 5.3.6 to 5.3.11 according to the number and classification 
of variants detected in order to group patients into useful categories for genotype-
phenotype correlations.  Section 5.3.6 reviews those patients in which two 
‘pathogenic’ or ‘possibly pathogenic’ mutations were identified.  In contrast section 
5.3.7 includes those patients in which two sequence variants were detected, but one 
was classified as ‘uncertain significance’.  These patients therefore have a possible 
diagnosis of PFIC but with a degree of uncertainty.  5.3.8, 5.3.9 and 5.3.10 include 
those patients in which one pathogenic or possibly pathogenic mutation was 
identified.  Lastly, patients with VUS only are reviewed in section 5.3.11. 
5.3.7. PFIC diagnoses 
Four patients were diagnosed with PFIC1; P08, P10, P19, P20 and P18 (Table 
5.2A).  The PFIC1 patients were found, respectively, to have a large homozygous 
deletion of three exons (section 5.3.3), a homozygous nonsense mutation, a 
homozygous intronic sequence change that is highly likely to cause aberrant mRNA 
splicing, and a homozygous missense change that has previously been reported to 
result in an 80% reduction in enzyme activity (Numakura et al., 2011).  The median 
Kirsten McKay Bounford   
177 
 
age of onset in this group was five months (mean five months, range from one to 
nine months) and all four patients presented with progressive cholestasis.  Two of 
the patients were reported to have metabolic bone disease which is likely to have 
resulted from decreased ability to absorb vitamins from the gut (Chen and Chang, 
2004).  P10 had developmental delay and dysmorphic features, which are unlikely to 
be related to PFIC1.   
Six patients were diagnosed with PFIC2; P03, P04, P05, P24, P28, P29 (Table 
5.2B).  The median age of onset for these patients was 6 months (range two weeks 
to 2 years).  No further clinical information was available for two of these patients, 
however progressive cholestasis was noted in the other four.   
No patients were diagnosed with PFIC3, which usually accounts for one third of 
PFIC cases (Davit-Spraul 2009).  This finding may reflect the fact that the low serum 
GGT levels associated with PFIC types 1 and 2 is a more distinct phenotype than the 
raised serum GGT levels associated with PFIC3, and therefore genetic testing is 
more often considered by clinicians for these patients.  
5.3.8. Possible diagnoses 
Two patients were found to carry two sequence variants in ABCB11 (P01 and P02) 
but there was uncertainty about the pathological significance of one of them in each 
case.  In addition, both patients were reported to have had an episode of cholestasis 
rather than progressive cholestasis, further emphasising that the contribution, if any, 
of the missense variants E1223D and R575Q to BSEP deficiency is unclear.  Patient 
P01 showed presence of MDR3 and BSEP immunostaining, a feature which is not 
inconsistent with missense mutations in ABCB11, but that had directed the clinicians 
away from a diagnosis of BSEP deficiency.  This patient also had the E297G 
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mutation in ABCB11, a mutation which has previously been associated with PFIC2 
and BRIC2 cases (van Mil et al., 2004b).  
Patients P16, P35 and P41 had two ABCB4 variants each.  P16 had a more severe 
and complicated presentation than the other patients, and both variants were in 
regions highly conserved at the nucleotide and amino acid level, suggesting that they 
might be contributing to her phenotype.  However, no information was known about 
the health of her relatives and therefore the clinical significance of her genotype is 
unclear.  Reduced MDR3 levels by immunostaining of liver biopsy would support the 
hypothesis of MDR3 deficiency and UDCA therapy would be indicated.  P35 was 
homozygous for the missense M516V and she presented with progressive 
cholestasis.  Cirrhosis and a relatively early age of onset indicate a more severe 
presentation than those patients with single heterozygous mutations (section 5.3.10).  
In contrast, P41 was homozygous for the missense A1004E and had clinical features 
similar to the patients with the single, severe, heterozygous mutations in ABCB4; 
suggesting that this missense might result in reduced rather than absence of MDR3 
protein function.  All four of these variants were missense changes with no previous 
reports in the literature or in normal populations and so have been classified as of 
uncertain significance (P72R, A601T, M516V and A1004E; see Table 5.1C).  If these 
variants are seen again in other patients it might help to clarify the significance of 
these variants in future. 
5.3.9. Cases with single heterozygous mutations in ATP8B1 
Patient P18 was an unusual case as he presented at age fifteen with unexplained 
cholestasis, pruritus and hepatomegaly. He had one pathogenic splice site mutation 
(c.1630+2T>G) and one novel missense change c.601C>A p.(R201S) of uncertain 
clinical significance.  His parents were tested and the sequence variants were shown 
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to be on different alleles of ATP8B1.  It was not clear whether the missense 
sequence change was contributing to this patient’s phenotype; however these results 
confirmed the clinician’s diagnosis of BRIC. 
One patient was identified with a single heterozygous ATP8B1 mutation.  P44 was 
female and presented at age 35 with an unexplained episode of cholestasis, pruritus 
and jaundice. 
5.3.10. Cases with single heterozygous mutations in ABCB11 
Six patients were identified who carried single heterozygous mutations (pathogenic 
or possibly pathogenic) in ABCB11 (P06, P21, P22, P25, P14 and P23).  This group 
all presented with episodic cholestasis at a median age of sixteen years (range two 
weeks to eighteen years, mean thirteen years).  Patient P06 presented much earlier 
than the other five patients suggesting that the presence of one loss of function 
mutation in ABCB11 was not the only contributory factor in this patient’s illness, and 
perhaps additional genetic or environmental factors played a role.  The future health 
of this child, including any subsequent episodes of cholestasis, may help to shed 
light on whether this is typical BRIC2 which happened to present initially in the 
newborn period, or whether the child has BSEP deficiency which is more progressive 
and severe than the ABCB11 genotype indicates.  In three out of five patients with 
single heterozygous ABCB11 mutations, use of oral contraceptives was identified as 
the trigger for the cholestasis episodes. 
5.3.11. Cases with single heterozygous mutations in ABCB4 
Eight patients (P31, P32, P36, P34, P38, P17, P39 and P40) were identified who 
were heterozygous for a ‘pathogenic’ or possibly pathogenic’ mutation in ABCB4 
(see Table 3.2C).  The median age of onset of symptoms in this group was age 
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twenty five years (mean twenty four years, min ten years, max thirty five years).  All 
had episodes of acute cholestasis, although in two it was recorded that they had 
signs of underlying progressive disease (P31 and P38).  Pregnancy and the oral 
contraceptive pill were identified as triggers for the episodes in five and one patients 
respectively; however no trigger was identified in the other three.  Gallstones were 
the most commonly associated feature, seen in three patients, and cholecystectomy 
had been carried out in another two (whilst the reason for the procedure wasn’t 
recorded, again gallstones is the most likely explanation).  A liver biopsy was carried 
out in seven of the patients and six showed mild biliary changes, two had fibrosis 
and one ductule proliferation.  In one case, ductopenia was the only feature noted 
(P40).  Patient P17 had an unusual presentation due to a significantly earlier age of 
onset (10 years), and severe fibrosis seen on liver biopsy.  It was noted that her 
mother had ICP which would be consistent with her also being a carrier of the same 
ABCB4 mutation.  No further mutations were identified in P17 in ATP8B1, ABCB11 
or ABCB4; however the possibility of other genetic or environmental factors 
contributing to her phenotype seems likely.   
 
All of the patients with ABCB4 mutations and VUS were female.  This is not 
surprising since they were mainly were young adults and had come to the attention 
of liver specialists following episodes of cholestasis during pregnancy or in response 
to taking oral contraception.  All eight patients had a family history of related 
conditions, and of those with the relationships recorded, all were first degree 
relatives.   
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5.3.12. Patients with VUS 
Several patients were found to be heterozygous for missense variants of uncertain 
clinical significance in ATP8B1 (P07, P09, P42, P43, P45 and P46), ABCB11 (P12, 
P13, P15, P26 and P27) and ABCB4 (P16, P35, P41, P30, P33 and P37).  T3K and 
R833Q in ATP8B1 have not previously been reported in the literature but in silico 
tools indicate these are weakly conserved nucleotides and are not likely to be 
damaging to the FIC1 proteins.  N45T and D70N have been reported in the literature 
as causing FIC1-associated disease however they are also present at significant 
rates in apparently healthy populations (see Table 5.1A).  E429A was reported by 
Klomp et al in 2004 as being of uncertain clinical significance; however since then it 
has also been identified in normal individuals in the 1000Genomes project.  This 
study has not provided any evidence that these three missenses are capable of 
leading to severe FIC1 deficiency as they were not detected in any PFIC1 cases; 
however it remains uncertain whether they can contribute to adult liver disease as 
observed in P42 and P43.  
In ABCB11, R698H has been reported as being of uncertain significance (Anzivino et 
al., 2013) and it is also present in normal individuals in several populations, 
indicating this is unlikely to be responsible for the phenotypes in patients P13, P26 
and P27.  Also in ABCB11, the E1223D missense was identified in P15.  This has 
been associated with prolonged neonatal hepatitis (Byrne et al., 2009), but has since 
also been found in normal African American individuals at a low frequency.  Clinical 
details were not reported in P15 therefore it is difficult to draw any conclusions about 
the effect of this missense.  The L580P missense has not previously been reported 
in the literature or in population frequency databases; in silico tools suggest it may 
have an effect on BSEP however it is not possible to be certain based on those 
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observations alone. It is worth noting that patients P07 and P09 presented as 
neonates, and P13 as a young child, and the single VUS identified do not explain 
their phenotypes. It is likely that another genetic or non-genetic cause is responsible. 
Three patients (P30, P33 and P37) were found to be heterozygous for novel 
missense variants in ABCB4; all of which protein prediction tools suggested were 
damaging to the MDR3 protein.  P33 presented age thirty with three episodes of 
cholestasis triggered by pregnancy. Her liver biopsy showed mild biliary changes 
and her grandfather had cirrhosis.  P37 also presented during pregnancy and had a 
personal and family history of gallstones.  There was no clinical information available 
for P30.  Hopefully, detection of these variants in affected patients or normal 
populations in future will help to clarify the significance of these variants in liver 
disease. 
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Table 5.2 Clinical features of patients with sequence variants in A - ATP8B1, B - ABCB11 and C - ABCB4. 
A – Patients with ATP8B1 variants 
# DNA change Classification 
Sex 
(Country) 
Age at 
presentation 
Cholestasis 
If Episodic, 
frequency and 
triggers 
Other features Liver biopsy 
Family 
history 
P08 Del Ex12-15 Hom Pathogenic F (UK) 5 months Progressive  
Abnormal liver 
enzyme levels, 
metabolic bone 
disease, liver failure 
Inflammation and 
cholestasis 
Not 
reported 
P10 
c.3040C>T 
p.(R1014*) Hom 
Pathogenic M (UK) 9 months Progressive  
Metabolic bone 
disease, pruritus, 
developmental 
delay, dysmorphic 
appearance, 
progressive 
diarrhoea and 
vomitting, deranged 
clotting 
Cholestasis and 
fibrosis 
Y possibly; 
a 
deceased 
uncle 
P19 c.2707+3G>C Hom 
Possibly 
pathogenic 
F (UK) 4 weeks Progressive  None 
Non-necrotising 
granulomas, 
paucity of bile 
ducts 
N 
P20 
c.2941G>A 
p.(E981K) Hom 
Pathogenic 
M 
(Ireland) 
6 months Progressive  Migraines 
Cholestasis and 
fibrosis 
N 
P18 
c.601C>A p.(R201S) 
 
c.1630+2T>G 
Possibly 
pathogenic 
Pathogenic 
M (UK) 15  years Episode 1, not identified 
Pruritis, 
hepatomegaly, finger 
clubbing, mild 
hypothyroidism 
Inflammation and 
cholestasis 
N 
P44 
c.811A/C>T 
p.(R271*) 
Pathogenic F (UK) 35 years Episode 1, not identified Jaundice, pruritus Not done N 
P07 c.8C>A p.(T3K) 
Uncertain 
significance 
M (UK) 3 weeks Episode 
1, newborn 
period 
None 
Fibrosis, 
ductopenia 
N 
P09 
c.1286A>C 
p.(E429A) 
Uncertain 
significance 
M (UK) 8 weeks Progressive 
1, newborn 
period 
Developed giant cell 
hepatitis, small bile 
ducts, extra digit, 
encephalopathy, 
liver failure 
Neonatal 
hepatitis, no bile 
plugging, ductular 
proliferation 
 
N 
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P42 c.134A>C p.(N45T) 
Uncertain 
significance 
F (UK) 39 years Episode 
6, during all 
pregnancies 
and with oral 
contraceptive 
pill 
N 
Inflammation, 
cholestasis, 
fibrosis 
N 
 
P43 c.208G>A p.(D70N) 
Uncertain 
significance 
F (UK) Adult Episode 1, pregnancy Pain Not done N 
P45 
c.2498G>A 
p.(R833Q) 
Uncertain 
significance 
F (UK) 29 years 
Slowly 
progressive 
 
Raised GGT levels, 
colitis 
Mild changes 
only 
N 
P46 
c.2498G>A 
p.(R833Q) 
Uncertain 
significance 
F (UK) 24 years Episode 2, pregnancy 
Epilepsy, vitamin 
deficiency, pruritus 
Mild changes 
only 
N 
 
B-Patients with ABCB11 variants 
# DNA change Classification Sex 
Age at 
presentation 
Cholestasis 
If Episodic, 
frequency and 
triggers 
Other features Liver biopsy 
Family 
history 
P03 
c.908+1G>A  
c.3703C>T p.(R1235*)  
Pathogenic 
Pathogenic 
F (UK) 6 months Not reported Not reported Not reported Not reported 
Not 
reported 
P04 
c.149T>C p.(L50S) 
c.890A>G p.(E297G) 
Pathogenic 
Pathogenic 
F (UK) 9 months Progressive  
Diarrhoea, ricketts, 
intermittant pale 
stools, pruritus 
N N 
P05 c.2012-8T>G Hom Pathogenic M (UK) 6 months Progressive  Pruritus, coagulopathy 
Fibrosis, giant 
cell hepatitis, 
paucity of bile 
ducts 
N 
P24 
c.1409G>A p.(R470Q) 
c.1146_1166del21 
p.(F383_A389del) 
Pathogenic 
Possibly 
pathogenic 
M (UK) 2 years Progressive  
Liver transplant at 5y 
N N 
P28 
c.3157C>T p.(Q1053*) 
Hom 
Pathogenic M (UK) Not reported Not reported Not reported Not reported Not reported 
Not 
reported 
P29 
c.3382C>T 
p.(R1128C) Hom 
Pathogenic M (UK) 13 days Progressive  
Bleeding, pale stools, 
failure to thrive 
N 
Yes, 3 
siblings 
P02 
c.890A>G p.(E297G) 
c.3669G>C 
p(E1223D)  
Pathogenic 
Uncertain 
significance 
F 
(Ireland) 
6 months Episode 1, gallstones None 
Non-specific, 
portal tract 
inflammation, 
N 
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rosettes, bile 
plugs, 
pericellular 
cytokeratin, loss 
of biliary 
staining 
P01 
c.673A>C p.(T225P) 
 
c.1724G>A p.(R575Q) 
Possibly 
pathogenic 
Uncertain 
significance 
F 
(Australia) 
5 months 
Episode, but 
signs of 
underlying 
progressive 
features 
1, infection None 
Y, 
immunostaining 
showed BSEP 
and MDR3 
present 
N 
P11 
c.149T>G 
p.(L50W)/c.3962G>A 
p.(S1321N) Hom 
Uncertain 
significance 
F (UK) 13 months Progressive  
Pruritus, 
hepatosplenomegaly 
Distorted 
architecture, 
fibrosis, no 
ductule 
proliferation, 
hepatitis, 
marked 
cholestasis. 
N 
P06 
c.3148C>T 
p.(R1050C) 
Pathogenic M (UK) 2 weeks Episode 
1, newborn 
period 
None 
Severe 
cholestasis, 
resetting.  
Immunostaining 
did not confirm 
PFIC 
N 
P21 c.890A>G p.(E297G) Pathogenic F (UK) 18 years Episode  Not reported Not reported Not reported 
Not 
reported 
P22 c.942G>A p.(W314*) Pathogenic F (UK) 16 years Episode 1, not identified Weight loss, pruritus Cholestasis N 
P25 c.2012-8T>G Pathogenic F (UK) 17 years Episode 
1, oral 
contraceptive 
pill 
Low serum GGT, 
jaundice 
N Y, mother 
P14 
c.3634G>T 
p.(V1212F) 
Possibly 
pathogenic 
F (UK) 14 years Episode 
1, oral 
contraceptive 
pill 
Pain, pruritus, 
vomiting, weight loss, 
lethargy 
N N 
P23 
c.1146_1166del21 
p.(F383_A389del) 
Possibly 
pathogenic 
F (UK) 17 years Episode 
1, 
Norethisterone 
Jaundice, pruritus N N 
P12 c.1739T>C p.(L580P) 
Uncertain 
significance 
M (UK) 6 years Episode 1, gallstones Gallstones 
Fibrosis and 
cholestasis 
N 
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P13 c.2093G>A p.(R698H) 
Uncertain 
significance 
F (UK) 5 years Episode 1, gallstones Gallstones, pruritus N N 
P15 
c.3669G>C 
p.(E1223D) 
Uncertain 
significance 
F (UK) 16 years Not reported Not reported Not reported Not reported 
Not 
reported 
P26 c.2093G>A p.(R698H) 
Uncertain 
significance 
F (UK) 33 years 
Episode but 
underlying 
progressive 
features 
1, 
contraceptive 
implant 
following 
normal 
pregnancy 
Gallstones Cholestasis N 
P27 c.2093G>A p.(R698H) 
Uncertain 
significance 
F (UK) 38 years Episode 1, not known Pain 
Loss of BSEP 
polarity and 
MDR3 staining 
N 
 
C-Patients with ABCB4 variants 
# DNA change 
 
Classification 
 
Sex 
Age at 
presentation 
Cholestasis 
If Episodic, 
frequency and 
triggers 
Other features Liver biopsy 
Family 
history 
P31 
c.1006_1009delGTTT 
p.(V336Ffs*6) 
Pathogenic F (UK) 34 years 
Acute 
episode but 
underlying 
progressive 
features 
1, pregnancy 
Abnormal liver 
enzyme results, pain, 
gallstones, 
cholecystectomy 
Biliary disease 
Y, father 
and paternal 
grandfather 
P32 
c.1085delG 
p.(G362Efs*6) 
Pathogenic F (UK) 30 years Episode 
1, oral 
contraceptive 
pill 
Acute severe 
hepatitis, gallstone 
Not done Y  
P36 c.1783C>T p.(R595*) Pathogenic F (UK) 31 years Episode 2, pregnancy None 
Mild biliary 
changes 
Y, mother 
P38 c.2211+1G>C Pathogenic F (UK) 30 years 
Acute 
episode but 
underlying 
progressive 
features 
1, not 
identified 
Abnormal liver 
enzyme results, 
cholecystectomy 
Biliary disease, 
moderate 
fibrosis 
Y, mother 
P17 c.2200G>T p.(Q734*) Pathogenic F (UK) 10 years Episode 
1, not 
identified 
Pruritus 
Severe fibrosis 
of ductular 
proliferation 
Y, mother 
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P39 c.2869C>T p.(R957*) Pathogenic F (UK) 40 years Episode 1, pregnancy 
Abnormal liver 
enzyme results, 
jaundice 
cholecystectomy 
Biliary disease 
Y, mother 
and 
maternal 
grandfather 
P40 
c.2939_2940delTT 
p.(I980Sfs*20) 
Pathogenic F (UK) 27 years Episode 1, pregnancy 
Abnormal liver 
enzyme results, 
gallstones 
Ductopenia 
Y, mother 
and sibling 
P34 c.1529A>G p.(N510S) 
Possibly 
pathogenic 
F (UK) 35 years Episode 
2, pregnancy 
and post-
pregnancy 
Pruritus 
Mild biliary 
changes 
N 
P16 
c.215C>G p.(P72R) 
c.1801G>A p.(A601T) 
Cmpd Het 
Uncertain 
significance 
Uncertain 
significance 
F 
(Australia) 
7 years 
Slowly 
progressive 
Deterioration 
following 
variceal 
haemorrhage 
Fever, lethargy, 
hepatosplenomegaly,  
portal hypertension, 
oesophageal varices, 
coagulopathy, 
malnutrition 
Chronic liver 
disease and 
cirrhosis, 
copper 
accumulation. 
Not reported 
P35 
c.1546A>G p.(M516V) 
Hom 
Uncertain 
significance 
F (UK) 19 years 
Slowly 
progressive 
 
Biliary cirrhosis with 
varices, some pruritus 
Moderate 
biliary fibrosis 
N 
P41 
c.3011C>A p.(A1004E) 
Hom 
Uncertain 
significance 
F (UK) 26 years Episode 1, pregnancy 
Gallstones, 
cholecystectomy 
Chronic 
inflammation 
Y, sibling 
P30 c.551T>C p.(I184T) 
Uncertain 
significance 
F (UK) 10 years Not reported Not reported Not reported Not reported Not reported 
P37 c.1801G>T p.(A601S) 
Uncertain 
significance 
F (UK) 32 years Episode 1, pregnancy 
Gallstones, 
cholecystectomy 
Not done Y, aunt 
P33 c.1505T>C p.(I502T) 
Uncertain 
significance 
F (UK) 30 years Episode 3, pregnancy 
Abnormal liver 
enzymes 
Mild biliary 
changes 
Y, 
grandfather 
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5.4. Discussion 
5.4.1. General observations 
Sequencing of the coding regions of these three genes known to be involved in 
cholestasis yielded a higher pickup rate in the over age twenty one group.  This 
probably reflects better patient selection in the non-urgent setting.  As previously 
discussed, cholestasis in infancy is much more heterogeneous in origin (Introduction 
section 1.3).   
Routine testing of patients suspected of PFIC and related conditions has detected 
twenty seven novel mutations, reflecting both that many families harbour discrete 
mutations and that studies of the UK population are not widely reported in the 
literature.  Although, dozens of mutations in these genes are known about, this study 
has uncovered several more.  In addition, twenty two of these novel sequence 
changes were found in UK patients.  This cohort of patients with sequence variants 
is larger than any previously reported UK cohort and thus is a significant contribution 
to the mutation spectrum of these genes. 
The remainder of the patients where no mutations were identified may have large 
exonic deletions or insertions, or deep intronic and promoter mutations, not 
detectable by the assays employed here.  MLPA testing in our ABCB4 cohort did not 
yield any further mutations, however the presence of a homozygous deletion in 
ATP8B1 was detected in patient P08.  Furthermore, it is possible that other genes 
may be responsible for cholestasis in the remainder of cases (Jacquemin, 2012). 
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5.4.2. PFIC-related deficiencies 
Diagnosis of the four patients with PFIC1 is likely to have been useful for clinicians 
for prognosis and management; one case was thought to be a lysosomal storage 
disorder prior to testing.  UCDA therapy and PEBD may help reduce symptoms of 
cholestasis; however it is not usually effective in all cases (Jacquemin, 2012).  Liver 
transplantation is an option, however extrahepatic features such as diarrhoea, may 
increase in severity following surgery therefore, PFIC1 patients are sometimes 
considered not suitable for transplant (Jacquemin, 2012).  The patient diagnosed 
with BRIC1 and the patient with a single ATP8B1 mutation can now be monitored for 
signs of progressive liver disease, as more becomes known in future about the 
disease course associated with such genotypes.  
A diagnosis of PFIC2, in contrast to PFIC1, would indicate liver transplantation.  
UCDA therapy and PEBD surgery might be successful in treating the cholestasis; 
however there is a high risk of liver cancer in early life in PFIC2 infants, therefore 
liver transplantation should be recommended (Davit-Spraul et al., 2009).  In addition, 
the extrahepatic complications found in PFIC1 patients following transplant are not 
observed in PFIC2.  A diagnosis of BSEP deficiency in the patient, who presented 
with an episode of cholestasis in the neonatal period, would be useful to allow close 
monitoring for signs of progressive liver disease in the future. 
The cohort of patients with single ABCB4 mutations all had a history of related 
symptoms in close relatives, highlighting that this type of MDR3 deficiency is 
inherited in an autosomal dominant manner, and suggests these pathogenic, severe 
ABCB4 alleles are highly penetrant by adulthood in females.  However, since 
environmental and other factors are involved in the expression of MDR3 deficiency, it 
is likely that other apparently asymptomatic relatives may also be carriers (i.e. 
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males).  Identification of asymptomatic and symptomatic carrier relatives is important 
as MDR3 deficiency responds well to UDCA therapy, which reduces gallstones and 
prevents severe complications such as fibrosis, cirrhosis and the need for 
cholecystectomy.  In addition, UDCA can be taken throughout pregnancy by high-
risk women, preventing the onset of severe ICP and the risks to the fetus. 
Furthermore, a review of patient P41 (5.3.7) suggests that two copies of a ‘mild’ 
mutation might lead to a similar clinical presentation as one copy of a ‘severe’ 
mutation. This would be supported if the total amount of MDR3 protein produced by 
the two scenarios was similar, and therefore protein studies would be important to 
confirm this hypothesis.  This hypothesis is also likely to apply to ABCB11 and 
ATP8B1 mutations. 
5.4.3. Significance of genetic diagnosis 
A genetic diagnosis of PFIC is useful for parents and families for many reasons 
including; having a name for the condition, allowing access to specific knowledge 
about a particular condition, allowing more accurate predictions of prognosis, more 
accurate assessment of genetic risk for siblings, future pregnancies and other 
relatives and allowing access to prenatal diagnosis or pre-implantation genetic 
diagnosis.  Similarly, diagnosis of PFIC-related disorders in adults can be useful to 
allow effective treatment planning, for example prior to pregnancy in females with 
ABCB4 mutations, and to allow screening of asymptomatic relatives. 
5.4.3. Variants of uncertain significance 
The cases described above (5.3.11) highlight the need for careful reporting of VUS, 
as it may be detrimental to patient care if a clinician assumed an incorrect diagnosis 
due to the misinterpretation of genetic findings.  In cases where VUS are identified, 
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testing of other affected relatives if available would be advised in order to provide 
evidence that the missense variant segregated with disease, or not.  Publication of 
additional patients with the same genetic variants would lead to greater 
understanding of their clinical significance in future.  It is also possible that other 
genetic and environmental factors are playing a role in these cases.  
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Chapter 6 – GENETIC TESTING IN 
PATIENTS SUSPECTED OF NPC AND CD 
6.1. Introduction 
6.1.1. Genetic characterisation of NPC 
Carstea et. al. mapped the disease-causing gene for Niemann Pick disease type C 
to a region on chromosome 18 and then later identified the NPC1 gene (Carstea, 
1997).  Disease heterogeneity was subsequently exposed and the NPC2 gene was 
identified (Naureckiene, 2000b). Since then a large number of mutations have been 
identified in these genes; although around 95% of NPC cases are linked to mutations 
in NPC1 (Vanier et al., 1996).  A large cohort of British NPC cases was reported in 
detail by Imrie et. al. in 2007 (Imrie et al., 2007). 
6.1.2. Genetic characterisation of CD 
SLC25A13 was identified as the gene responsible for adult-onset citrullinaemia type 
2 (CTLN2) in 1999 (Kobayashi et al., 1999).  It was first linked to liver disease in 
infants in 2002 by the same group (Saheki and Kobayashi, 2002).  NICCD and 
CTLN2 are therefore considered allelic conditions, together described as citrin 
deficiency or citrullinaemia type 2, and neither of them is fully penetrant.  This 
disease has been almost exclusively been described in patients of Japanese and 
Chinese ethnicity, however recently it has been discovered in other populations 
including in the UK (Hutchin et al., 2009); summarised by Woo et al., 2014).   
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6.1.3. Investigations in subjects suspected of NPC and CD 
Mutation detection in subjects suspected of NPC and CD was carried out by testing 
of patients referred to the West Midlands Regional Genetics Service between 
January 2010 and May 2014.  Subjects were tested using FS or tNGS after the 
assay had been developed in January 2013 (described in Chapter 3).  Both methods 
allowed interrogation of the coding regions of the genes plus the intron-exon 
boundaries allowing the findings to be collated.  Sequence variant interpretation was 
performed on all variants identified except those considered benign polymorphisms.  
Questionnaires were completed where possible by the referring clinicians for NPC 
patients in whom sequence variants were identified, in order to correlate phenotypes 
with genetic findings. 
6.1.4. Chapter 6 Objectives 
 To broaden the known mutation spectrum of the NPC1, NPC2 and 
SLC25A13 genes. 
 To evaluate genotype-phenotype correlations in the NPC1 gene.  
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6.2. Methods 
6.2.1. Patient material 
Patients suspected of NPC or CD were referred for diagnostic testing; mainly by 
consultant hepatologists or paediatricians, however occasional referrals were made 
from consultant neurologists, metabolic specialists or geneticists. Consent was taken 
by the referring clinicians for diagnostic testing, which included the anonymous 
reporting of sequence variants.  Samples received were mainly venous blood 
samples in EDTA or occasionally Lithium Heparin.  Some DNA samples were 
received from outside of the West Midlands region or from other countries.  All 
results were reported back to the patients via the referring clinicians. 
6.2.2. DNA extraction  
DNA was extracted from blood samples using Gentra Autopure method between 
January 2010 and February 2013.  At that point, the lab switched to the Qiagen 
Qiasymphony method.  Occasionally the phenol chloroform method was used for 
samples which appeared to be in poor condition, for example long transit time.  
Samples of very small volumes or from very young babies were extracted using a 
manual version of the Autopure method.  Quantification of DNA samples was done 
using the Nanodrop Spectrophotometer.  All methods are described in Chapter 2 
(2.2.1).   
6.2.3. PCR primer design 
PCR primers were designed for all coding exons of the NPC1, NPC2 and SLC25A13 
genes.  This was done using the online tools Exon-Primer (UCSC), Primer3 and 
Primer-Blast (NCBI) using 60oC as the optimal annealing temperature and at least 
30 bases of flanking intron each side (2.1.14).  All primer pairs were checked using 
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the NGRL SNPCheck tool to avoid polymorphisms of more than 1% in any 
population.  PCR primer sequences are listed in 2.1.12.1, Table 2.1. 
6.2.4. Analysis methods 
The methods for PCR (2.2.3.1), FS (2.2.6.1), and sequence analysis (2.2.8.1) are 
described in Chapter 2.  FS was also used to confirm sequence variants identified 
using the tNGS assay and to test those exons not covered by tNGS; NPC1 exons 1 
and 12, NPC2 exon 1 and SLC25A13 exon 1.  The methods relating to the tNGS 
assay are described in sections 2.2.3.4, 2.2.8.4 and 2.2.6.3 of Chapter 2. These 
processes were optimised and validated as discussed in Chapter 3.  The methods 
for MLPA are described section 2.2.7 and for GeneMarker analysis 2.2.8.2. 
6.2.5. Variant interpretation 
All sequence variants were investigated for potential pathogenicity using the variant 
interpretation pipeline described in Chapter 2 (2.2.10). 
6.2.6. Phenotype questionnaires 
Phenotype questionnaires were sent to referring clinicians for NPC referrals in whom 
sequence variants were identified in order to gather clinical information.  The clinical 
features were based upon the NPC index of suspicion tool (Wijburg et al., 2012). The 
template is shown in Appendix IV.  The NPC suspicion index score was available for 
some of the patients. 
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6.3. Results 
6.3.1. NPC testing 
6.3.1.1. Sequence variants detected in NPC 
One hundred and thirty one subjects with clinical suspicion of Niemann Pick disease 
type C (NPC) were tested for mutations in NPC1 and NPC2.  Forty three were two 
years of age or less, forty eight were between three and fifteen years of age and 
forty were sixteen years or older at the time of referral.  The majority were referred 
from centres in the UK, however thirty two were from Brazil and single samples were 
received from Norway, Greece and Canada.  Seventy seven of these were tested 
using the Sanger sequencing method (FS) and fifty four using the next generation 
sequencing method (tNGS), with Sanger sequencing to confirm any variants found 
and to complete any missing exons due to low coverage.  
The samples were screened for mutations in the NPC1 and NPC2 genes using DNA 
sequencing and MLPA, and Figure 6.1 summarises the method used to detect the 
mutations detected.  Thirty four sequence variants were identified, including fourteen 
variants which were classified as ‘pathogenic’, fourteen that were ‘possibly 
pathogenic’ and six were classified as of uncertain clinical significance (VUS).  Table 
6.1 lists the thirty four variants detected and includes nonsense, frameshift, splice 
site (+/- 1 or 2 bases from exon) mutations detected in this cohort, and also 
missense mutations that had previously been reported in the literature in association 
with cholestatic conditions.  In addition, this table includes variants that were novel 
but predicted to be likely pathogenic mutations (using in silico methods described 
2.2.10). In summary, twenty two were missenses, six were in the conserved splice 
sites, five altered the reading frame and one was a likely large deletion of an entire 
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exon. In addition, thirteen of the thirty four variants were novel (38%).  These were 
c.338_339dupGT, c.631+1G>T, P520S, Exon 11 deletion, E606Q, E718D, 
c.2533delG, c.2972delA, c.3477+2_+3dupTG, c.3477+4A>G, E1166K, F1207S and 
c.3746-3749delGTTA. 
Figure 6.2 summarises the mutation detection rate according to age at referral; 23% 
in patients under three years of age, 17% in patients between three and fifteen years 
of age and 25% of patients aged sixteen years or over. 
Figure 6.1: NPC variant detection rate by method 
 
Figure 6.2: Overall genetic outcome by age at referral
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Table 6.1 The sequence variants identified in the NPC cohort. 
KEY:  DNA change; standard genetic code using single amino acid code and HGVS nomenclature.  Type; MS=missense, 
FS=frameshift, NS=nonsense, SS=splice site, Int=intronic, Del=deletion. Population frequency; 1KG=1000 Genomes project using 
their three letter code for populations, ESP=exome sequencing project. NA cons=Nucleic acid conservation, AA cons=Amino acid 
conservation, AA diff=amino acid difference. The terms used were those generated using Alamut software.  Protein prediction; 
AGVGD=Align GVGD, S=SIFT, MT=Mutation Taster, PP=PolyPhen2.  Splicing prediction; SSF=Splice site finder, 
MES=MaxEntScan, NNS=NNSplice, GS=GeneSplicer, HSF=Human Splice Finder. 
# Gene DNA change Type 
Referenc
e 
Population 
frequency 
NA cons 
AA cons 
AA diff 
Protein prediction 
Splicing 
prediction 
Conclusion 
N5 
NPC
1 
c.338_339dupGT 
p.(S114Vfs*9) 
FS Novel None n/a  n/a n/a Pathogenic 
N11 
NPC
1 
c.530G>A 
p.(C177Y) 
MS 
(Ribeiro 
et al., 
2001) 
rs80358252 
No data 
High   
High   
Large 
AGVGD C0  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES Donor 
creation  
NNS No 
change  
HSF No change 
Possibly 
pathogenic 
N12 
NPC
1 
c.631+1G>T SS Novel No data High   n/a 
SS Donor site 
lost MES Donor 
site lost  
NNS Donor site 
lost  
HSF Donor site 
lost 
Pathogenic 
N18 
N19 
NPC
1 
c.1133T>C 
p.(V378A) 
MS 
(Millat et 
al., 2001) 
rs120074134 
No data 
High  
High  
Small 
AGVGD C25  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change NNS 
No change HSF 
No change 
Pathogenic 
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N1 
NPC
1 
c.1408G>C 
p.(A470P);  
 
c.2509A>G 
p.(I837V) 
MS 
 (Héron 
et al., 
2012) 
No data 
Moderate 
High 
Small 
AGVGD C0 
S Tolerated 
MT Disease-causing 
PP Probably 
damaging 
SS No change 
MES No 
change 
NNS No 
change 
HSF No change 
Possibly 
pathogenic 
No data 
Not   
Moderate 
Small 
AGVGD C0 
S Tolerated 
MT Polymorphism 
PP Benign 
SS No change 
MES No 
change 
NNS No 
change 
HSF Acceptor 
creation 
N24 
NPC
1 
c.1558C>T 
p.(P520S) 
MS Novel No data 
High  
High 
Moderate 
AGVGD C65  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change NNS 
No change HSF 
No change 
Uncertain 
significance 
N13 
NPC
1 
Exon 11 deletion 
Ex 
Del 
Novel No data High   n/a  n/a  Pathogenic 
N1 
NPC
1 
c.1816G>C 
p.(E606Q) 
MS Novel No data 
High  
High  
Small 
AGVGD C25  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change NNS 
No change HSF 
No change 
Possibly 
pathogenic 
N14 
NPC
1 
c.1990G>A 
p.(V664M) 
MS 
(Park et 
al., 
2003), 
(Bauer et 
al., 2013) 
rs376213990 
1KG No data 
ESP 1 EA 
allele  
High  
High  
Small 
AGVGD C0  
S Tolerated  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change NNS 
No change HSF 
No change 
Possibly 
pathogenic 
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N2 
NPC
1 
c.2154A>C 
p.(E718D) 
MS Novel No data 
Not  
Moderate 
Small 
AGVGD C0  
S Tolerated  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change NNS 
No change HSF 
No change 
Uncertain 
significance 
N20 
N21 
NPC
1 
c.2292G>A SS 
(Park et 
al., 2003) 
No data Weak   n/a 
SS Acceptor 
creation  
MES Acceptor 
creation  
NNS Acceptor 
creation  
HSF Acceptor 
creation 
Pathogenic 
N3 
NPC
1 
c.2533delG 
p.(V845Ffs*9) 
FS Novel No data n/a n/a n/a  Pathogenic 
N20 
NPC
1 
c.2594C>T 
p.(S865L) 
MS 
(Fernand
ez-Valero 
et al., 
2005) 
No data 
High  
High  
Large 
AGVGD C15  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Possibly 
pathogenic 
N10 
NPC
1 
c.2621A>T 
p.(D874V) 
MS 
(Millat et 
al., 
2001), 
(Bauer et 
al., 2013) 
rs372030650 
1KG No data  
ESP 1 EA 
allele 
Moderate 
Moderate 
Large 
AGVGD C0  
S Deleterious  
MT Disease-causing  
PP Benign 
SS No change  
MES No 
change  
NNS No 
change  
HSF Donor 
creation 
Pathogenic 
N15 
NPC
1 
c.2660C>T 
p.(P887L) 
MS 
(Garver 
et al., 
2010) 
No data 
High 
Moderate 
Moderate 
AGVGD C0  
S Deleterious  
MT Disease-causing  
PP Probably 
SS No change  
MES No 
change  
NNS No 
Possibly 
pathogenic 
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damaging change  
HSF No change 
N15 
NPC
1 
c.2861C>T 
p.(S954L) 
MS 
(Greer et 
al., 
1999), 
(Bauer et 
al., 2013) 
No data 
High  
High  
Large 
AGVGD C35  
S Deleterious  
MT Disease-causing  
PP Possibly 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Pathogenic 
N10 
NPC
1 
c.2882A>G 
p.(N961S) 
MS 
(Dvorako
va et al., 
2006) 
rs34084984 
dbSNP Het 
0.007  
1KG 1% of 
AFR,  
ESP 53 AA 
alleles 
Moderate 
Moderate 
Small 
AGVGD C0  
S Tolerated  
MT Disease-causing  
PP Benign 
SS No change  
MES No 
change  
NNS No 
change  
HSF Acceptor 
creation 
Uncertain 
significance 
N4 
NPC
1 
c.2972delA 
p.(Q991Rfs*6) 
FS Novel No data n/a n/a n/a Pathogenic 
N22 
N16 
NPC
1 
c.3019C>G 
p.(P1007A) 
MS 
(Greer et 
al., 
1999), 
(Bauer et 
al., 2013) 
rs80358257 
1KG 1 allele 
ESP 2 EA 
alleles 
High  
High  
Small 
AGVGD C25  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Pathogenic 
N2 
NPC
1 
c.3020C>T 
(p.P1007L) 
MS 
(Imrie et 
al., 2007) 
No data 
High  
High 
Moderate 
AGVGD C65  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES Acceptor 
creation NNS 
No change  
HSF No change 
Possibly 
pathogenic 
N17 
NPC
1 
c.3056A>G 
p.(Y1019C) 
MS 
(Fancello 
et al., 
2009) 
No data 
High  
High  
Large 
AGVGD C55  
S Deleterious  
MT Disease-causing  
SS No change  
MES No 
change  
Possibly 
pathogenic 
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PP Probably 
damaging 
NNS No 
change  
HSF No change 
N16 
N14 
NPC
1 
c.3104C>T 
p.(A1035V) 
MS 
(Ribeiro 
et al., 
2001) 
rs28942107 
No data 
High  
High  
Small 
AGVGD C0  
S Tolerated MT 
Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Possibly 
pathogenic 
N23 
NPC
1 
c.3107C>T 
p.(T1036M) 
MS 
(Fernand
ez-Valero 
et al., 
2005) 
rs28942104 
No data 
High 
Moderate 
Moderate 
AGVGD C15  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Possibly 
pathogenic 
N18 
N19 
NPC
1 
c.3182T>C 
p.(I1061T) 
MS 
(Yamamo
to et al., 
1999) 
rs80358259 
ESP 1 AA 
and 4 AE 
alleles 
High  
High 
Moderate 
AGVGD C25  
S Deleterious  
MT Disease-causing  
PP Possibly 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Pathogenic 
N9 
NPC
1 
c.3263A>G 
p.(Y1088C) 
MS 
(Yamamo
to et al., 
1999) 
rs28942106 
No data 
High  
High 
Large 
AGVGD C55  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Possibly 
pathogenic 
N11 
NPC
1 
c.3477+2_+3dupTG  SS Novel No data High   n/a 
SS Donor 
creation MES 
Donor creation  
NNS Donor 
creation  
Possibly 
pathogenic 
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HSF Donor 
creation 
N24 
NPC
1 
c.3477+4A>G SS Novel 
rs114073738 
dbSNP Het 
0.005  
1KG 13 
alleles 
ESP 26 AA 
and 2 EA 
alleles 
High   n/a 
SS Donor 
weakened  
MES Donor 
weakened  
NNS Donor lost  
HSF Donor 
weakened 
Uncertain 
significance 
N21 
NPC
1 
c.3496G>A 
p.(E1166K) 
MS Novel No data 
High  
High  
Small 
AGVGD C55  
S Deleterious  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES Acceptor 
creation  
NNS No 
change  
HSF Donor 
creation 
Possibly 
pathogenic 
N6 
NPC
1 
c.3591+4delA SS 
(Park et 
al., 2003) 
No data High   n/a 
SS No change  
MES Donor site 
lost/new donor  
NNS Donor site 
lost HSF Donor 
site lost/new 
donor 
Pathogenic 
N6 
NPC
1 
c.3620T>C 
p.(F1207S) 
MS Novel No data 
High  
High  
Large 
AGVGD C15  
S Tolerated  
MT Disease-causing  
PP Probably 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Possibly 
pathogenic 
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N7 
N8 
N9 
NPC
1 
c.3662delT 
p.(F1221Sfs*21) 
FS 
(Ribeiro 
et al., 
2001) 
No data n/a n/a n/a Pathogenic 
N10 
NPC
1 
c.3746-
3749delGTTA 
p.(S1249Tfs*2) 
FS Novel No data n/a n/a n/a Pathogenic 
N24 
NPC
2 
c.88G>A p.(V30M) MS 
(Park et 
al., 2003) 
rs151220873 
dbSNP Het 
0.002  
1KG 5 
alleles  
ESP 25 EA 
alleles 
Not  
Weak  
Small 
AGVGD C0  
S Tolerated  
MT Polymorphism  
PP Possibly 
damaging 
SS No change  
MES No 
change  
NNS No 
change  
HSF No change 
Uncertain 
significance 
N25 
N26 
N27 
N28 
NPC
2 
C.441+1G>A SS 
(Bauer et 
al., 2013) 
rs140130028 
dbSNP Het 
0.002  
1KG 5 
alleles  
ESP 7 AA 
and 76 EA 
alleles 
  n/a n/a 
SS Donor site 
lost MES Donor 
site lost  
NNS Donor site 
lost  
HSF Donor site 
lost 
Uncertain 
significance 
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6.3.1.2. Multiplex-ligation dependent probe amplification 
DNA sequencing by FS or tNGS will not detect whole exon deletions or duplications 
therefore MLPA was used to screen for these in NPC1 and  NPC2 (Schouten et al., 
2002).  One patient was identified with an apparent homozygous deletion of exon 11 
of NPC1.  In addition, no PCR product could be obtained using flanking primers, 
excluding the possibility of a homozygous sequence variant in the exon causing 
MLPA probe dropout. This deletion has not been fully characterised however is likely 
to extend at least to one or both of the PCR primer sequences (see Figure 6.3).  
Consequently, this is mostly likely a disease-causing mutation; ‘pathogenic’. 
Figure 6.3: A diagram showing sequence including NPC1 exon 11. 
The sequence of NPC1 exon 11 including PCR primer and MLPA probe sequences.  
Red is forward primer, green is reverse primer, blue is the exonic sequence, purple 
bold is the MLPA probe.  Red text is nucleotide numbering using the A of the first 
ATG as 1. Blue text is amino acid numbering. 
MLPA analysis for this patient showed no amplification of PCR product or MLPA 
product. Note that the PCR primers and the MLPA probe sequences do not overlap. 
 
TATTTCAGCAAACTCTTGTTTAATTCTTAGAGCCCAGAGATACAGTCCATAGCTCCAGTG 
AGAAATCTGTGTTGTGATTTTTCCCCTGGTATGTGTCTAATTTTCTGCATGCTTGTAATC 
                                                      560 
                                 .  .  .  .  .  .  .  |  .   
TGCTTTTTGATGTCACATTTTTCCTTTCTAGATCAAAACTACAATAACGCCACTGCCCTT 
                                    ^1660     ^1670     ^1680 
                        570                           580 
.  .  .  .  .  .  .  .  |  .  .  .  .  .  .  .  .  .  |  .   
GTGATTACCTTCCCTGTCAATAATTACTATAATGATACAGAGAAGCTCCAGAGGGCCCAG 
      ^1690     ^1700     ^1710     ^1720     ^1730     ^1740 
 
.  .  .  .  . 
GCCTGGGAAAAAGAGTGAGTCACTCATGGGTGTGAGCAGACTGTCCTTGCATTGTGGGAA 
      ^1750  ^1757   
GCTAGACACTTGCGGCAAGCACTTAAACTTCATTTTCTAAATTAACCAATGGCAGATCTG 
AGTTACGTAGTTTTGTTCACTTGGTACTAATGATGCTAAGAAGAAACTGTAAAC 
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6.3.1.3. NPC diagnoses 
Table 6.2 lists the clinical features of the patients with mutations where these could 
be obtained.  Disease subtype was assigned by the age of onset of symptoms where 
that information was available, or by the clinical features reported, e.g. neonatal 
cholestasis was used to assign the subtype ‘infantile’ and neurological features such 
as VSGP or gelastic cataplexy indicated ‘juvenile’. Where the age at presentation 
could not be determined ‘Not known’ was assigned and where the genetic diagnosis 
of NPC was in doubt ‘Not certain’ was assigned.   
Diagnoses were made in twenty three patients by the identification of at least one 
pathogenic or possibly pathogenic mutation (18%), and a further four patients had 
VUS only (3%).  There were thirteen infantile cases, seven juvenile cases and one 
adult case.  In addition, there were two cases diagnosed with NPC where the 
subtype was not clear (not known) and five cases were the diagnosis of NPC was 
not certain.  Four patients diagnosed with NPC were found with only single NPC1 
mutations and two mutant alleles were identified in the remaining nineteen 
diagnosed cases.  
Within the group of thirteen infantile cases, the age of onset was recorded in 8 
cases; this ranged from birth to 5 months of age, and averaged 55 days. Clinical 
features were recorded in eleven cases with visceral features being present in all of 
these, neurological features in eight cases and psychiatric features in three cases.  
In the group of seven juvenile cases, the age of onset was recorded in only one.  All 
seven cases had neurological features, four had psychiatric features and three had 
visceral features.  The single adult case presented at age 30 and had neurological 
and psychiatric features. 
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6.3.1.4. Infantile NPC patients 
The thirteen infantile cases were found to have a total of 18 different mutations, 10 of 
which were novel, indicating that these mutations are likely to seriously affect the 
NPC1 protein.  Patient N1 had a double missense allele A470P; I837V and a novel 
missense allele E606Q.  This patient presented at 12 weeks of age and had 
cholestasis, hepatosplenomegaly, hypotonia and delayed developmental milestones, 
indicating early-onset type NPC.  Patient N2 presented at 5 months, had cholestasis 
and hepatosplenomegaly, and the missense variants E718D and P1007L were 
identified.  Patient N3 was homozygous for the novel frameshift mutation c.2533delG 
p.(V845Ffs*9) and presented from birth. Similarly, patient N4 was homozygous for 
the novel frameshift c.2972delA p.(Q991Rfs*6) and presented before the age of 2 
years.  Patient N5 also had a novel homozygous frameshift mutation 
c.338_339dupGT p.(S114Vfs*9) and presented at two months of age.  Patient N6 
was compound heterozygous for the splice site mutation c.3591+4delA and the novel 
missense F1207S.  This patient presented by 9 days with cholestasis and 
splenomegaly and went on to have acute liver failure at 6 weeks of age.  N7 and N8 
was both homozygous for a previously reported frameshift mutation c.3662delT 
p.(F1221Sfs*21), whereas N9 was heterozygous for the same mutation but also 
carried the previously reported missense c.3263A>G p.(Y1088C).  All three had 
classical filipin staining patterns.  N10 presented at 6 weeks with cholestasis and 
hepatosplenomegaly. Sequencing analysis identified heterozygosity for the D874V 
missense and a complex allele containing a missense and frameshift; p(N961S; 
S1249Tfs*2).  Patient N11 was compound heterozygous for the missense C177Y 
and the novel frameshift c.3477+2_+3dupTG.  In patient N12, a novel splice site 
mutation was identified on one allele (c.631+1G>T), however no mutation was 
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detected on the other allele.  This patient presented at 8 weeks of age with 
cholestasis and hepatomegaly and went on to develop neurological and psychiatric 
symptoms of NPC.  Lastly, N13 had a likely deletion of all or part of exon 11 on both 
NPC1 alleles, presented at 6 weeks and had cholestasis, hepatosplenomegaly, 
hypotonia and spasticity.   
6.3.1.5. Juvenile and adult NPC patients 
The seven juvenile NPC cases were found to have a total of ten different mutations, 
only one of which was novel.  Ten of these were missense mutations and one was a 
splicing defect.  Patient N14 was found to be heterozygous for two missense 
mutations V664M and A1035V, had neurological and psychological features and a 
suspicion index score over 40. Patient N15 presented at age seven years with 
neurological features of NPC.  Heterozygosity for two missense mutations, P887L 
and S954L, was identified.  N16 had neurological features of NPC and splenomegaly 
and was found to be heterozygous for two missense mutations; P1007A and 
A1035V. Both N15 and N16 had variant filipin staining patterns.  N17 had 
neurological and psychiatric features of NPC, however only one heterozygous 
mutation was identified; Y1019C.  N20 also had neurological and psychiatric features 
of NPC, and was found to be heterozygous for the splice site mutation c.2292G>A, 
and the missense mutation S865L.  The splice-site mutation c.2292G>A was also 
identified in patient N21 along with the novel missense E1166K.  This patient had 
classical neurological symptoms of VSGP, ataxia, dysarthria and dystonia as well as 
splenomegaly.  Lastly, in patient N22 only the missense mutation P1007A was 
identified.  This patient had neurological features of NPC as well as splenomegaly 
and pre-senile cognitive decline or dementia. 
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There was one adult case which presented at age 30 years; N23.  This patient had 
neurological and psychiatric features and was found to be heterozygous for one 
missense mutation; T1036M. 
6.3.1.6. Patients with VUS only 
There were five patients in which the genetic findings did not fully confirm a 
diagnosis of NPC, as only VUS were identified.  Patient N24 presented at 10 months 
and had a complex phenotype consisting of cholestasis, hepatosplenomegaly, 
hypotonia, VSGP and spasticity, as well as coarse facial features and anaemia. In 
NPC1 the intronic variant c.3477+4A>G was identified; in silico splicing tools 
predicted this nucleotide is highly conserved and the change is likely to weaken the 
splice donor site of exon 22, however it has also been identified in normal 
populations at a low frequency making it less likely to be causative of NPC 
(rs114073738).  In addition, the novel NPC1 missense P520S was identified.  This is 
a highly conserved nucleotide and amino acid and in silico protein prediction tools 
indicate it is likely to be deleterious to the protein.  Lastly the NPC2 missense V30M 
was identified in patient N24.  This was reportedly identified in the heterozygous 
state in an NPC patient (Park et al., 2003), although a mutation on the other allele 
was not identified.  However, since then it has also been reported in normal 
populations (rs151220873) and it is not well conserved at the nucleotide or amino 
acid level.  In conclusion, there is little evidence that V30M is causative however the 
contribution of the two NPC1 variants is at this time uncertain.  Further 
characterisation of this patient using filipin staining or complementation studies may 
be useful to conclusively establish a diagnosis of NPC.   
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A further four patient (N25 to N28) were found to be heterozygous for the NPC2 
variant c.441+1G>A.  No other NPC1 or NPC2 variants were identified in these 
patients. 
In two of these patients (N25 and N26) no clinical data was reported, however 
patients N27 and N28 both presented in the first few weeks of life.  N27 had 
cholestasis and hepatomegaly, and N28 had cholestasis and splenomegaly, as well 
as VSGP and hypotonia. 
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Table 6.2 The genotypes and clinical features of patients with NPC sequence variants identified. 
KEY: Phase known; Yes or No indicates whether parents have been tested for the variants. SI>40 = NPC suspicion index score 
(Wijburg et al., 2012) greater than 40, Y/N or numerical value if reported. Age at presentation; d=days, w=weeks, m=months, 
y=years.  
Subtype was assigned by the age of onset of symptoms where that information was available, or by the clinical features reported, 
eg neonatal cholestasis was used to assign the subtype ‘infantile’ and neurological features such as VSGP or gelastic cataplexy 
indicated ‘juvenille’. Where the age at presentation could not be determined ‘Not known’ was assigned and where the genetic 
diagnosis of NPC was in doubt ‘Not certain’ was assigned. 
Clinical features Visceral; C=prolonged neonatal jaundice or cholestasis, S=Splenomegaly, H=Hepatomegaly, HF=Hydrops fetalis, 
SA=sibling with fetal ascites.  
Neurological; V=vertical supranuclear gaze palsy, G=Gelastic cataplexy, A=Ataxia, clumsiness or frequent falls, 
DA=dysarthria/dysphagia, DT=dystonia, SP=Acquired and progressive spasticity, HT=hypotonia, DD=delayed developmental 
milestones, SE=Generalised or partial seizures, M=myoclonus.  
Psychatric; D=Pre-senile cognitive decline or dementia, P=Psychotic symptoms, TR= treatment-resistant psychiatric symptoms, 
PS=other psychiatric symptoms, B=aggressive or disruptive behaviour 
# Country Allele 1 Allele 2 
Phase  
known 
SI>40 Subtype 
Age at 
presen
tation 
Clinical features 
Visceral Neurological Psychiatric 
NPC1 
N1 UK 
c.1408G>C;25
09A>G 
p.(A470P; 
I837V) 
c.1816G>C 
p.(E606Q) 
Yes 
Not 
known 
Infantile 12 w C, S, H,  HT, DD - 
N2 UK 
c.2154A>C 
p.(E718D) 
c.3020C>T 
(p.P1007L) 
No 
Not 
known 
Infantile 5 m C, H - - 
N3 UK 
c.2533delG 
p.(V845Ffs*9) 
c.2533delG 
p.(V845Ffs*9) 
Yes 
Not 
known 
Infantile 
From 
birth 
Not known 
N4 UK 
c.2972delA 
p.(Q991Rfs*6) 
c.2972delA 
p.(Q991Rfs*6) 
Yes 
Not 
known 
Infantile <2 y Not known 
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N5 UK 
c.338_339dup
GT 
p.(S114Vfs*9) 
c.338_339dup
GT 
p.(S114Vfs*9) 
Yes 
Not 
known 
Infantile 2 m C, S, H,  HT, DT - 
N6 UK c.3591+4delA 
c.3620T>C 
p.(F1207S) 
Yes 
Not 
known 
Infantile 9 d C, S - - 
N7 Brazil 
c.3662delT 
p.(F1221Sfs*2
1) 
c.3662delT 
p.(F1221Sfs*2
1) 
Yes 148 Infantile - C, S, SA,  
HY, DD, V, DA, 
DT, SP 
- 
N8 Brazil 
c.3662delT 
p.(F1221Sfs*2
1) 
c.3662delT 
p.(F1221Sfs*2
1) 
No 231 Infantile - S 
DD, V, A, DA, 
DT, SP 
D 
N9 Brazil 
c.3662delT 
p.(F1221Sfs*2
1) 
c.3263A>G 
p.(Y1088C) 
Yes 147 Infantile - C, S, SA,  
DD, V, A, DT, 
SP 
- 
N1
0 
UK 
c. 2882A>G; 
3746_3749del
GTTA p.( 
N961S; 
S1249Tfs*2) 
c.2621A>T 
p.(D874V) 
Yes 
Not 
known 
Infantile 6 w C, H - - 
N1
1 
Brazil 
c.530G>A 
p.(C177Y) 
c.3477+2_+3d
upTG  
Yes 276 Infantile - C, S,  
V, G, A, DA, 
DT, SP, SE 
D 
N1
2 
UK c.631+1G>T Not identified  n/a 
Not 
known 
Infantile 8 w C, H,  HY, DD, SE, M 
D, P, TR, 
PS, B 
N1
3 
UK 
Exon 11 
deletion 
Exon 11 
deletion 
No 
Not 
known 
Infantile 6 w C, S, H,  HT, SP - 
N1
4 
Brazil 
c.1990G>A 
p.(V664M) 
c.3104C>T 
p.(A1035V) 
No 116 
Juvenill
e 
- - 
V, A , DA, DT, 
SP, SE 
D 
N1
5 
Brazil 
c.2660C>T 
p.(P887L) 
c.2861C>T 
p.(S954L) 
No Yes 
Juvenill
e 
7 y - V, A, DT, SE - 
N1
6 
Brazil 
c.3019C>G 
p.(P1007A) 
c.3104C>T 
p.(A1035V) 
No 117 
Juvenill
e 
- S 
V, A, DA, DT, 
SE, SP 
- 
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N1
7 
Brazil 
c.3056A>G 
p.(Y1019C) 
Not identified  n/a 141 
Juvenill
e 
- - 
V, G, A, DA, 
SE, SP 
D, PS 
N1
8 
UK 
c.1133T>C 
p.(V378A) 
c.3182T>C 
p.(I1061T) 
No 
Not 
known 
Not 
known 
- Not known 
N1
9 
UK 
c.1133T>C 
p.(V378A) 
c.3182T>C 
p.(I1061T) 
No 
Not 
known 
Not 
known 
- Not known 
N2
0 
Brazil c.2292G>A  
c.2594C>T 
p.(S865L) 
No 106 
Juvenill
e 
- - V, A, DA, SP D 
N2
1 
Brazil c.2292G>A  
c.3496G>A 
p.(E1166K) 
Yes 130 
Juvenill
e 
- S V, A, DA, DT - 
N2
2 
Brazil 
c.3019C>G 
p.(P1007A) 
Not identified  n/a 256 
Juvenill
e 
- S 
V, A, DA, DT, 
SP, SE 
D 
N2
3 
UK 
c.3107C>T 
p.(T1036M) 
Not identified  n/a 
Not 
known 
Adult 30 y - G, A, DD D 
N2
4 
UK 
c.1558C>T 
p.(P520S) 
c.3477+4A>G 
No 
Not 
known 
Not 
certain 
10 m C, S, H V, SP, HT - NPC2 
c.88G>A 
p.(V30M) 
Not identified 
NPC2 
N2
5 
UK c.441+1G>A Not identified  n/a 
Not 
known 
Not 
certain 
- Not known 
N2
6 
Canada c.441+1G>A Not identified  n/a 
Not 
known 
Not 
certain 
- Not known 
N2
7 
UK c.441+1G>A Not identified  n/a 
Not 
known 
Not 
certain 
4 w C, H - - 
N2
8 
UK c.441+1G>A Not identified  n/a 
Not 
known 
Not 
certain 
8 w C, S V, HT - 
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6.3.2. Mutation detection in subjects suspected of CD 
51 patients with clinical suspicion of citrin deficiency (CD) SLC25A13 gene between 
2009 and 2015; 48 were from the UK and single cases were received from Germany, 
France and Brazil.  20 were under 2 years of age and 18 were between 2 and 17 
years of age at the time of referral. 45 of these were tested using the FS method and 
6 using the tNGS method, with FS used to sequence exon 1 of SLC25A13 and to 
confirm any variants found.  
9 mutations in the SLC25A13 gene were identified in 11 patients (21%) and the 
mutations identified are listed in Table 6.3; 4 missense, 3 nonsense and 2 frameshift 
mutations.  Five of the nine mutations identified in the SLC25A13 gene were 
previously reported, however four of them were novel and these are listed in Table 
6.4.  One was a nonsense mutation and the other 3 were missense variants that 
were not seen in normal populations, were conserved at the nucleotide and amino 
acid levels and were predicted to be deleterious to the protein.   
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Table 6.3: The SLC25A13 sequence variants found in the cohort.   
No parental testing has been done in the patients marked with *, therefore it has been assumed that the mutations are present on 
opposite alleles of SLC25A13.  
# 
Origin 
(ethnicity) 
Allele 1 Reference/Novel Allele 2 Reference/Novel 
C1* UK (Indian) c.550C>T p.(R184*) (Kobayashi, 2003) c.550C>T p.(R184*) (Kobayashi, 2003) 
C2 UK c.848G>T p.(G283V) Novel Not detected n/a 
C3* UK c.852_855delTATG p.(M285Pfs*2) 
(Kobayashi et al., 
1999) 
c.852_855dalTATG 
p.(M285Pfs*2) 
(Kobayashi et al., 
1999) 
C4* UK c.852_855delTATG p.(M285Pfs*2) 
(Kobayashi et al., 
1999) 
c.1095delT p.(F365Lfs*43) (Fu et al., 2011) 
C5 UK c.852_855delTATG p.(M285Pfs*2) 
(Kobayashi et al., 
1999) 
Not detected n/a 
C6 UK c.1173T>G p.(Y391*) Novel c.1173T>G p.(Y391*) Novel 
C7 UK c.1763G>A p.(R588Q) (Tabata et al., 2008) c.1763G>A p.(R588Q) 
(Tabata et al., 
2008) 
C8 UK c.1763G>A p.(R588Q) (Tabata et al., 2008) c.1763G>A p.(R588Q) 
(Tabata et al., 
2008) 
C9 UK c.1766C>T p.(S589F) Novel c.1766C>T p.(S589F) Novel 
C10 UK c.1781G>A p.(G594D) Novel c.1781G>A p.(G594D) Novel 
C11 Denmark c.1813C>T p.(R605*) (Yasuda et al., 2000) c.1813C>T p.(R605*) 
(Yasuda et al., 
2000) 
Kirsten Elizabeth McKay Bounford   
216 
 
 
Table 6.4: The novel mutations identified in the CD cohort.   
None were reported on dbSNP, on HGMD or in the literature.  None showed any 
effect on mRNA splicing according to 4 in silico tools (data not shown). KEY: 
N=nonsense, M=missense, NA = nucleic acid, AA = amino acid, cons = 
conservation, diff = difference.  Protein prediction tools AGVGD = Align GVGD, S = 
SIFT, MT = Mutation Taster, PP = PolyPhen2. Data from Alamut software (see 
2.1.13). 
 
 
  
Exon 
DNA 
change 
Type NA cons 
AA 
cons 
AA diff Protein prediction tools Conclusion 
8 
c.848G>T 
p.(G283V) 
M High High Moderate 
AGVGD - C0   
S - Deleterious  
MT - Disease-causing 
PP - Probably damaging 
Possibly 
pathogenic 
11 
c.1173T>G 
p.(Y391*) 
N n/a n/a n/a n/a Pathogenic 
17 
c.1766C>T 
p.(S589F) 
M High High Large 
AGVGD – C0 
S – Tolerated 
MT - Disease-causing 
PP – Possibly damaging 
Possibly 
pathogenic 
17 
c.1781G>A 
p.(G594D) 
M Moderate High Moderate 
AGVGD – C25 
S – Deleterious 
MT - Disease-causing 
PP – Probably damaging 
Possibly 
pathogenic 
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6.4. Discussion 
6.4.1. Observations from testing in patients suspected of NPC 
Mutations in NPC1 and NPC2 which were detectable using MLPA accounted for only 
3% of those detected in this cohort.  Such mutations are rare in NPC patients, and 
HGMD lists ten such mutations, compared to three hundred and seventy five 
mutations detectable by sequencing methods (Patterson 1993 GeneReviews, 
Human Gene Mutation Database). 6% of variants detected were present in NPC2 
however none of these were clearly pathogenic.  As a result, fewer mutations in 
NPC2 were detected than is reported for NPC worldwide (GeneReviews lists NPC2 
mutations as accounting for 4% cases); however it is similar to the genetic 
distribution for NPC previously reported in the UK population (Imrie et al., 2007).     
Thirteen novel sequence variants in NPC1 were identified; six of which were 
classified as pathogenic, four were possibly pathogenic and the rest were VUS.  This 
study highlights that despite there being dozens of NPC1 mutations reported in the 
literature, genetic testing of NPC patients is still likely to uncover novel mutations.  
This supports the evidence that many of the mutations in NPC1 are family-specific 
(Vanier and Millat, 2003).   
A detailed description of a large cohort of UK NPC patients previously found the 
common NPC1 allele I1061T accounted for 25.3% of allele (Imrie et al., 2007).  In 
this study, I1061T was found in only 3.6% of alleles in total and in 6.2% of alleles 
from UK patients (N18 and N19).  A smaller sample number and possibly the 
contribution of different ethnic groups to the two cohorts may account for this 
difference.  V378A was identified in combination with I1061T in two UK patients; 
however the rest of the UK patients had different NPC1 alleles. 
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Four patients (14%) were identified with only single heterozygous mutations in 
NPC1.  This observation has previously been reported in other NPC cohorts (Park et 
al., 2003) (Bauer et al., 2013).   
There was a higher pickup rate in the patients referred from Brazil than those from 
the UK (34% versus 13%).  This was expected as all the Brazilian patients had NPC 
suspicion index scores greater than 40 (Wijburg et al., 2012), increasing the 
likelihood of NPC in those referred. Most of the mutations found in the Brazilian 
patients had previously been reported in the literature.  
6.4.2. Genotype-phenotype correlations in NPC 
It can be assumed that mutations which lead to absence of NPC1 protein would be 
associated with a severe form of NPC, whereas missense mutations could have 
more variable effects on phenotype (Park et al., 2003).  The patients with mutations 
in this cohort were grouped by their phenotypes into Infantile, Juvenille and Adult 
groups and the mutations identified in these groups seem to correlate well with this 
hypothesis.   
In the thirteen infantile cases (those cases presenting under the age of three years 
where known or with cholestasis) the mutation was identified in twenty five of the 
twenty six alleles.  Twelve of the alleles were small deletions or insertions which 
would result in a frameshift.  Two alleles were a large deletion of an entire exon.  
Two alleles disrupted conserved splice-sites and another was a VUS but close to a 
splice-site.  The remaining eight mutations were missense changes, three of which 
were novel and five had previously been reported in the literature.   
Ribeiro et. al first identified C177Y and found it to be associated with a decreased 
level of NPC1 protein in cultured fibroblasts and unusually variant filipin staining 
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(Ribeiro 2001).  They reported one homozygous and one compound heterozygous 
patient with this mutation.  The homozygous patient had a moderate 
hepatosplenomegaly and early onset of neurological features with cataplexy noted at 
age three years. In contrast, Fernandez-Valero et. al found C177Y in four compound 
heterozygous patients and one homozygous patient and reported that all five cases 
had classical filipin staining.  The homozygous patient had hepatosplenomegaly and 
hypotonia at birth.  Patient N11 in this cohort had no filipin staining result, however 
was known to have had cholestasis and splenomegaly and a very high suspicion 
index score supporting the hypothesis that it associated with infantile-onset NPC.  
Homozygosity for P1007L has previously been identified in a UK patient presenting 
by age two years with hepatosplenomegaly and then developing neurological NPC 
features (Imrie 2007).  Y1088C has been reported in two patients with juvenile-onset 
NPC however on both occasions the mutation was compound heterozygous and so 
genotype-phenotype conclusions are difficult to ascertain (Yamamoto et al., 1999), 
(Chiba et al., 2014).  In contrast, Imrie et. al. reported a patient who presented at age 
8 years, however who was also noted to have had prolonged jaundice and 
hepatosplenomegaly at birth, indicating this was infantile-onset with hindsight (Imrie 
et al., 2007).  Héron et. al found the same complex allele A470P;I837V as found in 
patient N1 in this cohort, in the homozygous form in a patient with late-infantile onset 
of neurological features and a classical filipin staining pattern (Héron et al., 2012).  
Millat et. al. observed the homozygous D874V mutation in a NPC patient with a 
classical filipin staining pattern but whom had not developed neurological features by 
age seven years (Millat et al., 2001).  The observation of A470P;I837V and D874V 
associated with infantile-onset NPC in this cohort (patients N1 and N10 respectively) 
may represent variability in expression of these alleles or differences in phenotypic 
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classification between the different studies.  Lastly, the identification of the three 
novel missenses in infantile NPC cases (E606Q, E718D and F1207S) can therefore 
allow the assumption that they result in severely reduced or absent NPC1 protein 
function.   
Twelve of the fourteen mutant alleles were detected in the juvenile cases, as well as 
one of the two mutant alleles in the adult case.  In contrast to the infantile cases, all 
of the juvenile and adult mutation alleles detected in this cohort were missense 
changes.  There were nine different mutations detected in this group; one was novel 
and eight had previously been reported in the literature.  
V664M was first reported by Park et. al. in their cohort of clinically and biochemically 
diagnosed NPC patients, but they made no conclusion about the severity of the 
missense (Park et al., 2003).  Bauer et. al. also observed this mutation in an adult 
with psychiatric features of NPC, as compound heterozygous with another missense 
of uncertain clinical significance (Bauer et al., 2013).  Finally, Greenberg et. al. 
described a unusual adult case with old mild visceral symptoms and no neurological 
NPC features aged forty eight (Greenberg et al., 2015).  This patient had an 
abnormal filipin staining pattern and was compound heterozygous for V664M and 
V378A, indicating that both missenses are likely to result in reduced rather than 
absent NPC1 protein function.   
In 2003 Park et. al. reported the variant c.2292G>A in their cohort (Park et al., 2003).  
They made no conclusion about the severity of this mutation but did indicate that the 
synonymous change created a new splice site.  The in silico analysis performed in 
this study gave the same prediction using four different splice site tools. Fernandez-
Valero et. al. reported a patient who was compound heterozygous for S865L and a 
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nonsense presumed severe mutation (Fernandez-Valero et al., 2005).  This patient 
presented at age two years with hepatosplenomegaly and psychomotor retardation 
and had classical filipin staining.  Xiong et. al also reported this mutation in a 
Chinese patient with cognitive decline at age seven years (Xiong et al., 2012).  This 
patient was homozygous for S865L indicating that it is associated with reduced 
rather than absent NPC1 protein function.  Two patients in this cohort were 
compound heterozygous for c.2292G>A; N20 with S865L on the other allele and N21 
with the novel missense E1166K on the other allele.  As yet, the severity of the three 
mutations is not clear and will require additional case studies or functional studies.  
P887L was identified by Garver et. al. in a patient who was compound heterozygous 
with a frameshift on the other allele (Garver et al., 2010).  Unfortunately the clinical 
features of the case were not described and therefore no conclusions can be draw 
about the severity P887L.  A single S954L allele was described by Greer et. al. in a 
patient with an abnormal filipin staining pattern (Greer et al., 1999).   Jahnova et. al. 
identified S954L eight times in their cohort of Czech patients (Jahnova et al., 2014).  
In three juvenile-onset and one adult-onset case S954L was found to be 
heterozygous with a severe frameshift allele, suggesting that it is associated with 
reduced rather than absent NPC1 protein function.  P1007A is a commonly detected 
NPC1 allele and has been reported as having a moderate effect on NPC1 protein 
due to its identification in four patients with a variant filipin staining pattern, and either 
a nonsense mutation or the known severe I1601T mutation on the other allele (Millat 
et al., 2001).  Y1019C has been reported in the homozygous state in one patient 
however no clinical or biochemical features were described (Fancello et al., 2009). 
Lastly, A1035V was observed several times in the cohort described by Ribeiro et. 
al.(Ribeiro et al., 2001).  A1035V in the homozygous state was associated with the 
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classical filipin staiing pattern and decreased NPC1 protein.  The patient presented 
had early onset neurological features supporting its association with a severe effect 
on NPC1 protein.  The two patients in this cohort with A1035V were compound 
heterozygotes; N14 with V664M and N16 with P1007A, both assigned as 
mild/moderate NPC1 alleles. 
6.4.3. Observations from testing in patients suspected of CD 
GeneReviews estimates this testing strategy should detect over 95% of mutations 
causing CD.  The lower pickup rate in this cohort (21%) reflects a large number of 
referrals of infants who may have a non-specific clinical presentation.  Two patients 
were identified with only single heterozygous mutations in SLC25A13 (C2 and C5).  
It is possible another mutation not detectable by sequencing of the coding regions 
may be present in these patients, especially as these are likely from ethnic groups 
other than the extensively studied East Asian populations. 
The vast majority of the mutations reported in SLC25A13 are in patients of Chinese 
or Japanese ethnicity, therefore the testing of patients from the UK will expand the 
mutation spectrum known in this gene; as illustrated by the identification of four novel 
mutations found in patients referred from UK centres.  The UK population is 
increasingly ethnically mixed; therefore the mutations spectrum in all patients 
referred from UK centres is relevant.  Ethnic groups that favour consanguineous 
unions are likely to be over-represented in cohorts of patients with autosomal 
recessive genetic conditions (Bundey and Alam, 1993). 
Although a rare condition, NICCD is a clinically important one to diagnose because 
of the high risk of the life-threatening features of CTLN2 in later life (Saheki and 
Kobayashi, 2002).  In addition, siblings of an NICCD infant may be affected but were 
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not symptomatic in the neonatal period and are therefore also at risk of CTLN2.  
Once mutations have been identified in a family therefore, screening of siblings and 
other relatives is useful in order to pick up early signs of CTLN2.  This has been 
done in three of these families so far (C7, C8 and C10). 
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Chapter 7 – DISCUSSION 
7.1. Summary of thesis  
Patients presenting with neonatal and infantile cholestasis have often indistinct 
phenotypes and a wide variety of underlying aetiologies.  The known contribution of 
genetic disorders has increased in recent years with increased availability of 
diagnostic genetic testing.  New sequencing methods have the potential to increase 
the numbers of genes that can be sequenced in one test and thus reduce the cost 
of genetic testing.   
In Chapter 3, new sequencing methods (microarray sequencing and targeted next 
generation sequencing) have been assessed for their suitability in testing for 
genetic causes of cholestasis.  Targeted next generation sequencing has proven to 
be the method with most potential (in terms of both mutation detection capabilities 
and potential for increased capacity) and in the years since this work was begun 
has become the strategy of choice for many genetically heterogeneous conditions.  
Genetic testing for cholestasis is now available in diagnostic laboratories using this 
broad strategy; although the target enrichment method, sequencer and analysis 
methods have all been overtaken by new and improved methods. 
In Chapter 4, the assays designed and assessed in Chapter 3, were used to test 
over two hundred infants presenting with liver disease for mutations in the ATP8B1, 
ABCB11, ABCB4, NPC1, NPC2 and SLC25A13 genes.   Diagnoses were made in 
8.5% of patients, with PFIC type 2 being the most common diagnosis.  In addition, 
single heterozygous mutations were identified in 9% of patients, supporting the idea 
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that individuals with these genotypes are predisposed to liver disease in the 
infantile period. 
In Chapter 5, patients suspected of PFIC-related diseases were tested for 
mutations in the ATP8B1, ABCB11 and ABCB4 genes.  Significant genetic findings 
were observed in 17% of the patients tested and twenty seven novel genetic 
variants were identified.  Similarly in Chapter 6, patients suspected of Niemann 
Pick disease type C and patients suspected of citrin deficiency were tested for 
mutations in NPC1 and NPC2, and SLC25A13, respectively.  Thirteen novel 
mutations were identified in NPC1 and four novel findings were observed in 
SLC25A13.  In Chapters 5 and 6, the clinical phenotypes are presented along with 
the genotypes in order for conclusions about the contributions of novel or uncertain 
sequence variants to be drawn. 
7.2. Current methods in DNA sequencing 
Developments in DNA sequencing methods in the last 10 years have completely 
transformed the field of genetics research by allowing the conception of projects and 
research aims that were simply not feasible before.  The original human genome 
project used cloning and Sanger sequencing.  It involved several collaborating 
groups, took 13 years and cost around 2 billion US dollars to complete (“Human 
Genome Project Information,” 2014).  Nowadays a full human genome can be 
sequenced using one NGS machine in a week at a cost approaching $1000.  It is 
now possible to identify the gene for a rare genetic condition by sequencing the 
genomes of a few affected individuals and identifying which mutated gene or genes 
are in common.  This strategy means researchers do not require the previously 
essential large pedigrees or consanguineous families as study subjects.  Also time 
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consuming linkage analysis and candidate gene analysis strategies can be 
circumvented.  Obviously, whole genome or exome sequencing produces vast 
amounts of information and it can be difficult to identify the DNA variant responsible 
for a disease, especially if it is a missense change, therefore in some cases a 
combination of DNA sequencing and more traditional strategies, like linkage 
analysis, has the greatest power (Thomas et al., 2010).  However, NGS methods 
have led to a surge in the discovery of genes responsible for rare disease in recent 
years (Shen et al., 2015), and are also being applied to the fields of cancer, 
neurodevelopmental disorders and epidemiology amongst others (Deng et al., 2016; 
Schulze et al., 2016; Sener et al., 2016). 
7.3. Future developments in sequencing methodology 
Despite the rapid advancements in recent years, the field of sequencing 
technologies shows no sign of slowing down.  There are several current challenges 
that, if overcome, will again revolutionise sequencing in research and then 
subsequently in clinical settings.  These challenges are; the detection of copy 
number variants, the detection of changes in methylation, and the requirement for 
target enrichment (which always includes an element of selection bias).  
7.4. DNA sequencing in clinical practice 
Translation of NGS methods from the research setting into clinical laboratories 
requires additional considerations; sensitivity, cost, quality control, unsolicited 
findings, bioinformatics requirements, computing requirements etc.  As a result, 
targeted sequencing analysis is still regarded as the most appropriate testing 
strategy for the vast majority of patients suspected of heterogeneous genetic 
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conditions.  The targeting can be either at the technical stage prior to sequencing 
(using target enrichment methods/TEMs), at the bioinformatics stage after 
sequencing (filtering), or both (eg targeting groups of genes within an exome kit).  It 
is likely that as the costs of the sequencing component of the process continues to 
reduce, the trend towards bioinformatics-driven targeting will continue; to avoid the 
necessity for time-consuming and costly TEMs.  This trend will require increased 
sequencing capacity, bioinformatics expertise and computing capability. 
Even before the problem of fast, accurate, cheap DNA sequencing of the human 
genome has been completely solved, interpretation of the data is rapidly becoming 
the new bottleneck in the process.  Analysis of human exome data typically yields 
around 70,000 sequence variants per patient, at least 100 of which are likely to be 
loss of function; nonsense, frameshift, conserved splice site (Lindor et al., 2015).  
This list of variants needs to be filtered down to allow the precise disease-causing 
mutation or mutations to be identified.  This process is made more difficult when the 
DNA change results in a missense or synonymous change, when the DNA change is 
present in a gene not known to be associated with any aspect of the phenotype of 
the patient, and when the DNA change is present in a region of the exome with low 
depth of coverage in terms of sequencing reads.  The danger of filtering variant data 
is that the real disease-causing mutation is missed for one of these reasons whilst 
other seemingly important variants act as red herrings in the search.  Successive 
rounds of filtering using different parameters may prove to be a useful strategy.  In 
addition, the analysis of parent-patient trios can significantly reduce the number of 
variants to be investigated.   
One area where analysis of the entire genome is probably warranted is the diagnosis 
of developmental disorders and intellectual disability, where the DDD project and 
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other studies have shown there are a wide variety of causative lesions, ranging from 
copy number variants of several megabases down to single base changes 
(Deciphering Developmental Disorders Study, 2015).   
The advantages and limitations of different sequencing strategies, bioinformatics 
tools and variant filtering methods need to be fully appreciated to enable translation 
into diagnostic testing. 
7.5. Genetic testing for neonatal cholestasis 
Herbst and colleagues described a 93-gene panel for infantile cholestasis which has 
been developed for diagnostic use in Germany (Herbst et al., 2015).  Diagnoses 
were made in four of six patients; including one NPC case, one PFIC1 case, one 
PFIC2 case and one autosomal recessive polycystic kidney disease case.  
Therefore, this appears to be a small and highly selected group of patients, and it will 
be interesting to read about their diagnostic outcomes in a larger dataset in a future 
publication.  They should be able to shed light on the disorders most commonly 
involved in infantile cholestasis and the possibility of mutations in more than one 
gene contributing to the phenotypes. 
Goldschmidt and colleagues investigated the possibility of mutations in more than 
one gene contributing to phenotype using a microarray sequencing method to look 
for mutations in SERPINA1, JAG1, ATP8B1, ABCB11 and ABCB4 in 717 infants with 
idiopathic cholestasis (Goldschmidt et al., 2016).  Despite the inclusion of genes for 
Alagille syndrome (AGS; JAG1 gene) and alpha-1 anti-trypsin deficiency (AATD; 
SERPINA1 gene) their diagnosis rate was 7.5%, lower than found in the study 
described in Chapter 4.  In addition, they identified a statistically significant increased 
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rate of double and triple heterozygotes.  There were differences between the two 
studies, including different gene selection, different strategies for variant 
classification, and a broader patient selection for the Goldschmidt study compared to 
study described in Chapter 4; patient age ranged from six weeks to seventeen years 
compared to less than two years, respectively.  In this study, only a few patients 
were identified in Chapter 4 with more than one mutation; less stringent classification 
of variants in the Goldschmidt study may have increased the numbers in their cohort.  
Although the 1000 Genomes dataset is an excellent source of ‘normal’ variation, the 
frequencies of variants can vary widely in different populations.  Therefore, the lack 
of ethnically-matched controls may have contributed to this finding.  In addition, 
SERPINA1 mutations, other than that which results in the Z allele, are not known to 
be associated with cholestasis in alpha-1 anti-trypsin deficiency (AATD) patients.  
Therefore the significance of the identification of several patients with heterozygous 
variants in this gene is unclear.  It will certainly be interesting to see if this increase in 
double and triple heterozygotes is replicated by other studies, as since the PFIC 
proteins in particular contribute to common pathways; it seems possible that 
deficiencies from more than one gene might contribute to the phenotype.   
One particular advantage of gene-panel approaches compared to sequential 
sequencing approaches is that it avoids clinical mis-diagnosis, especially in an often 
clinically indistinct population of patients such as those with infantile cholestasis.  
Grochowski and colleagues describe the identification of compound heterozygous 
mutations in the ATP8B1 gene in a patient clinically diagnosed with Alagille 
syndrome (Grochowski et al., 2015).  Despite AGS being one of the more distinct 
clinical syndromes associated with cholestasis, and this case presenting with four of 
the five features suggestive of AGS, no mutations were identified in the JAG1 or 
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NOTCH2 genes.  Whole exome sequencing subsequently identified two clearly 
deleterious mutations in ATP8B1, and the inheritance of these was consistent with 
the mutations being present on opposite alleles of the gene.  This finding nicely 
illustrates the advantages of hypothesis-free testing strategies; those being to allow 
more accurate diagnosis, to allow more accurate genetic counselling for the family, 
to expand the recognised clinical presentations of established disorders. 
The use of genome-wide analysis methods like WES or WGS has led to the 
identification of new genes involved in cholestasis.  The NR1H4 gene which encodes 
the FXR protein has been a candidate gene for cholestasis since it was established 
at a regulator of both BSEP and MDR3 proteins (involved in PFIC2 and PFIC3, 
respectively).  N1HR4 mutations have been identified in ICP cohorts (Davit-Spraul et 
al., 2012; van Mil et al., 2007) and in one case of idiopathic infantile cholestasis 
(Chen et al., 2012).  More recently, Gomez-Ospina and colleagues described 
homozygous loss of function mutations in NR1H4 in four patients (two families) with 
neonatal cholestasis (Gomez-Ospina et al., 2016).  The group used whole exome 
sequencing and SNP microarrays to test two unrelated patients with neonatal 
cholestasis. The same genotype was then confirmed in an additional affected family 
member in each case.  One family had a homozygous stop codon and the other was 
compound heterozygous for an in-frame insertion of three nucleotides and 31kb 
deletion encompassing the same region; both alleles resulting in undetectable levels 
of NR1H4 mRNA. This gene looks likely to be a good candidate for PFIC-like 
patients in whom mutations in ATP8B1, ABCB11 and ABCB4 have been excluded. 
Another protein which may be important in the PFIC cohort is CDC50A (gene name 
TMEM30A).  This protein is known to be essential for the subcellular transport of 
FIC1 protein and its phospholipid flippase function (Paulusma et al., 2009).  At the 
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moment there is no known link to cholestasis but it might be an interesting gene to 
include on a large gene panel. 
7.6. Further areas of study 
There are many avenues of further study that would be possible using the work 
presented in this thesis as a basis.  Firstly, other sequencing methods could be 
evaluated and compared against those already studied.  In particular, use of larger 
capacity target enrichment methods and sequencers would allow the design of a 
much larger panel of relevant genes to be sequenced that the one described in 
Chapter 3.  The performance, workflow, cost and mutation detection rate of such a 
panel could be compared with this tNGS assay.  Such technologies could also allow 
the inclusion of intronic and promoter regions of genes; potentially a source of 
unidentified disease-causing mutations (Cebecauerová et al., 2012).  Investigation of 
copy number variation is another area where additional mutations may be 
discovered, and therefore methods for detecting these would be useful to 
investigate.  MLPA is the most convenient method for individual genes; however for 
large gene panels this method becomes impractical.  New methods which combine 
sequencing information and copy number information are sought after and are likely 
to be studied by others in the near future.  Whole genome sequencing (WGS) should 
allow the detection of sequence and copy number variants simultaneously, and 
targeted bioinformatics analysis could mean that virtual panels could be created 
using WGS as a basis.  Cost is the main barrier to this strategy at the moment, but is 
following a downward trend; therefore it may not be too far-fetched for an area of 
study soon.  WGS is likely to have advantages over WES, including better coverage 
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of GC-rich regions and less interference from pseudogenes or repetitive DNA 
sequences (Meienberg et al., 2016). 
Secondly, further investigation of novel variants and variants of uncertain 
significance would be an interesting area of study, and would help to reduce the 
number of patients in whom uncertainty over their diagnosis remains.  Mini-gene 
assays to investigate potential splicing defects and in vitro functional studies to 
investigate uncertain missense changes, could allow more important information to 
be gathered about these mutations and the proteins.  Assays such as fluorescent 
staining for the PFIC proteins on liver biopsy and the filipin staining test for NPC, are 
already available, but the results are not often correlated with the genetic results and 
the clinical phenotype.  Perhaps a multi-disciplinary team meeting to discuss patients 
with equivocal results would be useful in the clinical setting. 
A third area of potential future study, would be to continue to discover more genes 
associated with cholestasis, and then to determine the incidence of these in the 
neonatal cholestasis, infantile cholestasis and adult cholestasis populations.  Large-
scale sequencing projects that use genome-wide screens and a hypothesis-free 
testing strategy have the most potential to discover these new genes, although 
candidate gene approaches have also been successful.  The 100,000 Genomes 
Project, in particular, has gene discovery for rare disease in its remit.  It is probable 
that each newly discovered gene for cholestasis will account for only very few cases, 
however if a several rare causes of cholestasis are added to diagnostic testing 
panels, this could significantly increase the diagnosis rate in the near future.  It is 
also possible that small contributions from a couple or a few genes might contribute 
to cholestasis, especially when other environmental factors are also present (for 
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example, mutations or polymorphisms in more than one gene).  Elucidating these 
complexities would be another large area of work for the future. 
Lastly, the discovery of more of the genetic basis of cholestasis will also lead to a 
fuller understanding of the processes involved in bile formation, liver disease and 
response to environmental factors.  This knowledge should help towards developing 
strategies for new treatments for liver disease in future, for both the specific cases of 
cholestasis and the wider population of patients with liver disease. 
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Appendix III – PFIC QUESTIONNAIRE 
 
Did the patient present with cholestasis?  If not, describe presenting features. 
 
 
 
If patient had cholestasis, was it progressive or episodic? 
 
 
 
If episodic, please give frequency and duration of episodes? 
 
 
 
If episodic, was a trigger identified, eg pregnancy, contraceptive pill, another? 
 
 
 
 
Did the patient have or develop other clinical features?   
 
 
 
 
Was liver biopsy done and what were the results?  Include immunostaining if performed. 
 
 
 
  
 
Did the genetic findings alter the management and/or prognosis of the patient?  
 
 
 
 
 
Is there a family history of cholestasis or liver disease?  
 
 
 
Was the patient (or family) referred to Clinical Genetics? 
 
 
Patient details  Referrer details  
Patient identifier  Name  
Date of Birth  Centre  
Age at presentation  Completed by  
Age at diagnosis  Date  
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Appendix IV – NPC QUESTIONNAIRE 
 
Please indicate whether the above patient has (or has had) any of the following symptoms. 
 
Prolonged unexplained neonatal jaundice or cholestasis 
Isolated unexplained splenomegaly  
Hepatomegaly 
Hydrops fetalis 
Siblings with fetal ascites 
Vertical supranuclear gaze palsy 
Gelastic cataplexy 
Ataxia, clumsiness or frequent falls 
Dysarthria and/or dysphagia  
Dystonia 
Acquired and progressive spasticity 
Hypotonia 
Delayed developmental milestones 
Seizure (partial or generalised) 
Myoclonus  
Pre-senile cognitive ecline or dementia 
Psychotic symptoms (hallucinations, delusions and/or thought disorders) 
Treatment-resistant psychiatric symptoms 
Other psychiatric symptoms 
Disruptive or aggressive behaviour in childhood or adolescence 
Other, please expand. 
 
 
 
 
Was filipin staining performed in cells from this patient? 
If so, what were the results? 
 
 
 
Was an oxysterol measurement performed in a sample from this patient? 
If so, what were the results? 
 
 
 
Does this patient have any family members who also have symptoms of NPC (any of those 
listed above)? 
 
 
 
  
Patient details  Referrer details  
Patient identifier  Name  
Date of Birth  Centre  
Age at presentation  Completed by  
Age at diagnosis  Date  
Yes No 
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